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ABSTRACT OF DISSERTATION
POLYCHLORINATED BIPHENYL LIGANDS OF THE ARYL HYDROCARBON
RECEPTOR PROMOTE ADIPOCYTE-MEDIATED DIABETES
Numerous epidemiology studies suggest a correlation between exposures
to polychlorinated biphenyls (PCBs) and the development and severity of type 2
diabetes (T2D); however, mechanisms remain largely unknown. Previous studies
demonstrated that PCBs that are ligands of the aryl hydrocarbon receptor (AhR)
promote the expression of proinflammatory cytokines, including tumor necrosis
factor-α (TNF-α), that are linked to insulin resistance in adipocytes. To explore
potential mechanisms linking PCB exposures to diabetes, we developed a
mouse model of glucose and insulin intolerance induced by acute and chronic
exposures to PCB-77. We hypothesized that PCB ligands of AhR result in
adipocyte-specific elevations in TNF-α and dysregulated glucose homeostasis.
Results demonstrated that PCB77 resulted in rapid and sustained glucose and
insulin intolerance in low fat (LF)-fed mice, and that these effects were
associated with adipose-specific elevations in TNF-α. When mice were made
obese from consumption of a high fat (HF) diet, effects of PCB77 were lost
presumably due to concentration of the toxin in adipose lipids. However, upon
weight loss, mice exposed to PCB77 exhibit impaired glucose homeostasis.
These results suggest that lipophilic PCBs redistribute from adipose lipids with
weight loss and mitigate beneficial effects to improve glucose homeostasis. To
define the role of adipocyte AhR in PCB-induced diabetes, we created a mouse
model of adipocyte AhR deficiency using the Cre/LoxP system. Adipocyte-AhR
deficiency conferred protection from the development of PCB-77-induced
impairments in glucose and insulin tolerance in obese mice undergoing weight
loss. Unexpectedly, adipocyte-AhR deficient mice fed the HF diet exhibited
adipocyte hypertrophy, increased adipose mass and elevated body weight.
These results suggest that (1) adipocyte AhRs are responsible for effects of
PCB77 to impair glucose homeostasis during weight loss and (2) adipocyte AhRs
respond to the HF diet to regulate adipose mass and body weight. We used
resveratrol as a putative AhR antagonist to determine if the polyphenol confers
protection against PCB-77-induced diabetes. Resveratrol abolished acute effects
of PCB77 to impair glucose and insulin tolerance in LF-fed mice. Notably,
PCB77 administration abolished insulin-induced phosphorylation of Akt in
adipose tissue and these effects were abolished by resveratrol. Resveratrol also
abolished marked suppressions in glucose uptake in adipocytes exposed to
PCB77. These studies suggest the adipocyte AhR plays a potentially significant
role in the development of diabetes and obesity, and that resveratrol may
represent a novel therapeutic for PCB exposed populations.

Keywords: Polychlorinated biphenyls, adipocytes, diabetes, resveratrol, aryl
hydrocarbon receptor
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SECTION I. BACKGROUND
1.1 Polychlorinated biphenyls
1.1.1 Polychlorinated biphenyls
Polychlorinated biphenyls (PCBs) are the general name describing any of the
209 arrangements of organochlorides with 1 to 10 chlorine atoms attached to a
biphenyl structure (a molecule with two benzene rings) (Figure 1.1). They are
synthetic compounds that were primarily used as dielectric and coolant fluids
in transformers, capacitors,

and electric

motors.

In

light

of

emerging

environmental concerns and health impacts in humans and wildlife, PCB
manufacturing was banned by the United States Congress in 1979 and by
the Stockholm Convention on Persistent Organic Pollutants (POPs) in 2001
(1). According to the U.S. Environmental Protection Agency (EPA), PCBs can
cause cancer in animals, and there is causal evidence for a link to cancer in
humans (2-3).
The toxicity of PCBs became a topic of global concern when it was
discovered that compounds within this group can share a structural resemblance
and toxicity pathways with 3,4,7,8-tetrachlorodibenzo-p-dixon (TCDD). PCB
compounds within this group have positive associations with toxic effects of
TCDD; namely endocrine disruption, neurotoxicity, immune system suppression,
and reproductive effects (4).
1.1.1.1

PCB chemistry

PCB congeners are odorless, tasteless,

viscous liquids with

the chemical

formula C12H10-xClx (Figure 1.1). They are formed via electrophilic chlorination

1

of a biphenyl with chlorine gas. PCBs have low water solubility and low vapor
pressure at

room

temperature,

but

they

are

highly

soluble

in

most

organic solvents, oils, and fats (5). PCBs have high dielectric constants,
high thermal conductivity, high flash points and are fairly inert chemically; all
qualities which made the compounds ideal for use as coolants in electrical
systems (5). They are highly resistant to chemical degradation such
as oxidation, reduction, addition, elimination,

and electrophilic

substitution,

making PCB removal from the environment extremely problematic (5).
PCBs can be divided into two distinct categories with regards to their
structural relationship to toxicity; (1) coplanar or non-ortho-substituted arene
substitution patterns and (2) noncoplanar or ortho-substituted congeners. The
coplanar group members have 2 phenyl rings which occupy the same plane,
giving

the

molecule

structural

similarities

to polychlorinated

dibenzo-p-

dioxins (PCDDs) and dibenzofurans, and allowing coplanar PCBs to elicit similar
toxic effects via agonist activity at the aryl hydrocarbon receptor (AhR) in humans
and animals (5). Noncoplanar PCBs have chlorine atoms at the ortho position on
one or both of the biphenyl rings; this chlorine position causes steric hindrance
and forces the molecule to twist out of plane. Members of the noncoplanar group
have not been found to interact with AhR, but rather have been shown to bind
both the constitutive androstane receptor (CAR) and the pregnane x receptor
(PXR) (5).
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1.1.1.2

PCB lipophilicity

Part of the persistence of PCBs in the environment stems from their high
lipophilicity; the octanol:water partition coefficient of > 104 for most congeners
dictates that their accumulation in nonlipid substances will be minimal (6). We
have previously reported that mice orally gavaged with two doses of PCB-77
overwhelming accumulate the contaminant in adipose tissue, with secondary
tissue accumulation in liver and trace amounts in serum (7). These findings are
consistent with studies by Kodavanti et.al., in which rats were gavaged five times
per week for 4 weeks with Aroclor 1254 and the reported mean ratio of total PCB
in blood:liver:adipose tissue was 1:22:359 (8). Most likely as a result of their
lipophilicity, obese subjects store approximately two to three times the quantity of
total PCBs in adipose tissue, which would indicate that hydrophobic PCBs were
highly attracted to the large lipid pools present during obesity. Conversely, in
obese subjects experiencing drastic weight loss from bariatric surgery, serum
levels of PCBs increased and were suggested to decrease the beneficial effects
of weight loss with respect to liver toxicity markers and serum lipid parameters
(9).
These studies suggest that adipose tissue can store lipophilic PCBs and that
adipose tissue might be a target for the adverse health effects associated with
these chemicals. Furthermore, adipose tissue would represent a low-grade
internal source of stored PCBs which could then act systemically upon release
from adipose lipids.
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1.1.1.3 General health effects of PCBs
The toxicity of PCBs varies among congeners. The coplanar PCBs, due
to dioxin-like properties, are among the most toxic congeners. Since PCBs are
frequently found in complex mixtures due to their industrial use, the concept of
toxic equivalency factors (TEFs) has been developed to aid in risk assessment
and regulatory control. In the TEF system, more toxic PCB congeners are
assigned higher TEF values on a scale from 0 to 1, and the highest TEF value of
1 is assigned to TCDD (10) (Table 1.1).
Humans may be exposed to PCBs by breathing in contaminated air,
eating contaminated food, and through accidental skin contact with contaminated
materials. PCBs in foods tend to be most prevalent in meat (particularly beef)
and dairy products which are high in fat and conversely less prevalent in grain,
fruit, and vegetable food stuffs (11). Furthermore, PCB levels have been found to
be greater in farm raised salmon compared to wild caught fish, apparently due to
PCB contamination in commercial fish meal (12). PCBs can be excreted in feces
or stored in adipose tissue (13). Due to high lipophilicity, PCBs also tend to
collect in milk fat and can be transmitted to infants through breast-feeding (1415).
A frequently observed health effect in populations with very high levels of
PCB exposure are skin conditions (chloracne and rashes). In the Japanese
Yusho poisoning incident (1968), more than 14,000 people suffered mass
poisoning when 280 kg of PCB-contaminated rice bran oil was used as chicken
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feed (16). Reported symptoms included dermal and ocular lesions, including
unusual skin sores, fatigue, and lowered immune responses (17).
A growing body of evidence suggests that PCB exposure may have a
positive association with the development of non-Hodgkin lymphoma, a cancer of
the immune system (18-19), and they may also mimic the action of estrogen in
breast cancer cells and increase breast carcinogenesis (20). The U.S. EPA and
the International Agency for Research on Cancer (IARC) have concluded that
PCBs are probable carcinogens (2, 21). PCBs are also considered as probably
carcinogenic to humans by the World Health Organization (22).
Finally, TCDD and PCB exposure are positively correlated with the
development of T2D in numerous epidemiology studies (Tables 1.3, 1.4, and
1.5). These findings are consistent with the published opinion of the National
Institutes of Environmental Health Sciences (NIEHS) Division of the National
Toxicology Program (NTP), which reviewed many of the epidemiology studies
examining the correlation between PCBs and diabetes and concluded that there
is a positive association between these two factors and that more research is
needed to understand underlying mechanisms (23).
1.1.2 Aryl-hydrocarbon receptor (AhR)
The aryl-hydrocarbon receptor (AhR) is a member of the family of basic helixloop-helix transcription factors. The endogenous ligands of this receptor remain
unknown, although it binds numerous exogenous ligands including natural plant
flavonoids, polyphenolics, and indoles, and additionally synthetic polycyclic
aromatic hydrocarbons and dioxin-like compounds such as coplanar PCBs
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(Table 1.2). AhR is a cytosolic transcription factor which is inactive when bound
to several co-chaperones. Subsequent to ligand binding to chemicals such
as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the chaperones dissociate and
allow for AhR translocation to the nucleus and dimerization with aryl-hydrocarbon
receptor nuclear translocator (ARNT), initiating changes in gene transcription
(Figure 1.2).
1.1.2.1 Protein functional domains
The AhR protein contains a number of domains critical for function and is
classified

as

a

member

of

the basic

helix-loop-helix/Per-Arnt-Sim

(bHLH/PAS) family of transcription factors (24-25) (Figure 1.3). The bHLH motif
is located in the N-terminal of the protein (26). Transcription factors of the bHLH
superfamily have two highly conserved and functionally distinctive domains; the
basic-region (b), which is necessary for the binding of the transcription factor
to DNA, and the helix-loop-helix (HLH) region, which promotes protein-protein
interactions. In addition, the AhR contains two PAS domains, PAS-A and PAS-B;
sequences of 200 to 350 amino acids that display a high sequence homology to
the protein domains that were originally discovered in the Drosophila genes
period (Per), single-minded (Sim), and ARNT (27). The PAS domains facilitate
particular secondary interactions with other PAS domain-containing proteins,
specifically between AhR and ARNT, allowing the protein complex to form. The
ligand binding site of AhR is located within the PAS-B domain (28) and contains
conserved residues necessary for ligand binding (29). A Q-rich domain is
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contained in the C-terminal region of AhR and is needed for co-activator
recruitment and transactivation (30).
1.1.2.2 Aryl-hydrocarbon receptor ligands
AhR ligands can be broadly classified into synthetic or naturally occurring
categories (Table 1.2). The first recognized AhR ligands were synthetic
halogenated
dibenzofurans,

aromatic

hydrocarbons

and biphenyls)

(polychlorinated

and polycyclic

aromatic

dibenzodioxins,
hydrocarbons (3-

methylcholanthrene, benzo(a)pyrene, and benzoflavones) (31-32). More recently,
several studies have examined naturally occurring ligands, hinting toward the
identity of an endogenous ligand.
Potential endogenous ligands of AhR include the following: derivatives
of tryptophan such as indigo dye and indirubin (33), bilirubin (34), arachidonic
acid and ecosanoid metabolites lipoxin A4 and prostaglandin G (35), modified
low-density lipoprotein (36), and numerous dietary carotinoids (32).
1.1.2.3 Aryl-hydrocarbon receptor signaling pathways
AhR in the absence of ligand binding is located in the cytoplasm as an
inactive protein complex consisting of a dimer of Hsp90 (37-38), prostaglandin E
synthase 3 (Ptges3, p23) (39-42), the immunophilin-like protein hepatitis B virus
X-associated protein 2 (XAP2) (43) (previously known as AhR interacting protein,
AIP (44)), and AhR-activated 9 (ARA9) (45). The dimer of Hsp90 with p23 has
several functions in the protection of AhR from proteolysis, holding the receptor
in a conformation to facilitate ligand binding, and blocking the inappropriate
binding of ARNT (28, 40, 42, 45-47). XAP2 interacts with the carboxyl-terminal of
7

Hsp90

and

binds

to

the

AhR nuclear

localization

sequence

(NLS),

which prevents the premature trafficking of the receptor into the nucleus (48-50).
After ligand binding to AhR, XAP2 is released resulting in exposure of the
NLS and translocation into the nucleus (51). It is hypothesized that Hsp90
dissociates from AhR in the nucleus, exposing the two PAS domains to facilitate
the binding of ARNT (52-55). The activated AhR/ARNT heterodimer complex
interacts with DNA by binding to recognition sequences located in the 5’regulatory region of dioxin-responsive genes (52, 54, 56).
The conventional recognition motif of the AhR/ARNT heterodimer
complex, known as either the AhR-, dioxin- or xenobiotic- responsive element
(AHRE, DRE or XRE), includes the core sequence 5’-GCGTG-3’ (57) within the
consensus sequence 5’-T/GNGCGTGA/CG/CA-3’ (58-59) in the promoter
region of AhR responsive genes. The AhR/ARNT complex directly binds the
AHRE/DRE/XRE core sequence in a manner such that ARNT binds to 5’-GTG-3’
and AhR binds 5’-TC/TGC-3’ (60-61). Current publications postulate that the
element termed AHRE-II, 5’-CATG(N6)C[T/A]TG-3’, is capable of indirectly acting
with the AhR/ARNT complex (62-63). The culmination of these steps results in an
array of differential changes in gene expression.
1.1.2.4 Functional role of AhR in physiology and toxicology
Evolutionarily, the most primitive physiological role of AhR is in development.
AhR is believed to have evolved from invertebrates where the receptor
functioned in a ligand-independent manner in normal development processes
(64). The AhR homolog in Drosophila, spineless (ss) is required for development
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of the antenna and legs (65-66). In developing vertebrates, AhR appears to play
a role in cellular proliferation and differentiation (6, 67). AhR has been shown to
be involved in differentiation of several developmental pathways, including
hematopoiesis

(68), lymphoid

systems

(69-70), T-cells

(71), neurons

(72), hepatocytes (73), and adipocytes (6).
The adaptive response is evidenced by the induction of xenobiotic
metabolizing enzymes. Proof of the adaptive response was first detected from
the AhR-dependent induction of cytochrome P450, family 1, subfamily A,
polypeptide 1 (CYP1A1) due to TCDD exposure (74-76). The hunt for the
presence of DREs in the promoter region of genes has led to the identification of
an AhR gene battery of Phase I and Phase II metabolizing enzymes consisting
of CYP1A1, cytochrome

P450,

family

1,

subfamily

A,

polypeptide

2

(CYP1A2), cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1),
NADPH dehydrogenase quinine 1 (NQO1), aldehyde dehydrogenase family 3,
member A1 (ALDH3A1), UDP-glucuronosyltransferase family 1, polypeptide A2
(UGT1A2), and glutathione S-transferase A1 (GSTA1) (77). Through activation of
the classical AhR gene battery, vertebrates can detect a wide range of chemicals
at the cellular level which AhR is capable of binding to facilitate their
biotransformation and elimination. Intriguingly, a recent study by Lensu et.al.
implies that the AhR might signal the presence of toxins in food and cause
aversion to those foodstuffs (78).
The toxic response is an expansion of the adaptive response induced by
AhR activation. Toxicity may stem from two different arms of AhR signaling. In
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the first arm, the induction of metabolizing enzymes can result in the generation
of toxic metabolites. For instance, the AhR ligand benzo(a)pyrene (BaP), is
converted to a toxic metabolite via the induction of CYP1A1 and CYP1B1 in a
variety of tissues (79). The second arm of toxicity occurs through irregular
changes in global gene transcription beyond those seen in the classical AhR
gene battery, leading to global changes in gene expression and adverse
modifications in cellular processes and function (67, 80-85). Interestingly, recent
microarray analysis implies that different synthetic AhR ligands regulate distinct
genetic networks (86).
1.1.2.5 AhR in glucose homeostasis and metabolic studies
While the toxicological functions of the AhR have been vigorously studied, the
role of the AhR in glucose homeostasis and metabolism remains largely
unexplored. Wang et.al. examined glucose tolerance, insulin resistance,
expression of peroxisome proliferator–activated receptor-α (PPAR-α), and genes
affecting glucose metabolism and fatty acid oxidation rhythms in wild-type (WT)
versus AhR-deficient [knockout (KO)] mice (87). In this study, KO mice displayed
enhanced insulin sensitivity and improved glucose tolerance, accompanied by
decreased PPAR-α and key gluconeogenic and fatty acid oxidation enzymes,
indicating a link between AhR signaling and glucose metabolism. The authors
further conclude that hepatic activation of the PPAR-α pathway might be a
mechanism underlying AhR-mediated insulin resistance.
Further clues to the role of AhR in glucose metabolism can be found by
examining gene microarray studies utilizing high-affinity receptor ligands. Nault
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et.al. utilized livers from chow-fed C57BL/6 mice for gene microarray, 1, 3 and 7
days after a single oral gavage of 30 μg/kg TCDD (85). Administration of TCDD
resulted in robust activation of not only genes involved in the xenobiotic
response, but also genes associated with steroid, phospholipid, fatty acid, and
carbohydrate metabolism. Arzuaga et.al. performed gene DNA analysis on livers
from C57BL/6 mice fed diets enriched with high-linoleic acid oils (20% and 40%
as calories), with half of each group exposed to PCB77 (84). This study
demonstrated a significant interaction between dietary fat and PCB exposure,
such that deregulated genes were organized into patterns describing the
interaction of diet and PCB exposure. Control animals demonstrated a significant
high-fat mediated induction of genes associated with fatty acid metabolism,
triacylglycerol synthesis and cholesterol catabolism, but this effect was downregulated in animals exposed to PCB77. Several of these genes are regulated by
PPAR-α and as predicted, changes in PPAR-α gene expression followed the
same pattern as described above, demonstrating that dietary fat can interact with
environmental pollutants to compromise lipid metabolism. Taken together, the
results of these gene microarray studies would suggest not only that there is a
distinctive role for the AhR in metabolism, but that overall nutritional status and
the presence of lipids can modulate the interaction between AhR and exogenous
ligands.
Recent studies demonstrated that consumption of farmed salmon
containing persistent organic pollutants, including increased levels of seven
different PCBs, promoted glucose intolerance associated with elevations in
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adipose tissue expression of tumor necrosis factor-α (TNF-α) in high fat (HF) fed
C57BL/6 mice (88).Interestingly, when levels of pollutants were decreased by
feeding salmon purified fish oil, glucose tolerance improved and adipose
expression of TNF-α decreased. This study suggested that the adipocyte AhR
may be of importance in mediating some of the observed effects.
Another recent study tested the role of the AhR in obesity and fat
metabolism in the absence of exogenous ligands (89). Utilizing two congenic
mouse strains that differed at the AhR gene and encode AhRs with a 10-fold
difference in signaling activity, the mouse strains were fed low-fat (LF) diet or HF
diets. The HF diet differentially increased body weight and body fat to body mass
ratios in the mouse strain expressing the higher affinity and higher response
AhR. These results suggest that the AhR plays an important and broad role
in obesity and associated complications.
1.1.3 PCBs and type 2 diabetes
1.1.3.1 The pathophysiology of type 2 diabetes
Global estimates indicate 300 million people are affected by diabetes, with type 2
diabetes (T2D) accounting for 90% of diabetes prevalence (90). Moreover, the
world-wide diabetes incidence is anticipated to double in the next twenty years in
tandem with global population aging, a general decrease in physical activity, and
increasing rates of obesity. Women would appear to be at greater risk for
developing T2D, as are certain ethnic groups (90-92). Traditionally considered a
disease of adults, T2D is increasingly diagnosed in children in parallel with
rising obesity rates (90).
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T2D is a metabolic disorder that is characterized by high blood glucose in
the context of insulin resistance and relative insulin deficiency (93). This is in
contrast to diabetes mellitus type 1, where there is an absolute insulin deficiency
due to destruction of islet cells in the pancreas (93). Classical T2D symptoms
are polyuria, polydypsia, polyphagia, and weight loss (91). Many people,
however, have no symptoms during the first few years and are diagnosed on
routine testing. Long-term complications from unregulated high blood glucose
can

include heart

disease, strokes, diabetic

retinopathy

and

subsequent

blindness, kidney failure which may require dialysis, and poor circulation of limbs
leading to amputations (91). The development of T2D is caused by a
combination of lifestyle and genetic factors, with obesity believed to be a primary
contributing factor (91, 94).
T2D is initially managed by increasing physical activity and improved diet.
If blood glucose levels are not adequately lowered by these modifications,
medications such as metformin (to suppress hepatic gluconeogenesis and
enhance the insulin sensitivity of peripheral tissue) or insulin (in lieu of insufficient
endogenous insulin from the pancreas) may be required. For those on insulin,
patients must routinely check blood glucose levels.
T2D eventually progresses to insufficient insulin production from beta cells
in the pancreas due to chronic insulin resistance (IR) in peripheral tissues (91).
IR is typically observed in skeletal muscle, liver, and adipose tissue, and is
characterized by the inability of cells to respond adequately to insulin (91). Insulin
normally suppresses glucose production and release by the liver. In IR, because

13

the liver is no longer sensitive to insulin, inappropriate hepatic output of glucose
can occur (91). Other potentially significant mechanisms associated with T2D
and IR include the increased breakdown of lipids within adipocytes, high blood
glucagon levels, increased kidney retention of salt and water, and the
inappropriate

regulation

of

metabolism

by

the central

nervous

system

(93). However, not all people with IR are considered T2D, because an
impairment of insulin secretion by pancreatic beta cells is also required (93). For
example, prior to the development of T2D, most individuals will exhibit IR and a
“pre-diabetic” physiology where in response to IR in peripheral tissues the
pancreas will secrete more insulin than necessary. This disregulation of insulin
secretion leads to the subsequent beta cell dysfunction present in T2D (93).
1.1.3.2. General characteristics of adipose tissue
Adipose tissue is connective tissue composed primarily of adipocytes, but also
containing the stromal vascular fraction (SVF) of cells including preadipocytes,
fibroblasts, vascular endothelial cells and variety of immune cells. Adipocytes are
derived from preadipocyte stem cells. Adipose tissue stores energy in the form
of lipids and acts as a major endocrine organ (95) producing numerous
hormones such as adiponectin, estrogen, leptin, and the adipokine TNF-α.
Adipose tissue is classified into two distinct types: white adipose tissue (WAT)
and brown adipose tissue (BAT). In humans, adipose tissue is located beneath
the skin (subcutaneous fat), around internal organs (visceral fat), and in specific
locations (adipose depots).
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Visceral fat is white adipose tissue located inside the abdominal cavity and
is composed of several depots, including mesenteric, epidydmal, and perirenal.
An excess of visceral fat is linked to the development of T2D (96), IR
(97), inflammatory diseases (98), and other obesity-related diseases (99).
Most of the remaining nonvisceral fat is subcutaneous adipose tissue
found below the skin in the hypodermis. Subcutaneous fat is not thought to be
related to the development of the classic obesity-related pathologies, such as
heart disease and stroke, and some data even suggests it might be protective
against metabolic disease pathogenesis (100). Females generally deposit body
fat around the hips, thighs, and buttocks in subcutaneous fat depots (termed
gynoid distribution) which are believed to pose a lower health risk than visceral
fat that is typically present in males (termed android distribution) (100).
A specialized form of adipose tissue is brown adipose tissue (BAT),
primarily located near the neck and thorax in humans. This specialized adipose
tissue can generate heat via uncoupling of the respiratory chain of oxidative
phosphorylation within mitochondria.

When

protons

transit

along

the

electrochemical gradient across the inner mitochondrial membrane, the energy
from

this

process

is

released

as

heat

instead

of

being

used

to

generate adenosine triphosphate (ATP). This process is thought to be most
critical in neonates exposed to cold which would require thermogenesis to keep
warm (101). Until recently, BAT was thought to be found only in infants in
humans, but new studies have disproven this hypothesis. Metabolically active
tissue with temperature responses similar to BAT was first reported in adults in
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2007 (102), and the presence of BAT in adults was later verified by others (103105). Strategies to direct the differentiation of BAT may become a weight loss
therapy of the future.
1.1.3.3. Mechanisms of IR in adipose tissue
Adipocytes have a significant physiological role in sustaining triglyceride
and free fatty acid levels, in addition to contributing to IR. Visceral fat is more
prone than subcutaneous fat to display IR; thus, central obesity and waist
circumference are markers of impaired glucose tolerance (100).
Oxidative stress is the broad term for an imbalance between the systemic
expression of reactive oxygen species (ROS) and a biological system's capacity
to readily detoxify the reactive intermediates or to repair the resultant damage.
Disturbances in the normal redox state of cells can become the origin of toxic
effects via the production of peroxides and free radicals that can damage any
part of the cell, including proteins, lipids, and DNA. Additionally, some ROS act
as cellular messengers in redox signaling, and therefore can cause disruptions in
normal cellular signaling processes. The association between oxidative stress
and IR, particularly in adipose tissue, has been recognized for some time (106109). Furukawa et.al. demonstrated that production of ROS increased selectively
in the adipose tissue of obese mice, which was abolished by treatment with a
NADPH oxidase inhibitor (110). The inhibitor also attenuated the dysregulation of
adipocytokines, improved diabetes, and hyperlipidemia in obese mice (110).
These results suggest that increased oxidative stress in adipose tissue is an
early marker of metabolic syndrome.
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Adipokines also play a critical role in the development of adipose tissue
IR, with TNF-α being a well recognized modulator of this effect. TNF-α is a multifunctional regulatory cytokine with diverse roles in inflammation, cell apoptosis
and survival, cytotoxicity, production of other cytokines, and induction of IR in
adipose tissue (111-113). TNF-α is synthesized as a 26 kDa plasma membrane
bound monomer (114), and a secreted trimer is formed by proteolytic
cleavage of the membrane-bound precursor protein by the TNF-α converting
enzyme (TACE, also known as ADAM17) (115-116). Two TNF-α receptors, type I
and type II, mediate TNF-α signal transduction (117).
Both mRNA and protein levels of TNF-α are highly induced in the adipose
tissue of obese animals (111) and humans (118). Despite the fact that adipose
tissue is composed of a variety of cell types which are able to produce cytokines,
adipocytes are the principal source of TNF-α in adipose tissue (111, 113, 119),
and express both TNF-α receptors. Prolonged exposure of animals (120) to TNFα induces IR, and conversely neutralization of TNF-α increases insulin sensitivity
(121-122). Additionally, TNF-α and TNF-α receptor knock out mice demonstrate
improvements in insulin sensitivity in models of obesity (123-124). However,
systemic administration of TNF-α neutralizing antibody to obese humans with
type 2 diabetes did not improve insulin sensitivity (125). Because adipocytederived TNF-α is hypothesized to function principally in an autocrine or paracrine
manner in adipose tissue, systemic infusion might not be able to abolish the
biological activity of endogenous TNF-α in adipose tissue.
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Free fatty acids (FFA) can reduce glucose uptake and metabolism;
additionally, increased FFA oxidation can amplify the ratios of mitochondrial
acetyl-CoA:CoA and NADH: NAD+, and thus impair insulin-mediated glucose
utilization (126-127). FFA also inhibit insulin signaling (128-129) and glycogen
synthesis in muscle (130-132), and promote hepatic glucose production (133).
Systemic treatment with FFA inhibits glucose uptake in skeletal muscle in a
dose-dependent manner (130, 134). Conversely, reducing systemic FFA
improved glucose utilization (135-136) and ameliorated hyperinsulinemia in
subjects with T2D. Although data suggest elevated blood FFA are involved in IR
pathology, mechanisms which increase systemic FFA in T2D subjects are not
completely understood. Systemic FFA are a balance between production and
utilization, with lipolysis in adipocytes and in triglyceride-rich lipoproteins being
principal sources of blood FFA. It has been postulated that systemic FFA levels
are linearly correlated to the rate of adipose tissue FFA release (137), and that
blockade of adipose tissue FFA release via insulin suppresses systemic FFA
(138-139).

It

has

been

demonstrated

that

TNF-α

is

a

significant

autocrine/paracrine factor that can promote lipolysis and drive FFA release from
adipose tissue (140-141).
Adiponectin is a secreted protein that is expressed primarily by adipocytes
and is involved in regulating systemic glucose levels as well as fatty acid
breakdown. Insulin stimulates adiponectin secretion in cultured adipocytes (142),
however, TNF-α inhibits adiponectin mRNA levels (143). Adiponectin levels are
down-regulated in humans and experimental animals with T2D (144-145).
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Adiponectin knock out mice develop HF diet induced IR and hyperinsulimia, and
have elevated FFA and blood glucose (146-147).
Additionally, adipose tissue is now considered an endocrine organ that
can secrete several other bioactive molecules, such as leptin, resistin, IL-6, IL1ß, adipsin, metalloproteases, plasminogen activator inhibitor-1 (PAI-1), vascular
cell adhesion molecule-1 (VCAM-1) and angiotensinogen. While over 50
adipokines have been identified (148), it is probable that adipose tissue secretes
additional proteins that have not been identified yet. Taken as a whole, these
elements of adipose tissue constitute important factors in whole body energy
metabolism and insulin sensitivity.
1.1.3.4. Emerging evidence of a positive correlation between xenobiotic
AhR ligand exposure and the development of T2D: Agent Orange and
U.S. Vietnam veterans
Agent Orange is the code name for the herbicide used by the U.S. military during
the Vietnam War as part of its chemical warfare program known as Operation
Ranch Hand. Agent Orange that was extensively sprayed on Vietnam and parts
of Cambodia and Laos was later discovered to be contaminated with 2,3,7,8tetrachlorodibenzodioxin (TCDD). The purpose of Operation Ranch Hand was to
defoliate forested and agricultural land for two reasons; to deprive guerrilla
combatants of cover and to induce forced draft urbanization of Vietnam’s
agrarian population to further limit their aid to guerrillas (149).
Numerous studies have examined health effects linked to Agent Orange,
its component compounds, and its manufacturing byproducts (150). In 1969, it
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was revealed that Agent Orange was contaminated with TCDD and that this was
the likely cause of many of the previously unexplained negative health effects
which were correlated with exposure to the herbicide (151). Subsequently,
TCDD has been heavily studied. The National Toxicology Program has classified
TCDD as a known human carcinogen, associated with soft-tissue sarcoma, nonHodgkin's

lymphoma, Hodgkin's

lymphoma and chronic

lymphocytic

leukemia (152).
In 1991, the US Congress enacted the Agent Orange Act, giving
the Department of Veterans Affairs the authority to declare certain conditions
'presumptive' to exposure to Agent Orange, which meant veterans who served in
Vietnam were eligible to receive treatment and compensation for these
conditions (153). Through this process, the list of presumptive conditions has
grown to include: prostate cancer, respiratory cancers, multiple myeloma,
Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne and
notably, T2D.
U.S. Air Force veterans of the Vietnam war exposed to Agent Orange
contaminated with TCDD demonstrate increased risk of diabetes, reduced timeto-onset of disease, and increased diabetes severity (154). Moreover, Fujiyoshi
et.al. obtained adipose tissue samples from Agent Orange exposed veterans and
unexposed comparison veterans and found a reliable indicator of dioxininduced diabetes to be the ratio of mRNA of glucose transporter 4 (GLUT4) and
nuclear transcription factor kappa B (NFB) (155). This ratio demonstrated a
significant correlation to serum TCDD levels and fasting glucose among the
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Agent Orange exposed group. It is interesting to note that very low exposure
levels were detected in the Agent Orange group, in fact not much higher than
levels found in the general population, implying a need to address current
exposure levels linked to the development of diabetes. For further epidemiology
studies evaluating Agent Orange exposure and T2D risk, see Table 1.3.
1.1.3.5. Evidence of a positive correlation between PCB exposure and the
development of T2D: Anniston, AL Community
As diabetes incidence increases worldwide in tandem with increasing prevalence
of obesity and sedentary lifestyles, environmental factors are emerging as a
potentially important element of T2D risk. PCBs and dioxins are believed to play
a role in diabetes development, based on data from the National Health and
Nutrition Examination Survey (NHANES) (Lee 2006; Lee 2007) and studies from
the Slovak Republic (Langer 2002), Sweden (Lee 2011), Japan (Uemura 2008),
Taiwan (Wang 2008), and the United States (Codru 2007; Lee 2010; Lee 2011;
Vasiliu 2006)(see Tables 1.4 and 1.5 for summary of epidemiology studies
examining PCB/dioxin exposure and diabetes development); however the results
are not always consistent between studies and most focus on mixtures of POPs.
Additionally, commentaries (Jones et al. 2008; Porta 2006) have highlighted the
need for further research.
PCBs originating from the Monsanto Chemical Company in Anniston,
Alabama, leeched into Snow Creek, which then spread to the broader water
supply of northern Alabama. Today, the highest pollution levels remain
concentrated in Snow and Choccolocco Creeks (156). PCBs were manufactured
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at the Monsanto facility from 1929 to 1971. Residents of the Anniston community
exhibit some of the highest total body burdens of PCBs than any other location in
the world (157), making this unique population a focus of epidemiological study,
in particular because this population was exposed primarily to only PCBs (versus
exposure to POP mixtures in other studies). In a recent study by Silverstone
et.al., 774 residents of Anniston were given physical examinations and serum
PCBs were quantified to calculate the odds ratios to assess the relationship
between PCBs and diabetes (158). A statistically significant association of serum
PCB levels with increased diabetes prevalence was found in the population
overall, with women having a stronger association than men. Moreover, the most
highly exposed subjects who were more than 55 years old had an elevated risk
of diabetes. These findings are consistent with a recent publication by the
National Institutes of Environmental Health Sciences (NIEHS) Division of the
National Toxicology Program (NTP) which reviewed the bulk of epidemiology
studies examining the correlation between PCBs and diabetes and concluded
that there is a positive association between these two factors and that more
research is needed to understand underlying mechanisms (23)(see Tables 1.4
and 1.5 for summary of epidemiology studies examining dioxin and PCB
exposures, respectively, and diabetes development).
Most studies of PCB exposure in humans measure plasma or serum PCB
levels as an index of environmental PCB exposure and systemic PCB burden.
Efforts to associate PCB exposure with disease risk in many studies of this type
are often confounded by the broad range of human PCB exposures and the
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impact of statistically more powerful factors on overall disease risk. The
Silverstone study is significant for two reasons. First, that it identified PCB
exposure as a risk factor for development of T2D independent of other risk
factors (158). Second, the study gives clear ranges of serum PCB levels in
humans which are positively associated with the development of T2D. Subjects
were stratified by serum PCB levels and the adjusted odds ratio comparing the
prevalence of diabetes in the fifth versus first quintile of serum PCB levels was
2.78. In this study the fourth and fifth quintiles represented total serum PCB
levels (the sum of 35 PCB congeners) in the range of 4.34-170 parts per billion
(by weight). Assuming an average molecular weight of 325 and a serum density
of 1g/ml this represents serum PCB concentrations of 0.01-0.52 μM.
1.1.3.6. The role of PCBs in oxidative stress and inflammation
Coplanar PCBs exhibit their toxicity by binding to AhR and subsequently
increasing CYP1A1 gene expression. Coplanar PCBs can stimulate the
production of ROS by uncoupling the catalytic cycle during their metabolism by
CYP1A1 (159). Studies have shown that coplanar PCBs, including
PCB 77 and PCB 126, are proinflammatory in vascular endothelial cells and can
promote NF-B signaling (160-161). Arsenescu et.al. demonstrated that coplanar
PCBs, but not noncoplanar PCBs, can stimulate inflammatory adipokines in
adipose tissue (6). Besides stimulating an inflammatory response, PCBs can also
promote inflammatory conditions such as obesity and diabetes (6-7).
Many mechanisms and signaling pathways associated with inflammatory
diseases can be modulated by both diet and POPs. Several genes induced in
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insulin resistant tissues are sensitive to oxidative stress as an initiating stimulus,
suggesting that an imbalance in oxidative stress and/or ROS scavenging
mechanisms is a significant factor that may mediate effects. There is emerging
evidence to suggest that antioxidant nutrients might protect against exposure to
environmental pollutants via down-regulation of signaling pathways involved in
oxidative stress and inflammatory responses associated with diabetes (162).
1.1.4. PCBs and obesity
1.1.4.1 The pathophysiology of obesity
The World Health Organization classifies people as obese with a body mass
index (BMI) greater than 30 and overweight with a BMI of 25-29.9. Data from the
NHANES in 2009-2010 indicated that 35.7% of adults and approximately 17% of
children in the U.S. are obese (163). Obesity is an element of the metabolic
syndrome, a cluster of risk factors that substantially increase the risk for diabetes
development and includes increased waist circumference, blood pressure,
fasting blood glucose, triglycerides, and reduced HDL (164). Visceral obesity is a
primary factor of the metabolic syndrome and is independently associated with
each of the other factors (165).
Obesity is thought of as a problem representing an imbalance between
energy intake and expenditure, which can be influenced by any number of
genetic and environmental factors, including physical activity, regulation of
satiety, eating behaviors, hormonal imbalance, fetal programming, or exposure to
POPs. Regardless of cause, modifications in adipose tissue growth, function, and
remodeling dictate if an obese subject will develop obesity-associated disorders.
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In developing obesity, excessive caloric intake drives increases in adipocyte size.
Obesity is also correlated with increased macrophage infiltration into adipose
tissue (166) due to inappropriate adipose tissue remodeling to make room for
hypertrophied adipocytes (167). Chronic adipose tissue inflammation, in
combination with ectopic lipid deposition in other tissues, link obesity with other
elements of the metabolic syndrome to increase the risk of insulin resistance and
the subsequent development of diabetes (168).
1.1.4.2. Polychlorinated biphenyl-77 induces adipocyte differentiation and
proinflammatory adipokines and promotes obesity
Due to their lipophilicity, PCBs accumulate in adipose tissue and therefore the
total body burden of PCBs increases with obesity (7, 9, 169-170), but the effects
of PCBs on adipocytes, adipose tissue, obesity and diabetes are largely
undefined.
Arsenescu et.al. examined in vitro and in vivo effects of coplanar 3,3’,4,4’tetrachlorobiphenyl (PCB-77) on adipocyte differentiation, proinflammatory
adipokines, adipocyte morphology, and body weight. 3T3-L1 adipocytes were
incubated with PCB-77 either during adipocyte differentiation or in already
differentiated adipocytes. Low concentrations of PCB-77 increased adipocyte
differentiation and expression of peroxisome proliferator–activated receptor
gamma (PPAR), while higher concentrations inhibited adipocyte differentiation.
This result is consistent with adipose wasting effects and reduced preadipocyte
differentiation seen at high doses of TCDD in other published in vitro and in vivo
studies (171-173). PCB-77 promoted the expression and release of numerous
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proinflammatory cytokines from 3T3-L1 adipocytes, including TNF-α. In in vivo
studies, C57BL/6 wild-type (WT) or AhR deficient (AhR–/–) mice were treated
with vehicle or PCB-77 (49 mg/kg, by intraperitoneal injection) and body weights
were measured over a six week period. Administration of PCB-77 increased body
weight gain in WT but not AhR–/– mice. These findings suggest that PCB-77
may promote the development of obesity and obesity-associated diseases such
as T2D.
1.2 Resveratrol
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid, a natural polyphenol
commonly found in food stuffs such as red wine, grapes, peanuts, and chocolate,
albeit in very minute quantities (red wine contains approximately 0.1-14.3 mg/L
(174)). Resveratrol

can

also

be

chemically

(175) and

biotechnologically

synthesized (176-177), and is sold as a nutritional supplement. The effects of
resveratrol are currently a topic of numerous animal and human studies. In
animal studies, anticancer (178-181), anti-aging (182-183), anti-inflammatory
(184-186), anti-diabetic (182, 187-192), anti-obesity (187, 193-198) and
additional beneficial cardiovascular effects (199-211) of resveratrol have been
reported. Conversely, a limited number of human studies have reported generally
positive effects on measured outcomes, but certainly not the robust disease
ablation effects of resveratrol reported from animal studies. Very high doses (3–
5 g) of resveratrol used in one small positive human trial significantly
lowered blood glucose in T2D patients (212). A larger clinical trial which
administered 250 mg/d of resveratrol to sixty-two T2D diabetes patients for 3
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months also reported a significant reduction in fasting blood glucose and mean
hemoglobin A1C (213). Timmers et.al. reported that in eleven healthy but obese
men treated with 150 mg/d of resveratrol for 30 days fasting blood glucose was
reduced and HOMA index of insulin sensitivity improved (214). Conversely, a
recent study demonstrated that resveratrol had no effect on glucose homeostasis
in lean individuals (215), suggesting that resveratrol requires the presence of an
existing metabolic disturbance for efficacy in relation to glucose or insulin
tolerance. Due to some promising results and the easy availability of resveratrol,
research on beneficial effects of the compound are expanding. However, the
long-term effects of resveratrol supplementation in humans are not known (174).
1.2.1. General mechanism of action of resveratrol
Resveratrol’s effects to increase longevity appear to mimic the biochemical
effects of calorie restriction. Resveratrol has been shown to activate Sirtuin 1
(SIRT1) (216) and peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC-1α), which are thought to contribute to the compounds effects to
improve mitochondrial function (187). However, evidence is conflicting as other
studies have not link resveratrol to activation of SIRT1 and effects of calorie
restriction (217-219).
Resveratrol has been shown to interfere with the initiation, promotion, and
progression of certain cancers. In vitro experiments demonstrate that potential
mechanisms could include modulation of the transcription factor NF-κB (220)
and inhibition of CYP1A1 (221) (however this mechanism may not be pertinent to
CYP1A1-mediated bioactivation of POPs) (222).
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Resveratrol

also

possesses potent

antioxidant and

anti-

inflammatory properties (183, 223). Resveratrol has been shown to increase
intracellular glutathione in a nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
dependent manner via upregulation of gamma-glutamylcysteine ligase in lung
epithelial cells, which subsequently conferred protection against cigarette smoke
extract-induced oxidative stress (224). Additionally, a recently published study
showed that male C57BL/6 fed a HF diet supplemented with 0.4% resveratrol
had lower levels of TNF-α systemically and in adipose tissue (225).
Resveratrol can competitively inhibit key phosphodiesterases, resulting in
increased cyclic adenosine monophosphate (cAMP), a second messenger for the
activation of the pathway Epac1/CAMMKß/AMPK/SIRT1/PGC-1α. Rising cAMP
levels increase fatty acid oxidation, mitochondrial biogenesis, mitochondrial
respiration, and gluconeogenesis (226-227).
1.2.2. Resveratrol dosing in rodent and human studies
Approximately 70% of orally administered resveratrol is absorbed by humans;
however oral bioavailability is about 1% as a result of extensive hepatic
gluconuridation and sulfation (228). When subjects were administered a
substantial oral dose of resveratrol (2.5 and 5 g), blood resveratrol levels did not
reach the concentration believed to be essential for systemic cancer prevention
(229). A proprietary formulation of oral resveratrol, SRT-501 (3 or 5 g), resulted in
blood resveratrol levels which were five to eight times higher than those reported
by Walle et.al., which did mirror concentrations with demonstrated efficacy in
animal and in vitro experiments (212). However, in 2010 GlaxoSmithKline
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suspended a small clinical trial of SRT-501 being used as a treatment for patients
with multiple myeloma due to safety concerns, and ultimately terminated the
study later in the same year when several patients developed kidney failure
(230). It should be noted that it is not clear if the kidney failure resulted from
SRT-501 administration or from the underlying disease (the type of kidney failure
observed in this trial is a common complication of multiple myeloma) (231).
Bioavailability of resveratrol would seem to be dependent in some cases
on meal composition. In a pharmacokinetic study of oral resveratrol (2 g)
administered twice daily in humans, interactions of resveratrol during concurrent
ingestion of ethanol, quercetin, and high fat meals were examined (232). Mean
peak serum resveratrol levels were 1,274 ng/ml at steady-state, but this was
reduced by 46% when ingested with a high fat meal, although there was no effect
of concurrent oral administration of quercetin or ethanol. This study reported no
adverse health effects, but was limited by the small number of subjects (8) who
were observed in the two week study.
In humans and rats less than 5% of the oral dose has been reported as
the parent molecule resveratrol in blood (228, 233-236). The most abundant
resveratrol metabolites in humans, rats, and mice are trans-resveratrol-3-Oglucuronide and trans-resveratrol-3-sulfate (237). Walle et.al. hypothesized that
sulfate conjugates are the primary source of resveratrol bioactivity (228), Wang
et. al. suggest that it is the glucuronides (238), and Boocock et al. emphasize the
need for further research on the effects of resveratrol metabolites (233).
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Some have suggested that resveratrol from wine might have higher
bioavailability than resveratrol from supplements (234). However, this concept
has been refuted by several studies (239-240). Studies which have administered
moderate amounts of wine to human subjects have only detected trace amounts
of resveratrol in blood that are insufficient to explain the French paradox,
suggesting that the beneficial effects of wine might require the presence of
alcohol (239) or the complex of substances that wine contains (240).
1.2.3. Effects of resveratrol on glucose and insulin tolerance
Resveratrol has well documented anti-diabetic effects in rodents, which has
driven a number of clinical trials to utilize the compound as a therapy for
diabetes. Resveratrol has been demonstrated to lower blood glucose and lipids
in rats with streptozotocin (STZ)-induced diabetes as well as rats with STZnicotinamide-induced diabetes (189, 193). In numerous studies in rodents,
resveratrol demonstrates antidiabetic effects such as the abolishment of IR and
glucose intolerance (182, 187-193). A recent clinical study of T2D patients
treated with oral resveratrol supplements for three months reported significant
improvements in nearly all biomarkers associated with the disease (213).
However, evidence also suggests that resveratrol has no effect in lean
individuals (215), or that resveratrol improves adipose tissue glucose
homeostasis only under insulin resistant conditions (241). In general, resveratrol
has been shown to improve symptoms of T2D via three main mechanisms:
reduction of blood glucose, preservation of pancreatic ß cells, and improvement
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in insulin action. Studies indicate that the beneficial effects of resveratrol in
relation to T2D comprise all these mechanisms.
Maintenance of blood glucose in the physiological range is pivotal for the
treatment

of

T2D,

because

hyperglycemia

causes

numerous

diabetic

complications (242). Thus, treatment with hypoglycemic drugs (metformin or αglucosidase inhibitors) are administered in clinical practice to lower blood
glucose, but these drugs are not without unfavorable side effects (243).
Resveratrol has been well documented to lower hyperglycemia in humans and
animals, with apparently limited side effects. The blood glucose lowering action
of resveratrol has been demonstrated in obese rodents (244) and in two animal
models of diabetes: in rats with streptozotocin-induced diabetes or streptozotocin
nicotinamide-induced diabetes (189, 192-193, 245-247). Administration of
resveratrol to diabetic rats lowered levels of glycosylated hemoglobin (HbA1C),
which suggests the prolonged reduction of glycemia (189, 248). The blood
glucose lowering effect of resveratrol seen in diabetic animals is believed to stem
from a stimulatory action on intracellular glucose transport. Interestingly, in
experiments on isolated hepatocytes, adipocytes, and skeletal muscle from
diabetic rats, resveratrol stimulated glucose uptake in the absence of insulin
(193). Enhanced glucose uptake induced by resveratrol appears to occur due to
increased activity of glucose transporters in the plasma membrane. Studies of
rats with experimentally induced diabetes administered resveratrol showed
increased expression of the insulin-dependent glucose transporter (GLUT4)
compared to controls (192, 249).
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Development of T2D is a prolonged process, usually accompanied by
insulin resistance. Initially, blood glucose is maintained in the physiological range
because

of

the

compensatory

increase

in

insulin

secretion.

Chronic

overstimulation of pancreatic ß cells exhausts and degrades these cells,
diminishing insulin secretion over time (250). Resveratrol appears to modulate
blood insulin concentrations in rodents. Resveratrol effectively reduced blood
insulin in animal models of hyperinsulinemia; in mice on a high-fat diet (182, 187,
251-252), in rats on a high cholesterol-fructose diet (188), and in obese Zucker
rats (253). In vitro, resveratrol reduced insulin secretion by isolated rat pancreatic
islets (254-256). The inhibition of insulin secretion caused by resveratrol was
shown to result from metabolic changes in pancreatic ß cells. During
physiological conditions, glucose-induced insulin secretion from ß cells is
predicated on the following series of events: intracellular transport of glucose and
its oxidative metabolism, hyperpolarisation of the inner mitochondrial membrane,
increased ATP synthesis, closure of ATP-sensitive potassium channels,
depolarization of the plasma membrane, opening of voltage-sensitive calcium
channels, and the rise in cytosolic calcium ions.The increase in cytosolic calcium
ions triggers secretion of insulin (93). In this sequence leading to increased
secretion of insulin, resveratrol has been shown to act on ATP formation.
Pancreatic islets treated with resveratrol released more lactate, and glucose
oxidation was decreased compared to controls (255). It should be noted that the
inhibition of insulin secretion by resveratrol was apparently reversible and was
not due to permanent changes in pancreatic ß cells (254-255). Because chronic
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overstimulation of ß cells is known to stimulate their degradation, inhibition of
insulin secretion by resveratrol might attenuate these effects.
Resveratrol may also protect the endocrine pancreas via other
mechanisms. In vitro, exposure of isolated rat pancreatic islets to cytokines
resulted in increased DNA binding of NF-B, increased production of NO, and
expression of iNOS, with all effects being suppressed by resveratrol (257). The
protective effect of resveratrol against cytokine-induced dysfunction of ß cells is
due in part to the ability of resveratrol to activate NAD+ dependent protein
deacetylase SIRT1 (257).
Resveratrol may also protect against T2D via antioxidant activity.
Pancreatic ß cells are known to be uniquely sensitive to the oxidative damage
(258-259). In a recent study of diabetic rats, the levels of lipid peroxides and
protein carbonyls in the pancreatic tissue were significantly increased compared
with non-diabetic animals, indicative of oxidative damage; inversely, the activity
of enzymes involved in radical scavenging was significantly reduced (260).
Administration of resveratrol abolished the oxidative damage and increased the
activities of antioxidant responsive enzymes (248).
T2D is typically accompanied by insulin resistance, defined as the
impaired action of insulin on target cells, mainly adipocytes, hepatocytes, and
skeletal muscle cells. IR develops primarily in overweight or obese individuals
with T2D (261), and decreased adiposity improves insulin action (262). Calorie
restriction and exercise are clinical recommendations to improve insulin
sensitivity in T2D. Numerous animal studies have demonstrated that resveratrol
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improves insulin action during diet-induced T2D symptoms, likely by acting as a
calorie restriction or exercise mimetic (182, 187, 194, 251, 253).
The improvement in insulin action caused by resveratrol may stem from a
variety of effects, including reduced adiposity. High doses of resveratrol reduce
body weight / fat mass in rodents on a HF diet (187, 194-198), with effects which
are similar to those induced by calorie restriction (183, 263). Consistent with
rodent studies, in vitro experiments demonstrated decreased ATP content (264)
and reduced accumulation of triglycerides in isolated rat adipocytes treated with
resveratrol (265). Moreover, resveratrol increased lipolytic response to
epinephrine and decreased lipogenesis (266), results that are suggestive as to
how resveratrol may contribute to reduced adiposity in rodents. Kennedy et.al.
utilized human adipocytes to demonstrate that resveratrol abolished linoleic acidinduced

insulin

resistance

(267).

Furthermore,

resveratrol

suppressed

inflammatory cytokines induced by linoleic acid. Potential mechanisms of the
protective effects of resveratrol on human adipocytes include the attenuation of
oxidative stress, prevention of activation of extracellular signal-related kinase,
inhibition of inflammatory gene expression, and increase in peroxisome
proliferator-activated receptor  (PPAR-) activity (267).
Resveratrol-induced improvement in insulin action has also been
attributed to the activation of SIRT1 and 5’-AMP-activated protein kinase (AMPK)
(182, 187, 195-196, 257). In AMPK-deficient mice fed a high-fat diet, resveratrol
had no effect and neither reduced body fat nor improved insulin action (194).
However, contrary findings have been reported by Pacholec et al., which
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demonstrated that resveratrol is not a direct activator of SIRT1, which would
suggest that the role of SIRT1 in the mechanism of resveratrol action should be
reconsidered. While the exact mechanism of resveratrol action is still poorly
understood, there is ample evidence that this compound is able to improve
insulin action in a variety of animal models of insulin resistance.
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Figure 1.1 Chemical Structure of PCBs

Figure 1.2 AhR Signaling Pathway
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Figure 1.3 Protein functional domains of AhR

Compound

WHO TEF

2,3,7,8‐TCDD

1

3,3',4,4'‐tetraCB (PCB‐77)

0.0001

3,3',4,4',5‐pentaCB (PCB‐126)

0.1

Table 1.1 World Health Organization TEF values of TCDD and selected
PCBs

Synthetic

Naturally Occuring

2,3,7,8‐TCDD

Derivatives of tryptophan

Coplanar PCBs

Lipoxin A4

Polychlorinated dibenzofurans

Bilirubin

Benzo (a) pyrene

Prostaglandin G2

Benzoflavones

Curcumin

Benzanthracenes

Modified low‐density lipoprotein

Table 1.2 Synthetic and naturally occuring AhR ligands
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Publication

Population

ADVA 2005b

Vietnam veterans

ADVA 2005a

Diagnosis

Exposure

Vietnam veterans

Diabetes (death
certificate)
Diabetes (death
certificate)

Agent Orange

AFHS 2005

Vietnam veterans

Diabetes (verified
history)

Agent Orange

CDC 1988

Vietnam veterans

Diabetes (self report)

Vietnam service

Fujiyoshi 2006

Vietnam veterans

Diabetes (physican
diagnosed)

TCDD

Henriksen 1997

Vietnam veterans

Diabetes (physican
diagnosed)

TCDD

Kang 2006

Vietnam veterans

Kim 2003

Vietnam service

Vietnam veterans

Diabetes (self report)
Diabetes (clinical
exam)

Vietnam service
Agent Orange

Kern 2004

Vietnam veterans

Insulin sensitivity
(ivGTT,QUICKI)

TCDD

Longnecker 2000

Vietnam veterans

Diabetes (self report)

TCDD

Michalek 2003

Vietnam veterans

Diabetes (physican
diagnosed)

TCDD

Michalek 2008

Vietnam veterans

Diabetes (physican
diagnosed)

TCDD

Steenland 2001

Vietnam veterans

Diabetes (physican
diagnosed)

TCDD

Risk Estimate
SMR = 0.52 (Vietnam veterans vs.
general population)
SMR = 0.3 (deployed vs. nondeployed)
RR = 1.3 (within Ranch Hand
veterans, adjusted for prior TCDD
measurements)
adjOR = 1.2 (deployed vs. nondeployed)
r = 0.07, p = 0.40 (Operation Ranch
Hand veterans vs. non-Ranch Hand
veterans)
RR = 1.5 (time to develop diabetes
decreased with high TCDD
exposure)
OR = 1.50 (sprayed herbicides in
Vietnam vs. never)
OR = 2.69 (Vietnam veterans vs.
non-veterans)
ß = -0.00639, p = 0.02 (w/in pair
differences for lower insulin
sensitivity in Operation Ranch Hand
veterans)
adjOR = 1.56 (4th quartile of TCDD
exposure, Operation Ranch Hand
veterans vs. non-Ranch Hand
veterans)
no relationship after adjustment for
covariates (diabetic Operation Ranch
Hand veterans vs. non-diabetic
Ranch Hand veterans)
RR = 1.21, p = 0.16 (Operation
Ranch Hand veterans vs. non-Ranch
Hand veterans)
OR = 1.18, (TCDD exposed
Operation Ranch Hand veterans vs.
non-exposed Ranch Hand veterans)

SMR = standardized mortality ratio
RR = relative risk
adjOR = adjusted odds ratio
Table 1.3 Summary of studies investigating the correlation between Agent
Orange/TCDD exposure in Vietnam veterans and the development of type 2
diabetes.
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Publication
Bertazzi 2001

Population
Residents of Seveso
during 1976 incident

Calvert 1999

Workers employed at
plants in NJ and MO

Diagnosis
Diabetes (death
certificate)
Diabetes
(physician
diagnosis)
Non-diabetics w/
metabolic
syndrome
Diabetes
(physician
diagnosis)

Exposure
TCDD
TCDD

Risk Estimates
RR = 1.7 (males), RR = 0.8 (females)
(cause of death vs. reference population)
adjOR = 1.97 (4th quartile of TCDD
exposure vs. unexposed workers)
adjOR = 1.7 (insulin resistance in lowest
3 quartiles vs. 4th quartile of TCDD
exposure)
adjOR = 2.44 (PCDD/PCDF
concentration and diabetes vs. nondiabetics)
no significant correlations with serum
insulin or QUICKI results in adjusted
models

Collins 2009

Residents living near
dioxin factory
Recidents living near
municipal waste
incinerators in Tiawan
Non-diabetic pregnant
women living near
incinerators in Tiawan
Plant workers w/
occupational
exposure vs. US
population

Consonni
2008

Residents of Seveso
during 1976 incident

Cranmer 2000

Residents living near
AK Superfund site

Diabetes (death
certificate)
Fasting insulin
and glucose;
OGTT

Fierens 2003

Residents living near
Belgium industrial
sites vs. rural areas

Diabetes (self
report)

Lee 2007

Adults from NHANES
1999 - 2002

Insulin sensitivity
(HOMA)

dioxins,
PCBs
PCDDs,
PCDFs,
coplanar
PCBs,
noncoplanar
PCBs, OC
pesticides

Residents of Seveso
during 1976 incident
Workers from 12 US
plants that produced
TCDD-contaminated
products
Workers from NJ and
MO plants that
produced TCDDcontaminated
products
Finnish fishermen and
fishermen's wives
General population of
Japan from urban,
agrarian, and fishing
areas
Research on Cancer
International (IARC)
study of herbicide
production workers

Diabetes (death
certificate)

TCDD

adjOR = 2.3 (PCDD), 1.4 (coplanar
PCBs), 2.3 (noncoplanar PCBs) (highest
percentile vs. lowest percentile)
RR = 1.1 (males, Zone R), 1.2 (females,
Zone R) (Zone R vs. population of
Lombardy region)

TCDD

SMR = 1.08 (diabetes, multiple causes
and beyond) (total cohort industrial
cohorts vs. US population)

Chang 2010
Chen 2006
Chen 2008

Pesatori 1998
Steenland
1999

Sweeney 1997
Turunen 2008

Uemura 2008

Vena 1998

dioxins

Non-diabetics

PCDDs,
PCDFs
PCDDs,
PCDFs,
PCBs

Diabetes (death
certificate)

TCDD

Diabetes (death
certificate)

Diabetes (medical
exam)
Diabetes (death
certificate)

TCDD
TCDD

SMR = 1.1 (workers vs. US population)
RR = 1.03 (Zone A), 1.32 (Zone B), 1.26
(Zone R) (reference territory vs. Zones A,
B, and R)
adjOR = 8.5 (high fasting insulin for
highest exposure percentile vs. lowest
exposure percentile)
adjOR = 5.07 (17 dioxins or PCDD/Fs),
13.3 (4 coplanar PCBs [77, 81, 126,
169]), 7.58 (12 other PCBs [3, 8, 28, 52,
101, 118, 138, 153, 180, 194, 206, 209])
(highest percentile for dioxin vs. all other
percentiles)

OR = 1.12 (workers [mean 220 pg/g lipid]
vs. referents [mean 7 pg/g lipid])

Diabetes (self
report)

TCDD
dioxins,
PCBs
7 PCDDs,
10 PCDFs,
12 coplanar
PCBs

SMR = 0.43 (males), 0.83 (females)
adjOR = 2.21 (highest tertile for
PCDDs+PCDFs), 6.82 (highest tertile for
coplanar PCBs), 3.81 (highest tertile for
total dioxins)

Diabetes (death
certificate)

TCDD

RR = 2.25 (Poisson regression analysis
of diabetes mortality)

Table 1.4 Summary of studies investigating the correlation between dioxin
exposure and the development of type 2 diabetes.
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Publication
Chen 2008
Codru 2007
Everett 2007

Fierens 2003
Jorgensen
2008

Langer 2002
Langer 2009
Lee 2006
Lee 2007
Lee 2010
Mullerova
2008
Patel 2010
RignellHydbom
2009
RignellHydbom
2007
Rylander
2005
Turunen
2008
Turyk 2009a
Turyk 2009b

Uemura 2008
Vasiliu 2006
Wang 2008

Population
Non-diabetic
pregnant women
Mohawks from
Akwesasne River
for > 5 years
NHANES 1999 –
2002 (adults)
Belgians living
near industrial
sites vs. rural
areas
Greenlanders
from three areas
of West
Greenland
Workers from a
PCB factory vs.
residents of rural
East Slovakia
Adults from
industrial areas of
Slovakia
Adults from
NHANES 1999 2002
Adults from
NHANES 1999 2002
Young Adults
CARDIA cohort
Obese women vs.
non-obese
women
NHANES 1999 2006 (total of four
cohorts)
Fisherman's wives
from the Swedish
east and west
coasts
Participants of
WHILA diagnosed
w/ T2D
Swedish
fisherman and
fisherman's wives
Finnish fishermen
Participants of
GLCHA
Participants of
GLCHA
Japanese from
urban, agrarian,
and fishing areas
Adults in the
Michigan PBB
cohort
Yucheng cohort
study

Diagnosis
Non-diabetics
Diabetes (use
of diabetes
medication)
Diabetes (self
report)
Diabetes (self
report)
Diabetes
(OGTT or FBG;
IR by HOMA)
Anti-GAD
antibody serum
levels > 1.21
U/mL
glucose,
insulin, lipids,
BMI
Diabetes (self
report)
Insulin
sensitivity
(HOMA)
Diabetes (use
of diabetes
medication)
HOMA index;
fasting glucose
and insulin

Exposure
PCDDs, PCDFs,
PCBs
PCBs, PCB-153,
PCB-74, DDE,
mirex, HCB
PCB-126, p,p'DDT, HxCDD

dioxins, PCBs
Coplanar (3) and
noncoplanar (10)
PCBs, 11 OC
pesticides

PCBs
PCBs

40.4% vs. 10.5% (frequency of anti-GAD
antibodies in exposed workers vs.
unexposed rural dwellers)
chi-square = 110.55, p < 0.0001 (increased
FG), 11.89, p = 0.0182 (increased fasting
insulin)

55 POPs

adjOR = 6.8 (PCB-153) (diabetes in highest
percentile vs. non detectable)
adjOR = 2.3 (PCDD), 1.4 (coplanar PCBs),
2.3 (noncoplanar PCBs) (highest percentile
vs. lowest percentile)
OR = 2.8 (PCB-74), 2.0 (PCB-153), 2.2
(PCB-170), 2.8 (PCB-180) (2nd quartile vs.
1st quartile of incident diabetes)

Diabetes (FG >
126 mg/dL)

PCB-153
heptachlor
epoxide, PCB170

no correlation between PCB-153 and study
group (p > 0.05)
OR for PCB-170 = 2.3, p = 0.02 (1999-2000
cohort), 4.5, p = 0.01 (2003-2004 cohort),
2.2, p < 0.001 (1999-2004, 3 cohorts)

Diabetes (self
report)

PCB-153, p,p'DDE

OR = 1.4 (PCB-153) (PCB-153 per 100
ng/g lipid increase in serum level)

Diabetes
(OGTT)

PCB-153, p,p'DDE

Diabetes (self
report)
Diabetes (death
certificate)
Diabetes (self
report)
Diabetes (self
report)

PCB-153, p,p'DDE

OR = 1.6 (PCB-153) (> 7 years after
baseline)
OR = 1.20 (men, PCB-153), 1.06 (women,
PCB-153) (PCB-153 per 100 ng/g lipid
increase in serum level)

dioxins, PCBs

SMR = 0.43 (males), 0.83 (females)

DDE, total PCBs

PBBs, PCBs

RR = 1.8 (total PCBs)
OR = 1.9 (highest quartile for total PCBs),
2.1 (highest tertile for total coplanar PCBs)
adjOR = 2.21 (highest tertile for
PCDDs+PCDFs), 6.82 (highest tertile for
coplanar PCBs), 3.81 (highest tertile for
total dioxins)
Incidence density ratio = 1.74 (males,
highest PCB quartile), 2.33 (females,
highest PCB quartile)

PCBs

OR = 1.7 (males), 5.5 (females)

Diabetes (self
report)
Diabetes (self
report)
Diabetes (self
report)

PCB-153, DDE,
HpCDD
PCDDs, PCDFs,
PCBs, OC
pesticides

Risk Estimates
no significant correlations with serum insulin
or QUICKI results in adjusted models
OR = 3.2 (total PCBs), 2.4 (PCB-153), 4.5
(PCB-74) (Diabetes, highest tertile vs.
lowest tertile)
adjOR = 1.67 (PCB-126) (total diagnosed
and undiagnosed diabetes)
adjOR = 5.07 (17 dioxins or PCDD/Fs), 13.3
(4 coplanar PCBs [77, 81, 126, 169]), 7.58
(12 other PCBs [3, 8, 28, 52, 101, 118, 138,
153, 180, 194, 206, 209])
adjOR = 1.2 (coplanar PCBs [105, 118,
156]), 1.2 (noncoplanar PCBs [28, 52, 99,
101, 128, 138, 153, 163, 170, 180]) (1st
[referent] vs. 4th quartile)

DDE, total PCBs
7 PCDDs, 10
PCDFs, 12
coplanar PCBs

Table 1.5 Summary of studies investigating the correlation between PCB
exposure and the development of type 2 diabetes.
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STATEMENT OF THE PROBLEM
Emerging evidence supports a link between exposures to polychlorinated
biphenyls (PCBs) and the development of type 2 diabetes (T2D).
mechanisms for this link are unclear.

However,

Because of their lipophilicity, PCBs

accumulate markedly in adipose lipids. Thus, obesity increases the body burden
of PCBs.

Notably, studies have demonstrated that weight loss results in

redistribution of PCBs to the systemic circulation, and this redistribution is
associated with adverse health effects.

However, it is unclear if release of

greater quantities of PCBs stored in adipose tissue of obese subjects following
weight loss adversely influences the control of glucose homeostasis. Moreover,
it is unclear if therapeutic strategies can be developed to mitigate harmful effects
of liberated PCBs on glucose homeostasis.
Previous studies in our laboratory demonstrated that coplanar PCBs that
are ligands of the aryl hydrocarbon receptor (AhR) promote the expression and
release of proinflammatory cytokines from cultured adipocytes. Tumor necrosis
factor-α (TNF-α), an inflammatory cytokine known to exert several effects that
impair insulin sensitivity, was increased by PCB-77 in 3T3-L1 adipocytes.
However, mechanisms for PCB-induced increases in inflammatory cytokine
expression in adipocytes and the pathophysiologic consequences of this effect
on glucose homeostasis are unknown.
The purpose of this study was to determine mechanisms linking coplanar PCB
exposures to the development of T2D. We initially defined effects of coplanar
PCBs (dose-dependency, sustainability) on measures of glucose homeostasis in
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lean mice. To determine potential sites for PCB-induced impairment of glucose
homeostasis, we quantified effects of PCBs on TNF-α expression in adipose
tissue, liver and muscle, tissues that are major sites of insulin-mediated glucose
uptake. Since obesity is a well known contributor to the development of T2D, we
defined effects of a coplanar PCB on measures of glucose homeostasis during
the weight gain phase in mice with diet-induced obesity. Moreover, we examined
effects of PCBs administered during the weight gain phase of obesity on glucose
homeostasis during weight loss.

We hypothesized that release of increased

body burdens of PCBs in obese mice experiencing weight loss would impair
glucose homeostasis. To determine if effects of coplanar PCBs to impair glucose
homeostasis were adipose-specific and AhR-mediated, we examined effects of
PCBs on glucose homeostasis in lean and obese mice (during the weight gain
and weight loss phase) lacking AhR specifically in adipocytes. Finally, we used
supplemental doses of resveratrol as a therapeutic entity to prevent PCB-induced
impairment of glucose homeostasis in lean mice. We also defined mechanisms
of resveratrol to protect against PCB-induced oxidative stress, impairment of
glucose uptake and disruptions in insulin signaling. We focused on stimulation of
anti-oxidant pathways by resveratrol.

The overall hypothesis of this dissertation is that coplanar PCBs act at adipocyte
AhR to impair insulin signaling and glucose uptake and that resveratrol protects
against PCB-induced impairment of glucose homeostasis. The following specific
aims were designed to test this hypothesis:

42

Specific Aim 1: Define effects of coplanar PCBs (PCB-77, PCB-126) on glucose
homeostasis in lean versus obese C57BL/6 mice.
A. Define effects (dose-dependency, sustainability) of PCB-77 on glucose
homeostasis in lean mice.
B. Define effects of PCB-77 on glucose homeostasis in mice during the weight
gain versus weight loss phases of diet-induced obesity.
C. Define mechanisms for PCB-induced impairment of glucose homeostasis in
3T3-L1 adipocytes.
Specific Aim 2: Determine if dietary administration of resveratrol is an effective
nutritional therapy against PCB-77 induced diabetes in lean C57BL/6 mice.
A. Determine the effect of resveratrol supplementation in mice with acute PCB77 exposure.
B. Determine the effect of resveratrol on oxidative stress and glucose uptake in
3T3-L1 adipocytes exposed to PCB-77.
Specific Aim 3: Determine the role of the adipocyte AhR on the development of
PCB-77 induced diabetes.
A. Determine the effect of adipocyte-AhR deficiency on parameters of glucose
and insulin tolerance in lean versus obese (with and without weight loss) mice
administered vehicle or PCB-77.
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SECTION II. SPECIFIC AIM 1
2.1 Summary
Previous studies demonstrated that coplanar polychlorinated biphenyls
(PCBs) promote proinflammatory gene expression in adipocytes. PCBs are
highly lipophilic and accumulate in adipose tissue, a site of insulin resistance in
persons with type 2 diabetes. We investigated the in vitro and in vivo effects of
coplanar PCBs on adipose expression of tumor necrosis factor α (TNF-α) and on
glucose and insulin homeostasis in lean and obese mice.
We quantified glucose and insulin tolerance, as well as TNF-α levels, in
liver, muscle, and adipose tissue of male C57BL/6 mice administered vehicle,
PCB-77, or PCB-126 and fed a low fat (LF) diet. Another group of mice
administered vehicle or PCB-77 were fed a high fat (HF) diet for 12 weeks; the
diet was then switched from HF to LF for 4 weeks to induce weight loss. We
quantified glucose and insulin tolerance and adipose TNF-α expression in these
mice. In addition, we used in vitro and in vivo studies to quantify aryl hydrocarbon
receptor (AhR)-dependent effects of PCB-77 on parameters of glucose
homeostasis.
Treatment with coplanar PCBs resulted in sustained impairment of
glucose and insulin tolerance in mice fed the LF diet. In PCB-77–treated mice,
TNF-α expression was increased in adipose tissue but not in liver or muscle.
PCB-77 levels were strikingly higher in adipose tissue than in liver or serum.
Antagonism of AhR abolished both in vitro and in vivo effects of PCB-77. In

44

obese mice, PCB-77 had no effect on glucose homeostasis, but glucose
homeostasis was impaired after weight loss.
Coplanar PCBs impaired glucose homeostasis in lean mice and in obese
mice following weight loss. Adipose-specific elevations in TNF-α expression by
PCBs may contribute to impaired glucose homeostasis.
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2.2 Introduction
Type 2 diabetes (T2D) affects 300 million people, and diabetes prevalence
is anticipated to double world-wide over the next 20 years (90). Recent
epidemiological studies suggested that exposure to low concentrations of
polychlorinated biphenyls (PCBs) similar to current exposure levels in humans
increases diabetes risk (268). Multiple cross-sectional analyses of National
Health and Nutrition Examination Survey (NHANES) cohorts from 1999–2006
found concentrations of PCB-170 in urine or blood with an adjusted odds ratio of
4.5 for T2D, predicting up to 15% risk (269). Remarkably, this increased risk
appeared in individuals who were not overweight or obese (270). Similar
observations linking PCB exposures to T2D have been reported in other
populations (271-272). Recently, a significant association between elevated PCB
levels and diabetes was found in the Anniston Community Health Survey (158).
Collectively, accumulating evidence supports a link between PCB exposure
levels and the development of diabetes, but mechanisms linking PCBs to
diabetes are largely unknown.
Because of their lipophilicity, PCBs accumulate in lipid stores of adipose
tissue (8), suggesting that adipocytes experience continuous low-grade exposures to PCBs. Extension of these findings to the setting of obesity suggests that
the total body burden of PCBs would increase in obese subjects because of the
inherent lipophilicity of these compounds. Recent studies demonstrated an
inverse relationship between serum levels of several PCBs and body mass
index, suggesting that sequestration of PCBs in adipose tissue is enhanced by
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obesity (273). It is unclear whether this enhanced sequestration limits effects of
PCBs systemically. Given the epidemic of obesity and T2D in the United States,
a large percentage of the population strives to lose weight. Weight loss, through
dietary restriction or increased physical activity, typically reduces adipose tissue
mass through liberation of lipid stores (274). Lim et al. (275) reported that plasma
concentrations of organochlorines were increased and significantly correlated to
reductions in body mass index in obese subjects undergoing a weight-loss
program. Further, Pelletier et al. (276) found that plasma concentrations of 13 of
17 organochlorines in serum increased in obese subjects experiencing weight
loss. The consequences of increased liberation of PCBs following weight loss in
obese subjects with T2D are unknown.
Previous studies in our laboratory demonstrated that low concentrations of
coplanar PCB-77 (3,3´,4,4´-tetrachlorobiphenyl), a ligand of the aryl hydrocarbon
receptor (AhR), promoted adipocyte differentiation and the production of
proinflammatory

adipokines

(6).

Recent

studies

showed

that

PCB-126

(3,3´,4,4´,5-pentachlorobiphenyl), a coplanar AhR ligand, promoted inflammatory
gene expression in human preadipocytes and adipocytes, and also increased
inflammatory gene expression in adipose tissue from wild-type, but not AhRdeficient, mice (277). Among several inflammatory cytokines stimulated by
coplanar PCBs in adipocytes (6, 277), tumor necrosis α (TNF-α) is a recognized
contributor to insulin resistance (278-279). TNF-α promotes insulin resistance
through downstream alternative phosphorylation of the insulin receptor (IR)
docking protein, insulin receptor substrate-1 (IRS-1) (280), which prevents
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phosphorylation of protein kinase B (Akt) (281) and impairs transport of glucose
transporter type 4 vesicles in skeletal muscle and adipose tissue to the plasma
membrane (282). TNF-α can indirectly contribute to adipocyte insulin resistance
by promoting lipolysis (283) and/or by inhibiting differentiation (284).
In the present study, we defined dose-dependent effects of coplanar PCBs
on glucose homeostasis in lean mice. To define mechanisms for PCB-induced
impairment of glucose and insulin tolerance, we quantified expression levels of
TNF-α in organs contributing to insulin resistance. Moreover, we defined the
sustainability of PCB-induced impairment of glucose homeostasis in lean mice in
reference to organ and serum concentrations of PCBs. To delineate the role of
AhR in effects of PCBs, we examined in vitro and in vivo effects of an AhR
antagonist on parameters of glucose homeostasis. Because T2D is frequently
associated with obesity, we examined effects of a coplanar PCB on glucose
homeostasis in obese mice. In addition, because PCBs redistribute from adipose
tissue to the circulation during weight loss, we determined effects of previous
PCB exposures on glucose homeostasis in obese mice experiencing weight loss.
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2.3 Materials and Methods
2.3.1 Chemicals
We purchased PCB-77 and PCB-126 from AccuStandard Inc. (New
Haven, CT). 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl-amide; CH-223191) was a generous gift from H. Swanson (University of
Kentucky, Lexington, KY).
2.3.2 Animal treatments and sample collection
All experimental procedures met the approval of the Animal Care and Use
Committee of the University of Kentucky. We treated animals humanely and with
regard for alleviation of suffering. Male C57BL/6 mice (2 months of age; The
Jackson Laboratory, Bar Harbor, ME) were given ad libitum access to food and
water and housed in a pathogen-free environment. Initial studies examined
glucose and insulin tolerance in mice administered vehicle (tocopherol-stripped
safflower oil), PCB-77 (2.5, 50, or 248 mg/kg; by oral gavage given as two
separate doses over 2 weeks; n = 10 mice/group), or PCB-126 (0.3, 1.6, or 3.3
mg/kg once by oral gavage; n = 10 mice/group). Mice in dose–response studies
were fed a low fat diet (LF; 10% kcal as fat; Research Diets Inc., New Brunswick,
NJ).
To define the sustainability of PCB effects, we performed temporal studies
in mice fed a LF diet. Mice were administered vehicle or PCB-77 (50 mg/kg by
oral gavage) once in week 1 and once in week 2. For mice examined at later time
points (12 weeks), a second set of treatment by oral gavages was administered
in weeks 9 and 10. Mice in each treatment group (vehicle or PCB-77) were
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examined at weeks 2, 4, or 12 after onset of feeding with LF diet. Body weights
were quantified weekly in all studies. At the study end point, mice were
anesthetized (ketamine/xylazine, 10/100 mg/kg, by intraperitoneal (ip) injection]
for exsanguination and tissue harvest (liver, soleus muscle, and visceral
adipose). A subset of mice (n = 5/group) in each treatment group were
administered insulin [10 U/kg (285)] 10 min before exsanguination to elicit insulin
signaling pathways.
For studies examining obesity and weight loss, male C57BL/6 mice (2
months of age; n = 10/group) were fed a high fat diet (HF; 60% kcal as fat;
Research Diets Inc.) for 12 weeks and administered vehicle or PCB-77 (50
mg/kg by oral gavage) at weeks 1, 2, 9, and 10. Body weight was quantified
weekly. At 12 weeks of HF feeding, a subset of mice (n = 3/group) was
anesthetized for exsanguination and tissue harvest. The remaining mice in each
treatment group were then fed the LF diet for 4 weeks to induce weight loss.
To determine whether in vivo effects were AhR-mediated, we fed male
C57BL/6 mice (2 months of age; n = 7/group) the LF diet and orally gavaged
them with vehicle or CH-223191 daily (10 mg/kg/day) (286-287) starting 1 week
before administration of vehicle or PCB-77 and through the remainder of the
study. After 1 week of pretreatment with CH-233191, mice were administered
vehicle or PCB-77 (50 mg/kg by oral gavage, given as two separate doses in
weeks 1 and 2). Within 48 hr after the last dose of vehicle/PCB-77, we performed
glucose and insulin tolerance tests.
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2.3.3 Glucose tolerance tests (GTT) and insulin tolerance tests (ITT)
Mice were fasted for 6 hr or 4 hr prior to quantification of GTT or ITT,
respectively. Blood collected from the tail vein was tested for glucose
concentration using a handheld glucometer (Freedom Freestyle Lite; Abbott
Laboratories, Abbott Park, IL). Mice were injected with d-glucose (20% in saline,
ip) or human insulin (Novolin, 0.0125 μM/g body weight, ip) and blood glucose
was quantified at 0–120 min. Total area under the curve (AUC; arbitrary units),
which is obtained without the presence of a baseline, calculates the area below
the observed concentrations and, in comparison studies, was reported to
compare favorably to the positive incremental area method for statistical
analyses of glucose tolerance data (288).
2.3.4 Quantification of PCBs
Frozen tissue samples (epididymal adipose tissue, liver, and skeletal
muscle) or mouse sera were spiked with surrogate standards (100 μL of 0.35
ng/μL PCB-166 in isooctane). After the addition of 1.0 g of diatomaceous earth,
the mixture was grained into fine powders and transferred into an extraction cell
filled with Ottawa Sands (Thermo Fisher Scientific, Pittsburgh, PA). Extraction
with hexane (30 mL) was performed using an ASE 200 accelerated solvent
extractor (Dionex Corporation, Sunnyvale, CA). Lipids were removed by the
addition of an equal volume of concentrated sulfuric acid. For adipose samples
containing high lipid content, hexane extracts were subjected to delipidation by
passing them over a Florisil SPE column, according to the manufacturer’s
instructions, before acid treatment. The hexane layer containing PCBs was
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collected and concentrated to 2 mL using a Heidolph Synthesis1 evaporator
(Heidolph, Schwabach, Germany) and then to 100 μL using a gentle stream of
nitrogen. Then, 10 μL of of internal standard PCB-209 (1.0 ng/μL) was added.
Gas chromatographic analysis was performed with a gas chromatography
(GC)–mass spectrometry (MS) system (Agilent 6890N GC, G2913A auto
sampler, and 5975 MS detector; Agilent Technologies, Santa Clara, CA) using an
HP-5MS 5% phenyl methyl siloxane column (30 m length, 0.25 mm internal
diameter, 0.25 μm film thickness). The column temperature was held at 60°C for
1 min, increased to 200°C at a rate of 40°C/min, followed by a rate of 4°C/min to
280°C, and then held for 5.5 min. The injector temperature was 250°C. The
carrier gas was ultrapure helium, and the makeup gas was nitrogen. PCBs were
identified on the basis of their retention times relative to standards. Quantification
was achieved based on calibration curves obtained using PCB standards. The
recovery efficiency was calculated from the surrogates and the sample weight.
2.3.5 Quantification of plasma components
We quantified plasma insulin concentrations using a commercial ELISA
(Crystal Chem, Downers Grove, IL). Plasma TNF-α and interleukin-6 (IL-6)
concentrations were quantified using a commercial Milliplex MAP Mouse Serum
Adipokine kit (Millipore, St. Charles, MO).
2.3.6 Extraction of RNA and quantification of mRNA abundance using realtime polymerase chain reaction (PCR)
Total RNA was extracted from tissues using the SV Total RNA Isolation
System kit (Promega Corporation, Madison, WI) (6). RNA concentrations were
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quantified and cDNA was synthesized from total RNA and amplified using an
iCycler (Bio-Rad, Hercules, CA) with the Perfecta SYBR Green Fastmix for iQ
(20 μL; Quanta Biosciences, Gaithersburg, MD). Using the difference from 18S
rRNA (reference gene) and the ΔΔCt method, we calculated the relative
quantification of gene expression. The PCR reaction was 94°C for 5 min, 40
cycles at 94°C for 15 sec, 58°C or 64°C (based on tested primer efficiency) for 40
sec, 72°C for 10 min, and 100 cycles from 95°C to 45.5°C for 10 sec. Primer
sequences were as follows: 18S, forward 5´AGTCGGCATCGTTTATGGTC-3´,
reverse 5´-CGAAAGCATTTGCCAAGAAT-3´; CYP1A1 (cytochrome P450 1A1),
forward

5´AGTCAATCTGAGCAATGAGTTTGG-3´,

reverse

5´-

GGCATCCAGGGAA GAGTTAGG-3´; F4/80 (macrophage marker), forward 5´CTTTGGCTATGGGCTTCCAGTC-3´,

reverse

GCAAGGAGGACAGAGTTTATCGTG-3´;

TNF-α,

5´forward

5´-

CCCACTCTGACCCCTTTACTC-3´, reverse 5´-TCACTGTCCCAGCATCTTGT3´.
2.3.7 Western blotting
Tissues (liver, soleus muscle, and epididymal adipose tissue) were
homogenized in mammalian protein extraction reagent (M-PER; Thermo
Scientific, Rockford, IL), sonicated, and centrifuged, and supernatants were used
to quantify protein. Proteins were resolved on 4–15% precast polyacrylamide
gels (Bio-Rad) and transferred onto a polyvinylidene difluoride transfer membrane (GE Healthcare, Buckinghamshire, UK); nonspecific proteins were blocked
for 1 hr at room temperature [5% nonfat milk in phosphate-buffered saline (PBS)
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in 0.1% Tween-20 for 60 min at 25°C]. Membranes were then incubated with
primary antibody: rabbit anti-TNF-α (1:1,000; Novus Biologicals, Littleton, CO),
mouse β-actin (1:5,000; Cell Signaling Technology, Beverly, MA) in diluted PBS
overnight at 4°C. After stripping primary antibody, membranes were incubated
with secondary goat anti-rabbit IgG horseradish peroxidase–linked antibody
(1:5,000; Cell Signaling Technology) for 1 hr at room temperature. Protein levels
were quantified using Kodak Molecular Imaging Software (Carestream Health
Inc., Rochester, NY).
2.3.8 Cell culture
3T3-L1 mouse preadipocytes, obtained from American Type Culture
Collection (Manassas, VA) were cultured as described previously (6).
Differentiation was induced by incubating cells for 2 days with media containing
insulin (0.1 μM; Sigma Chemical Co., St. Louis, MO), dexamethasone (1 μM;
Sigma), and isobutylmethyl xanthine (IBMX; 0.5 mM; Sigma), and then
incubating with insulin for 1 additional day. Assays (n = 3/group) were performed
on duplicate wells of cells. Differentiated adipocytes (day 8) were incubated with
vehicle [0.03% dimethyl sulfoxide (DMSO)] or PCB-77 (3.4 μM) for 24 hr (6). The
concentration of PCB-77 was based on the maximum serum level of PCB-77
(0.84 μg/g, converted to ≈ 3 μM) measured in experimental mice, as described
above, at week 2 after administration of PCB-77 (50 mg/kg). Adipocytes from
each treatment group were incubated with the AhR antagonist α-naphthoflavone
(α-NF; 20 μM) for 30 min before adding vehicle or PCB-77 (3.4 μM).
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2.3.9 Statistical analysis
Data are represented as mean ± SE. Total AUC and mRNA abundance
data were log-transformed. We used one-way analysis of variance (ANOVA;
SigmaPlot, version 12.0; Systat Software Inc., Chicago, IL) to define treatment
effects of different doses of PCBs and for studies using CH-223191. In studies
examining sustainability of PCB effects in lean mice, total AUC was analyzed
using two-way ANOVA with the Holm-Sidak method for post hoc analysis. In
studies of obese mice and mice undergoing weight loss, we performed a mixed
model analysis of repeated measures and analyzed total AUC using two-way
ANOVA (JMP, version 10; SAS Institute Inc., Cary, NC). Statistical significance
was defined as p < 0.05.
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2.4 Results
2.4.1 Coplanar PCBs dose-dependently impair glucose and insulin tolerance
in LF-fed mice in an AhR-dependent manner
We defined dose-dependent effects of two coplanar PCBs (PCB-77 and
PCB-126)—both of which are prevalent in the environment (289) and/or linked to
T2D (270, 290)—on glucose and insulin tolerance in LF-fed mice. Forty-eight
hours after the final dose, animals treated with PCB-77 (50 mg/kg) or PCB-126
(1.6 mg/kg) showed a significant increase in blood glucose concentrations,
compared with controls, in response to a bolus of administered glucose (Figure
2.1A and B, respectively; p < 0.05). The total AUC for blood glucose
concentrations was significantly increased in mice treated with PCB-77 or
PCB-126 (Figure 2.1C and D, respectively; p < 0.05). Similarly, blood glucose
concentrations in response to insulin administration were significantly increased
in mice administered PCB-77 (50 mg/kg) or PCB-126 (3.3 mg/kg) (Figure 2.2A
and B, respectively; p < 0.05), resulting in a significant increase in total AUC
(Figure 2.2C and D, respectively; p < 0.05). Fasting plasma insulin concentrations were similar in mice administered vehicle (mean ± SE, 0.18 ± 0.10) or
PCB-77 (0.19 ± 0.09 ng/ml; p > 0.05). On the basis of a higher prevalence of
PCB-77 in food compared with PCB-126 (291), we used PCB-77 in further
studies examining mechanisms of glucose and insulin intolerance.
To determine whether in vivo effects of PCB-77 are AhR-mediated, we
defined effects of CH-223191, an AhR antagonist, on PCB-77–induced
impairment of glucose and insulin tolerance in LF-fed mice. Administration of
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PCB-77 significantly impaired glucose and insulin tolerance compared with
vehicle, and these effects of PCB-77 were abolished in mice administered CH223191 (Figure 2.3; p < 0.05).
2.4.2 PCB-77 treatment results in sustained impairment of glucose and insulin
tolerance in LF-fed mice
To define the duration of PCB-induced impairment of glucose tolerance,
we administered vehicle or PCB-77 (50 mg/kg) to LF-fed (12 weeks) male
C57BL/6 mice in two doses in weeks 1 and 2 of LF feeding, and then again in
weeks 9 and 10 of LF feeding. Body weight was not significantly different in mice
administered vehicle (mean ± SE, 27 ± 1 g) or PCB-77 (28 ± 1 g; p > 0.05).
Glucose tolerance was significantly impaired in PCB-77–treated mice compared
with controls from weeks 2 to 12 of LF feeding (Figure 2.4A). Insulin tolerance
was significantly impaired in PCB-77–treated mice compared with controls on
weeks 2 and 4 (Figure 2.4B).
Due to their lipophilicity, PCBs accumulate in adipose tissue (8). We
quantified levels of PCB-77 in retroperitoneal white adipose (RPF), liver, skeletal
muscle, and serum following administration of PCB-77. PCB-77 levels were
undetectable in tissues or serum from vehicle-treated mice; in addition, PCB-77
was not detected in skeletal muscle from either treatment group. At week 2,
PCB-77 levels in RPF (mean ± SE, 192 ± 36 μg/g) were 10 and 384 times those
in liver or serum (19 ± 1 and 0.5 ± 0.2 μg/g, respectively). At week 3, PCB-77
levels in RPF (91 ± 37 μg/g) were decreased (by 53%) compared with those in
week 2 (192 ± 36 μg/g) and were markedly decreased by weeks 4 and 12.
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Previous studies showed that PCB-77 increased TNF-α mRNA abundance
in 3T3-L1 adipocytes (6). Thus, we contrasted effects of PCB-77 on TNF-α
expression in adipose tissue compared with liver and skeletal muscle. As
evidence of AhR activation by PCB-77, mRNA abundance of CYP1A1, an AhR
target gene (32), was significantly increased in adipose tissue from PCB-77–
treated mice compared with controls (Figure 2.5A). By comparison, CYP1A1
mRNA abundance was significantly increased in livers of PCB-77–treated mice
compared with controls at week 2 but not at later time points (Figure 2.5B).
Although TNF-α mRNA expression in adipose tissue of PCB-77–treated mice did
not reach statistically significant levels (Figure 2.6A), TNF-α protein was
significantly increased at week 4 (Figure 2.7; p < 0.05). Plasma concentrations of
TNF-α were significantly increased in PCB-77–treated mice compared with controls (Figure 2.8A; p < 0.05). Plasma concentrations of IL-6 were significantly
increased at week 12 in mice administered PCB-77 compared with vehicle
controls (Figure 2.8B; p < 0.05).
Infiltration of macrophages into adipose tissue has been suggested as a
mechanism contributing to low-grade inflammation from obesity and the
development of insulin resistance (292). Adipose tissue from mice administered
PCB-77 exhibited statistically similar mRNA abundance of the macrophage
marker F4/80 compared with controls (Figure 2.6B).
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2.4.3 Effects of PCB-77 to promote glucose and insulin intolerance are lost in
mice with diet-induced obesity, but manifest when obese mice lose weight
Obesity is associated with the development of insulin resistance in T2D
(293). Moreover, obesity increases the total body burden of lipophilic PCBs (9).
Thus, we examined effects of PCB-77 on glucose and insulin tolerance in mice
fed a HF diet for 12 weeks (weight gain phase). In addition, we examined effects
of PCB-77 on glucose and insulin tolerance in HF-fed obese mice (12 weeks)
that were switched to the LF diet for 4 weeks to induce weight loss (weight loss
phase). During the weight gain phase, PCB-77 treatment had no significant effect
on body weight in mice fed either the LF or HF diet compared with controls
(Figure 2.9A). Surprisingly, PCB-77 treatment had no effect on glucose or insulin
tolerance in HF-fed mice (weeks 4 or 12; Figure 2.10A and B; weight gain
phase). Moreover, abundance of TNF-α mRNA in adipose tissue was not
significantly different in PCB-77–treated mice compared with controls (Figure
2.11). At 12 weeks, adipose tissue levels of PCB-77 (1.8 ± 0.5 μg/g tissue, wet
weight) in mice fed the HF diet were 2 times those observed in adipose tissue
from LF-fed mice.
Previous studies showed that plasma concentrations of PCBs increased in
obese subjects experiencing weight loss (294). Thus, we defined effects of
PCB-77 administered during the weight gain phase of HF feeding on glucose
homeostasis during weight loss. Administration of PCB-77 during the weight gain
phase had no effect on body weight reductions during the weight loss phase
(Figure 2.9B). Glucose tolerance was significantly improved by weight loss in
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vehicle- or PCB-77–treated mice (week 16 vs. week 12; Figure 2.10A; p < 0.05).
Insulin tolerance was also significantly improved by weight loss in vehicle-treated
mice (week 16 vs. week 12; Figure 2.10B; p < 0.05). However, compared with
controls, mice administered PCB-77 exhibited impaired glucose (Figure 2.10A; p
< 0.05) and insulin tolerance (Figure 2.10B; p < 0.05) during the weight loss
phase. Weight loss resulted in a significant decrease in TNF-α mRNA abundance
in adipose tissue from mice administered vehicle or PCB-77 (Figure 2.11; p <
0.05). However, PCB-77–treated mice had significantly increased TNF-α mRNA
abundance in adipose tissue during weight loss (Figure 2.11; p < 0.05).
2.4.4 PCB-77 results in an AhR-dependent increase in expression of TNF-α in
3T3-L1 adipocytes
Previous studies demonstrated that PCB-77 increased mRNA abundance
of TNF-α in 3T3-L1 adipocytes (6). TNF-α is an intermediate in reactive oxygen
species generated by 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), an AhR
ligand (295). To define mechanisms for effects of coplanar PCBs to promote
glucose and insulin intolerance, we examined effects of PCB-77 on TNF-α
expression in 3T3-L1 adipocytes. Moreover, to determine whether effects of
PCB-77 are AhR-mediated, we incubated cells with an AhR antagonist, α-NF.
Incubation of differentiated 3T3-L1 adipocytes with PCB-77 significantly
increased CYP1A1 mRNA abundance, indicative of AhR activation (Figure
2.12A; p < 0.05), which was abolished by α-NF. Similarly, PCB-77-induced
increases in TNF-α mRNA were abolished by α-NF in 3T3-L1 adipocytes (Figure
2.12B; p < 0.05).
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2.5 Discussion
Results from this study indicate that coplanar PCBs induce rapid and
sustained glucose and insulin intolerance in lean mice in an AhR-dependent
manner. These effects were associated with pronounced accumulation of PCB to
adipose tissue, most likely contributing to adipose-specific increases in
expression of TNF-α. Remarkably, in PCB-exposed mice that became obese
from consumption of a HF diet, the harmful effects of the toxicant promotion of
glucose and insulin intolerance were lost. However, when the PCB-exposed
obese mice lost weight, glucose and insulin tolerance were impaired, mitigating
the beneficial effects of weight loss to improve glucose homeostasis. Moreover,
adipose expression levels of TNF-α, while not influenced by PCB-77 during the
weight gain phase of HF feeding, were increased upon weight loss. In cultured
adipocytes, PCB-77 promoted TNF-α expression through an AhR-dependent
mechanism. These results suggest that PCBs could promote insulin resistance
through adipose-specific increases in TNF-α. Moreover, these results suggest
that in obese mice with a greater body burden of PCBs, the concentration of PCB
was increased in adipose tissue, resulting in increased adipose TNF-α
expression and insulin resistance upon liberation of PCBs during weight loss.
Increasing evidence suggests that background exposure to persistent
organic pollutants is linked to the development of T2D. U.S. Air Force veterans of
the Vietnam War who were exposed to Agent Orange contaminated with dioxin
had increased risk of diabetes, reduced time-to-onset of disease, and increased
diabetes severity (154). In a cross-sectional study among the general population
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of Japan and covering the years 2002–2006, blood levels representing the
highest quartiles of PCB-126 and PCB-105 had adjusted odds ratios of 9.1 and
7.3, respectively (296). Recent results from the Anniston Community Health
Survey demonstrated significant associations between elevated PCB levels and
diabetes (158). Serum levels of PCB-77 in the present study (≈ 3 μM) were
similar to levels (1.43 ppb, equivalent to ≈ 0.5 μM) observed in the lowest quartile
of subjects from the Anniston study (158). Our results demonstrate that lean mice
respond to coplanar PCBs with impaired glucose and insulin tolerance,
supporting an interaction between PCB exposures and the development of
insulin resistance. We used this mouse model of PCB-induced glucose and
insulin intolerance to define mechanisms linking PCB exposures to dysregulated
glucose homeostasis.
In the present study we demonstrated that PCB-77, a coplanar PCB
abundant in the environment (289), as well as PCB-126, a coplanar PCB that has
been linked to diabetes (290), both resulted in dose-dependent rapid impairment
of glucose and insulin tolerance in lean mice. Interestingly, mice exposed to the
highest dose of either PCB did not have impaired glucose or insulin tolerance;
however, these mice demonstrated abnormal behavior (lethargy, tremors),
polyuria, and gained minimal weight (unpublished observations), suggesting that
higher doses of PCB had deleterious health consequences. Recent studies
demonstrated that consumption of farmed salmon containing persistent organic
pollutants, including increased levels of seven different PCBs, promoted glucose
intolerance associated with elevations in adipose tissue expression of TNF-α in
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HF-fed mice (88). Interestingly, when levels of pollutants were decreased by
feeding farm-raised salmon purified fish oil, glucose tolerance improved and
adipose expression levels of TNF-α decreased. Our results are in agreement with
these findings, and extend these studies by demonstrating that individual
coplanar PCBs promote glucose and insulin intolerance associated with adiposespecific elevations in expression of TNF-α. Moreover, similar to previous findings
(88), adipose contained markedly higher PCB levels than did liver and serum,
suggesting that chronic exposures of adipocytes to PCBs most likely contributed
to selective increases in TNF-α expression in adipose tissue but not in liver or
muscle.
Previous studies in our laboratory demonstrated that coplanar PCBs
increased abundance of TNF-α mRNA in cultured adipocytes (6). Results from
the present study demonstrate that PCB-77–induced increases in TNF-α
expression are AhR mediated. Moreover, the concentrations (3.4 μM) of PCB-77
used in our in vitro studies with cultured adipocytes were comparable to serum
levels (3 μM) of PCB-77 that induced glucose and insulin intolerance in mice.
Kim et al. (277) reported that exposures of 3T3-L1 adipocytes to dioxin increased
mRNA abundance of several proinflammatory factors, including TNF-α receptors.
In that study, when dioxin was administered to mice fed standard mouse diet,
abundance of TNF-α mRNA in adipose tissue was markedly increased, and this
effect was abolished in AhR deficient mice. Results of the present study confirm
and extend previous studies by demonstrating that in vivo effects of PCB-77 to
impair glucose homeostasis are AhR mediated. An interesting finding of our
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study was that levels of PCB-77 in adipose tissue were markedly decreased 4
weeks after the last dose; however, mice continued to exhibit glucose and insulin
intolerance. PCB-induced activation of AhR induces CYP1A1 gene expression,
which hydroxylates the toxicant to increase water solubility for elimination. Our
findings of rapid declines in levels of PCB-77, in the face of sustained impairment
of glucose homeostasis, suggest that metabolites of PCB-77 may have
contributed to long-lasting impairment of glucose and insulin intolerance in mice.
In this study, although PCB-77 impaired glucose and insulin tolerance in
lean mice, these effects were lost when mice were fed a HF diet. The lipophilic
nature of PCBs results in their accumulation in adipocyte lipid-containing
droplets. For example, in humans, body mass index is inversely correlated with
serum levels of PCBs, supporting the concept that an expanded adipose mass
results in redistribution of PCBs away from the circulating compartment (273). In
support, Kim et al. (9) reported an increased (2.9-fold) total body burden of PCBs
in obese subjects. Thus, sequestration of PCB-77 in adipocyte lipid pools, as
demonstrated by higher levels in adipose tissue from HF-fed mice in the present
study, most likely resulted in restricted access to AhR, contributing to a lack of
effect of PCB-77 on glucose and/or insulin tolerance in obese mice. Alternatively,
effects of PCB-77 to impair glucose homeostasis may have become apparent
with longer durations of HF-feeding. Previous studies found that plasma levels of
13 of 17 measured organochlorines in human serum increased with weight loss
(276). Similarly, obese subjects experiencing drastic weight loss from bariatric
surgery had increased serum levels of PCBs, which decreased the beneficial
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effects of weight loss (9). In agreement with previous findings, our results
demonstrate that beneficial effects of weight loss to improve glucose and insulin
tolerance in mice were blunted in mice administered PCB-77. Moreover, our
results extend previous findings by showing that elevations in TNF-α in adipose
tissue may have contributed to impaired glucose and insulin tolerance in PCBexposed mice experiencing weight loss.
Results from this study demonstrate that coplanar PCBs cause rapid and
sustained impairment of glucose and insulin tolerance in mice through an AhRdependent mechanism associated with an adipose-specific increase in TNF-α
expression. Although harmful effects of PCB-77 on glucose and insulin tolerance
were absent in obese mice, beneficial effects of weight loss to improve glucose
and insulin tolerance were mitigated in mice previously exposed to PCB-77.
These results suggest that sequestration of lipophilic coplanar PCBs to adipose
tissue may contribute to AhR-mediated increases in TNF-α and the development
of adipocyte insulin resistance, an effect manifest in lean conditions as well as
during weight loss when adipose-derived toxicants may be liberated.
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Figure 2.1. PCB-77 (A) and PCB-126 (B) impair glucose tolerance in LF-fed
mice. (A), Blood glucose concentrations following a bolus of glucose in mice
administered vehicle (VEH), 2.5, 50 or 248 mg/kg of PCB-77 (48 hours after the
second dose). (B), Blood glucose concentrations following a bolus of glucose in
mice administered vehicle, 0.3, 1.6 or 3.3 mg/kg of PCB-126 (48 hours after the
second dose). Data are mean ± SEM from n = 5 mice/dose of PCB. *, P < 0.05
compared to VEH within a time point. (C,D), Quantification of total area under
the curve (AUC) for data in A, B, respectively. *, P < 0.05 compared to VEH.
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Figure 2.2.

Insulin tolerance tests in mice administered vehicle (VEH),

PCB-77 (2.5, 50 or 248 mg/kg, A) or PCB-126 (0.3, 1.6 or 3.3 mg/kg, B). At 48
hours after the last dose, insulin (0.0125 µM/gm body weight) was administered
to mice from each treatment group and blood glucose concentrations quantified
at several time points. (C, D), Total area under the curve (AUC) for data in A, B,
above. Data are mean ± SEM from n = 5 mice/group. *, P < 0.05 compared to
vehicle.
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Figure 2.3. Glucose (A) and insulin (B) tolerance tests in mice administered
vehicle (VEH), CH-223191 (10 mg/kg/day), or PCB-77 (50 mg/kg).

(C, D)

Total area under the curve (AUC) for data in A, B, above. Data are mean ± SEM
from n ≥ 7 mice/group. *, P < 0.05 compared to vehicle. **, P < 0.05 compared
to PCB77.
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Figure 2.4.

PCB-77 results in sustained impairment of glucose (A) and

insulin (B) tolerance in LF-fed mice. Mice were administered vehicle (VEH) or
PCB-77 (50 mg/kg, two divided doses during weeks 1 and 2, a second set of 2
doses during weeks 9 and 10 for mice studied at 12 weeks). At 2, 4 or 12 weeks,
mice in each treatment group were administered a bolus of glucose (20%
glucose, A) or insulin (0.0125 µM/gm body weight, B) and blood glucose
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concentrations were quantified.

Total area under the curve (AUC) for blood

glucose concentrations were quantified.

Data are mean ± SEM from n > 5

mice/group. *, P < 0.05 compared to VEH within time point.
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Figure 2.5. PCB-77 increases mRNA abundance of CYP1A1 in adipose (A)
and liver (B) of LF-fed mice. Mice were administered vehicle (VEH) or PCB-77
(50 mg/kg, 2 doses in weeks 1 and 2, second 2 doses in weeks 9 and 10 for 12
week mice). (A), CYP1A1 mRNA abundance was increased in adipose at 1 and
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4 weeks, but not 12 weeks after PCB-77 administration. (B), CYP1A1 mRNA
abundance was increased in liver at week 2, but not week 4 after PCB-77
administration. Data are mean ± SEM from n > 3 mice/group. *, P < 0.05
compared to VEH.
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Figure 2.6. TNF-α (A) and F4/80 (B) mRNA abundance in adipose from mice
administered vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses in weeks 1, 2, and
then in weeks 9, 10 for mice euthanatized at week 12). Data are mean ± SEM
from n = 6 mice/group.
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Figure 2.7. PCB-77 results in elevated TNF-α expression in adipose, but
not in liver or soleus muscle of LF-fed mice. Mice were administered vehicle
(VEH) or PCB-77 (50 mg/kg, 2 doses) and expression levels of TNF-α quantified
in adipose, liver or soleus muscle 2 weeks later (week 4). Data are mean ± SEM
from n = 3 mice/group. *, P < 0.05 compared to VEH.
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Figure 2.8.

Plasma concentrations of TNF-α (A) and IL-6 (B) following

administration of vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses in weeks 1 and
2, second 2 doses in weeks 9 and 10). Data are mean ± SEM from n = 10
mice/group. *, P < 0.05 compared to VEH.
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Figure 2.9. Body weight in LF and HF-fed mice administered vehicle (VEH)
or PCB-77 (50 mg/kg, doses in weeks 1, 2, 9, and 10) during the weight
gain phase of HF feeding (A), and after mice are switched to a LF diet at
week 12 – 16 to induce weight loss (B). Body weight was increased in HF
compared to LF-fed mice beginning on week 4 (A). Data are mean ± SEM from
n > 5 mice/group.
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Figure 2.10. PCB-77 has no effect on glucose (A) or insulin (B) tolerance in
HF-fed mice during weight gain, but impairs glucose homeostasis during
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weight loss. (A), Total area under the curve (AUC) for glucose tolerance in mice
administered vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses during weeks 1 and 2
and a second 2 doses during weeks 9 and 10) during weight gain (weeks 4, 12 of
HF feeding) or weight loss (at week 16 after mice are switched to a LF diet).
Data are mean ± SEM from n > 5 mice/group. *, P < 0.05 compared to week 12
within treatment group. **, P < 0.05 compared to VEH within time point.
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Figure 2.11. TNF-α mRNA abundance in adipose from mice during weight
gain (week 12 of HF feeding), and after mice are switched to a LF diet to
induce weight loss (week 16). Data are mean ± SEM from n > 3 mice/group. *,
P < 0.05 compared to week 12 within treatment group. **, P < 0.05 compared to
VEH within time point.
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Figure 2.12.

CYP1A1 (A) and TNF-α (B) mRNA abundance in 3T3-L1

adipocytes incubated with vehicle, α-NF, PCB-77, or PCB-77 + α-NF. Data
are mean ± SEM from n = 3 experiments. *, P < 0.05 compared to vehicle. **, P
< 0.05 compared to PCB-77.
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SECTION III. SPECIFIC AIM 2
3.1 Summary
Resveratrol (RSV) is a plant polyphenol that exhibits several favorable
effects on glucose homeostasis in adipocytes.

Recent studies from our

laboratory demonstrated that coplanar polychlorinated biphenyls (PCBs) that are
ligands of the aryl hydrocarbon receptor (AhR) impair glucose homeostasis in
mice. PCB-induced impairment of glucose homeostasis was associated with
augmented expression of inflammatory cytokines in adipose tissue, a site for
accumulation of lipophilic PCBs. This study determined if RSV protects against
PCB-77 induced impairment of glucose disposal in vitro and in vivo, and if these
beneficial effects are associated with enhanced nuclear factor erythoid 2-related
factor 2 (Nrf2) signaling in adipose tissue. PCB-77 increased oxidative stress
and abolished insulin stimulated 2-deoxy-D-glucose (2DG) uptake in 3T3-L1
adipocytes.

These effects were restored by RSV, which resulted in a

concentration-dependent

increase

in

NAD(P)H:quinone

(NQO1), a downstream target of Nrf2 signaling.

oxidoreductase

1

We quantified glucose and

insulin tolerance and components of Nrf2 and insulin signaling cascades in
adipose tissue of male C57BL/6 mice administered vehicle or PCB-77 (50 mg/kg)
and fed a diet with or without resVida® (0.1%, or 160 mg/kg/day).

PCB-77

impaired glucose and insulin tolerance, and these effects were reversed by RSV.
PCB-77 induced reductions in insulin signaling in adipose tissue were also
abolished by RSV, which increased NQO1 expression.

These results

demonstrate that coplanar PCB-induced impairment of glucose homeostasis in
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mice can be prevented by RSV, potentially through stimulation of Nrf2 signaling
and enhanced insulin stimulated glucose disposal in adipose tissue.
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3.2 Introduction
Polychlorinated biphenyls (PCBs) are persistent organic pollutants that are
highly lipophilic and tend to bio-accumulate in the environment.

Although

industrial use of these compounds was banned in the U.S. in the 1970’s, recent
studies have estimated that the average American is exposed to approximately
33 ng of PCBs per day through the diet (11). Several epidemiological studies
suggest that exposure to low concentrations of PCBs may promote type 2
diabetes (T2D) in humans (268, 297). Notably, recent results from the Anniston
Community Health Survey demonstrated significant associations between
elevated PCB levels and diabetes risk (158).

Largely resulting from

accumulating evidence linking PCB exposures to diabetes, the National Institute
of Environmental Health Studies (NIEHS), Division of the National Toxicology
Program (NTP) hosted a workshop to review approximately seventy-five different
epidemiology studies linking persistent organic pollutants (POPs), including
coplanar PCBs, to T2D outcomes. A publication from the workshop concluded
that there is evidence for a positive association between POP exposures and the
development of T2D (23).

The summary of the workshop also called for

additional studies to define mechanisms linking PCBs and other POPs to
increased risk for diabetes.
We recently demonstrated that coplanar PCBs that are ligands of the aryl
hydrocarbon receptor (AhR) impair glucose homeostasis in C57BL/6 mice (7).
These effects were associated with inflammation in adipose tissue, a site for
pronounced PCB accumulation (7). Similarly, recent studies demonstrated that
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2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), an AhR ligand, promoted low grade
inflammation in adipocytes in vitro and in vivo (277).

Generation of reactive

oxygen species (ROS) by AhR ligands such as TCDD or PCBs in adipocytes
may contribute to low grade inflammation and the development of insulin
resistance (298).
The plant polyphenol, resveratrol (RSV), exerts several protective effects
in adipocytes. In 3T3-L1 adipocytes RSV inhibited stimulation of inflammatory
adipokines (265, 299-304).

As a mechanism for protective effects of RSV,

reductions in oxidative stress by RSV are associated with activation of nuclear
factor erythoid 2-related factor 2 (Nrf2) (247, 305-306), a component of the antioxidant pathway.

RSV had been demonstrated to protect against insulin

resistance in cultured adipocytes (241).

Moreover, administration of RSV

improves glucose tolerance and reduces insulin resistance resulting from
consumption of a high fat diet (182, 187, 307), in genetically obese rodents (253,
308-309) and in humans with T2D (213). Notably, RSV interacts with the AhR,
resulting in translocation of the receptor to the nucleus; however this interaction
does not appear to result in transactivation (310-311).

Accordingly, RSV

attenuates toxic effects of AhR ligands in vitro and in vivo (310, 312-315).
However, it is unclear if protective effects of RSV extend to PCB ligands of AhR,
and whether this protection includes restoration of measures of insulin sensitivity
in adipocytes, a primary site for PCB-induced activation of inflammatory
cytokines that are linked to the development of insulin resistance (6-7).
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In this study, we tested the hypothesis that RSV protects against in vitro
and in vivo effects of a coplanar PCB (PCB-77) to induce measures of insulin
resistance. We selected coplanar PCB-77 for these studies based on its high
toxicity and abundance within the food chain (289, 291).

Since PCBs

accumulate markedly in adipose tissue and have been demonstrated to promote
inflammatory cytokines linked to insulin resistance (6-7), we focused on
adipocytes as the cell target of PCBs and/or RSV to regulate glucose
homeostasis. As a mechanism for effects of PCB and/or RSV, we quantified
oxidative stress and induction of the Nrf2 anti-oxidant signaling pathway. Our
results suggest that RSV may provide therapeutic benefit against PCB-induced
dysregulation of glucose homeostasis and the development of diabetes.
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3.3 Materials and Methods
3.3.1 Materials
3,3’,4,4’-tetrachlorobiphenyl (PCB-77) was purchased from AccuStandard
Inc. (New Haven, CT). 2-deoxyglucose (2DG), bovine insulin (0.1 μM for
adipocyte differentiation), dexamethasone (1 μM), and isobutylmethyl xanthine
(0.5 mM, IBMX) were obtained from Sigma Aldrich (St. Louis, MO). The resVida®
(>99% pure trans-resveratrol) was provided by DSM Nutrition Products, Inc
(Heerlen, NL).
3.3.2 Quantification of PCB-77, RSV, and metabolites in serum and tissues
PCB-77, hydroxyPCB-77 and RSV were measured using a Shimadzu
UFLC coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap triple
quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode. d6PCB-77 was used as internal standard for PCB-77 and hydroxyPCB-77
measurements. D4-RSV was used as an internal standard for resveratrol and its
metabolite measurements. The mass spectrometer was operated in the positive
APCI mode for PCB-77 measurements and in negative ESI mode for
hydroxyPCB-77 and RSV measurements with optimal ion source settings
determined by synthetic standards. PCB-77 was analyzed using Kinetex 2.6 u
C18, 100 A, 100 X 2.10 mm (Phenomenex) column. The mobile phase consisted
of water as solvent A and acetonitrile as solvent B. For the analysis of PCBs the
separation was achieved using a gradient of 20 % B to 60 % B for 1 min, 60% B
to 100% B in the next 7 min, and maintained at 100% B for the last 2 min with a
flow rate of 0.25 ml/min. MRM transitions monitored were as follows: 291.9/
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222.1 and 291.9/220 for PCB-77; and 297.9/228.1 and 297.9/226.2 for d6-PCB77. In the MRM ion transition the precursor ion represents the M⁺· and the
product ion represents either [M-Cl] ⁺ or [M-2Cl]⁺.
HydroxyPCB-77 was analyzed using Luna 3 u C18 (2), 100 A, 250 X 2.00
mm (Phenomenex) column with a flow rate of 0.25 mL/min. The mobile phase
consisted of 75/25 of methanol/ water with formic acid (0.5%) and 5 mM
ammonium formate (0.1%) as solvent A and 99/1of methanol/ water with formic
acid (0.5%) and 5 mM ammonium formate (0.1%) as solvent B. HydroxyPCB-77
was eluted using a gradient of 10 % B to 100 % B in 4 min and maintained at
100% B for the next 11 min. MRM transitions monitored were as follows:
352.8/306.9 for hydroxyPCB-77 and 368.8/322.9 for dihydroxyPCB-77. Precursor
ion of the ion transition is a formic acid adduct: [M+FA-H]- and product ion is [MH]-.
3.3.3 Cell culture
3T3-L1 mouse preadipocytes purchased from Zen-Bio (Research Triangle
Park, NC) were cultured in standard Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) enriched with 10% fetal bovine serum (FBS;
Gemini Bio-Products, Woodland, CA) and 1% penicillin/streptomycin in 6-well
culture dishes.

Cells (passage number 5 or lower) were grown to 100%

confluence at 37°C in a humidified 5% CO2 atmosphere.

Differentiation to

mature adipocytes was induced as previously described (7). Assays (n =
2/group) were performed in triplicate.
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To examine the effects of PCBs, we incubated differentiated adipocytes
(day 8) with vehicle [0.03% dimethyl sulfoxide (DMSO)] or PCB-77 (3.4 µM (6-7))
for 24 hours in the absence or presence of RSV (0.1 μM, 1 μM, or 10 μM). RSV
was added to culture media 30 minutes prior to the addition of vehicle or PCB-77.
Cells were harvested for glucose uptake and oxidative stress assays in addition
to mRNA quantification of gene expression.
3.3.4 Measurement of insulin-stimulated uptake of 2DG
To measure uptake of 2DG, differentiated 3T3-L1 adipocytes were
incubated with appropriate treatments in serum-free media for 6 hours. Cells
were washed three times and then incubated with insulin (1 µM) in glucose-free
Krebs buffer (pH 7.4) containing 2% bovine serum albumin for 20 minutes at
37oC.

2DG (1 mM) was added to each well and incubated at 37oC for 20

minutes. Cells were washed three times with buffer, and 10 mM Tris-HCl was
added to each well. Following sonication, cell lysates were collected and 2DG
uptake was quantified per the manufacturer’s instructions (2-Deoxyglucose
Uptake Measurement kit, Cosmo Bio Co. Ltd., Tokyo, Japan). 2DG uptake was
normalized to cellular protein.
3.3.5 Measurement of oxidative stress
To measure oxidative stress, differentiated 3T3-L1 adipocytes were incubated
with appropriate treatments for 24 hours. Cellular oxidation was determined by
2’,7’-dichlorofluorescein (DCF) fluorescence via the OxiselectTM Intracellular ROS
Assay kit (Cell Biolabs, Inc., San Diego, CA). Briefly, this method is based on the
conversion of 2’,7’-dichlorofluorescin into fluorescent DCF through oxidation by
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reactive oxygen species, including super oxide radicals and peroxides. Following
appropriate treatments, cells were incubated with 100 µM 2’,7’-dichlorofluorescin
diacetate for 30 minutes. A multi-well fluorescent plate reader (Molecular
Devices, CA) was utilized for measuring relative oxidative stress; excitation and
emission wavelengths were 480 and 530 nm, respectively.
3.3.6 Animals and experimental diets
All experimental procedures met the approval of the Animal Care and Use
Committee of the University of Kentucky. Two month old, male, C57BL/6 mice
(The Jackson Laboratory, Bar Harbor, ME) were housed in a pathogen-free
environment and given ad libutum access to water and standard mouse diet in
the absence or presence of 0.1% resVida® (#5SSG, 14.6% kcal as fat, TestDiet,
Richmond, IN). Mice were pre-fed diets for 1 week prior to administration of
vehicle (tocopherol stripped safflower oil, Dyets Inc., 10 µL/g of body weight) or
PCB-77 (49.6 mg/kg)(n=10 mice/group), given in two divided doses during weeks
1 and 2. Body weights were recorded bi-weekly. Glucose and insulin tolerance
tests were performed within 48 hours after the second dose as described below.
At study endpoint, mice were fasted for 4 hours and anesthetized with
ketamine/xylazine (100/10 mg/kg intraperitoneal (ip) injection). Following
ketamine injection, a sub-set of mice in each group were injected (i.p.) with 10
U/kg body weight human insulin (Novolin) to stimulate insulin signaling pathways,
using methods as described previously (285).
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3.3.7 Glucose tolerance test (GTT) and insulin tolerance test (ITT)
For glucose (GTT) and insulin tolerance tests (ITT), sub-sets of mice in
each group were examined within 48 hours after the second dose. Mice were
fasted for 4 or 6 hours for ITT or GTT, respectively, and fasted blood glucose
was measured by tail vein using a hand held glucometer (Freedom Freestyle
Lite, Abbott Laboratories, Abbott Park, IL).

Mice were injected (i.p.) with D-

glucose (Sigma, 20% in saline, 10 µL/g of body weight) for GTT and blood
glucose was measured at 15, 30, 60, 90, and 120 minutes later. For ITT, mice
were injected (i.p.) with human insulin (Novolin, 0.0125 µM in saline/g of body
weight), and plasma glucose was measured at 30, 60, 90, and 120 minutes later.
Total area under the curve (AUC; arbitrary units) was calculated as previously
described (7).
3.3.8 Quantification of adipose tissue Akt and P-Akt.
Epididymal adipose tissue was homogenized and centrifuged, and
supernatants were stored in 1X Cell Lysis Buffer (Cell Signaling, Danvers, MA).
Akt and p-Akt concentrations were quantified as per the manufacturer’s
instructions using a commercial ELISA (Cell Signaling, Beverly, MA), and
normalized to adipose tissue protein.
3.3.9 RNA isolation and gene expression analysis using real-time polymerase
chain reaction (PCR)
Total RNA was extracted from epididymal adipose tissue using the SV
Total RNA Isolation System kit (Promega Corporation, Madison, WI), per the
manufacturer’s instructions.

RNA from 3T3-L1 cells was extracted in Trizol.
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RNA concentrations were determined using a NanoDrop 2000 spectophotometer
and associated software (Thermo Scientific, Logan, UT). cDNA was synthesized
from 0.4 µg total RNA with qScript cDNA SuperMix (Quanta Biosciences,
Gaithersburg, MD) in the following reaction: 25°C for 5 minutes, 42°C for 30
minutes, and 85°C for 5 minutes. The cDNA was diluted 1:50 to achieve a
concentration of 0.4 ng/µL. The diluted cDNA was amplified with an iCycler (BioRad, Hercules, CA) and the Perfecta SYBR Green Fastmix for iQ (Quanta
Biosciences, Gaithersburg, MD).

Components of the PCR reaction were as

follows: Perfecta SYBR Green FastMix (10 µL), forward and reverse primers
(0.125 µL), nuclease free water (4.75 µL), and diluted cDNA (5 µL for 2 ng of
cDNA/reaction).

Using the difference from GAPDH (glyceraldehydes 3-

phosphate dehydrogenase) rRNA (reference gene) and the comparative Ct
method, the relative quantification of gene expression in each sample was
calculated. Primers (Eurofins MWG Operon, Huntsville, AL) were designed using
the primer design program available from PubMed.gov (sequences presented in
Table 3.1). The PCR reaction was as follows: 94°C for 5 minutes, 40 cycles at
94°C for 15 seconds, 58°C or 64°C (based on tested primer efficiency) for 40
seconds, 72°C for 10 minutes, and 100 cycles from 95°C to 45.5°C for 10
seconds.
3.3.10 Statistical analysis
Data are represented as mean + standard error of the mean (SEM). Data
was log transformed prior to statistical analysis. A one-way or two-way analysis
of variance (ANOVA; SigmaPlot, version 12.0; Systat Software Inc., Chicago, IL)
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were used as appropriate to determine statistical significance, which was defined
as p < 0.05. Glucose and insulin tolerance tests were analyzed using repeated
measure, two-way ANOVA. Holm-Sidak method was used for post-hoc analyses,
except in Figures 3.1D and 3.4B which used Dunnett’s method and basal and
non-insulin stimulated groups as controls for comparison, respectively.
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3.4 Results
3.4.1 RSV promotes Nrf2 signaling, suppresses oxidative stress, and restores
insulin-stimulated glucose uptake in PCB-77 treated adipocytes.
RSV has been demonstrated to promote the anti-oxidant Nrf2 signaling
pathway and reduce oxidative stress in a variety of cell types (247, 306, 316).
We quantified effects of PCB-77 on Nrf2 and one of its downstream signaling
targets, NQO1, and oxidative stress in the absence or presence of increasing
concentrations of RSV in 3T3-L1 adipocytes. In the absence of RSV, PCB-77
had no significant effect on mRNA abundance of Nrf2 or NQO1 in 3T3-L1
adipocytes (Fig. 3.1A,B, respectively). However, in the presence of PCB-77,
RSV significantly increased mRNA abundance of Nrf2 and NQO1 in a
concentration-dependent manner (Fig. 3.1A,B; P<0.05).

PCB-77 significantly

increased fluorescence of DCF as a measure of oxidative stress, and this effect
was abolished by RSV (1 µM; Fig. 3.1C, P<0.05).
To determine if PCB-77-induced oxidative stress influenced glucose
homeostasis in 3T3-L1 adipocytes, and whether RSV could restore adipocyte
function, we quantified 2DG uptake. In the presence of insulin, 2DG uptake
increased 4-fold in 3T3-L1 adipocytes (DMSO versus basal; Fig. 1D, P<0.05).
However, PCB-77 totally abolished 2DG uptake in insulin-stimulated adipocytes
(Fig. 3.1D). Effects of PCB-77 to impair glucose uptake by adipocytes were
reversed in a concentration-dependent manner by RSV (Fig. 3.1D, P<0.05).
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3.4.2 RSV has no effect on tissue levels of PCB-77 or PCB-77 metabolites.
RSV has been demonstrated to have AhR antagonist properties (310311), which could influence metabolism of PCBs by cytochrome P-450 1A1
(CYP1A1). We quantified mRNA abundance of CYP1A1 as an index of AhR
activation in adipose tissue of mice administered PCB-77 in the absence or
presence of RSV. PCB-77 resulted in a significant increase in CYP1A1 mRNA
abundance in adipose tissue of mice administered vehicle (VEH) or RSV (Fig.
3.2; P<0.05). We then quantified levels of PCB-77 and its major metabolites
(hydroxyPCB-77, dihydroxyPCB-77) in serum, liver or adipose tissue from mice
in each treatment group. Similarly, we quantified levels of the parent compound,
trans-RSV, and 2 metabolites (RSV-3-O-glucuoride, trans-RSV-3-O-sulfate). As
demonstrated previously (7), adipose tissue concentrations of PCB-77 were
markedly higher than liver or serum (Table 3.2). Moreover, the ratio of PCB-77
to its quantified metabolites was greater in adipose tissue (5:1) than liver
(0.02:1). Significantly higher concentrations of RSV metabolites were detected in
serum, liver and adipose tissue than the parent molecule, RSV. However, there
was no significant effect of RSV on levels of PCB-77 or its metabolites.

In

addition, administration of PCB-77 had no significant effect on levels of RSV or
its metabolites.
3.4.3 RSV improves glucose tolerance and insulin signaling in adipose tissue
of mice administered PCB-77
There was no significant effect of PCB-77 or RSV on body weight (data
not shown). As reported previously (7), PCB-77 significantly impaired glucose
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and insulin tolerance (Fig. 3.3A,B, respectively), as indicated by a significant
increase in the area under the curve (AUC) for blood glucose levels following
administration of glucose (GTT) or insulin (ITT) (Fig. 3.3C,D, respectively). While
RSV had no effect on either glucose or insulin tolerance in mice administered
vehicle, RSV totally abolished effects of PCB-77 to impair glucose and insulin
tolerance. Based on findings from 3T3-L1 adipocytes demonstrating that RSV
stimulated the Nrf2 signaling cascade (Fig. 3.1A), we quantified mRNA
abundance of Nrf2 and NQO1 in epididymal adipose tissue from insulinstimulated mice. There were no significant effects of PCB-77 or RSV on Nrf2
mRNA abundance in adipose tissue (data not shown).

However, in mice

administered PCB-77, RSV resulted in a significant increase in mRNA
abundance of NQO1 (Fig. 3.4A, P<0.05). We quantified levels of phosphorylated
Akt (pAkt, normalized to total Akt) as an index of the insulin signaling pathway in
adipose tissue of mice administered insulin. Administration of insulin significantly
increased pAkt expression in adipose tissue, which was totally abolished by
PCB-77 (Fig. 3.4B, P<0.05). While RSV had no effect in the absence of PCB-77,
it totally restored insulin-stimulated levels of pAkt in adipose tissue (Fig. 3.4B,
P<0.05).
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3.5 Discussion
Results from this study demonstrate that supplementation with RSV in the
diet totally prevents PCB-77 induced impairment of glucose and insulin tolerance
in mice.

Notably, PCB-77 resulted in pronounced suppression of insulin-

stimulated levels of pAkt in adipose tissue, and this effect was abolished by RSV.
In cultured adipocytes, PCB-77 increased oxidative stress and reduced insulinstimulated glucose uptake, and these effects were attenuated in a concentrationdependent manner by RSV.

Mechanisms of RSV to protect against PCB-

induced oxidative stress and impairment of glucose uptake in 3T3-L1 adipocytes
may involve activation of the anti-oxidant Nrf2 signaling pathway, as RSV
stimulated Nrf2 and/or NQO1 expression in cultured adipocytes and elevated
NQO1 expression in adipose tissue of mice.

In contrast, RSV did not alter

systemic or tissue distribution of PCB-77 and/or its major metabolites, or levels of
CYP1A1 in adipose tissue, suggesting that regulation of PCB metabolism did not
contribute to effectiveness of RSV. These results demonstrate that RSV can
attenuate PCB-77-induced insulin resistance in adipose tissue potentially by
stimulating the NRF2 pathway and preventing oxidative damage.

RSV may

provide an effective therapy to protect against PCB-induced dysregulation of
glucose homeostasis.
Increasing evidence suggests that exposures to environmental pollutants,
including PCBs, may be a contributing factor for an increased risk of T2D
development. Similar to recent findings (7), in the present study administration of
PCB-77 to C57BL/6 mice resulted in impaired glucose and insulin tolerance.
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Results from this study extend previous findings by demonstrating that PCB-77
administration totally abolished levels of phosphorylated Akt in adipose tissue as
an index of insulin signaling. We recently reported that serum levels of PCB-77
in experimental mice are lower than total serum PCB levels in populations with
known accidental exposures (7). In the present study, mice administered PCB77 had serum levels of approximately 0.07 + 0.01 µM, consistent with total PCB
levels reported in subjects from the highest quintile of the Anniston Community
Health Survey Population that exhibit an increased odds ratio for T2D (158).
Moreover, as reported previously (7-8), PCB-77 accumulated markedly in
adipose tissue compared to serum or liver. An interesting finding of the present
study was the higher ratio of parent PCB-77 compound to its metabolites in
adipose tissue, as compared to liver. These results suggest that in comparison
to liver where PCBs are predominately metabolized through CYP1A1 activation,
sequestration of the parent PCB-77 molecule in adipose lipids may hinder
effective metabolism of the toxin. However, upon release of sequestered PCBs
from adipose tissue during lipolysis, adipocytes may experience more
pronounced effects of the toxin at adipocyte AhR.
In the present study, serum RSV concentrations (0.6 nM) in 4 hour fasted
mice were lower than concentrations (1 µM) that effectively abolished PCB-77
induced oxidative stress and impaired glucose uptake by 3T3-L1 adipocytes.
Previous investigators demonstrated that fasted (4 hrs) C57BL/6 mice
administered 100 mg/kg of RSV via oral gavage had appreciable amounts of the
RSV-3-O-glucuronide metabolite (317).

These results suggest that protective
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effects of RSV observed during fasting of mice in this study may have resulted
from RSV metabolites. Importantly, neither levels of RSV and metabolites, nor
levels of PCB-77 and metabolites, were influenced by co-administration of these
compounds to mice, suggesting that protective effects of RSV against PCBinduced impairment of glucose homeostasis did not result from changes in
distribution or metabolism of either compound.
In the present study we demonstrated that supplementation with RSV
effectively protected against the diabetogenic effects of PCB-77 in vitro and in
vivo. A recent clinical study of T2D patients treated with oral RSV supplements
for three months reported significant improvements in nearly all biomarkers
associated with the disease (213). However, other groups have not been able to
show improvements in insulin sensitivity or glucose regulation with RSV (215,
318).

The dietary dose of RSV used in this study (approx. 160 mg/kg/day)

equates to a human equivalent dose of just under 800 mg/day for a 60 kg
individual (319). This dose of RSV would not be achievable in humans without
the aid of supplementation. A potential RSV treatment therapy in PCB exposed
populations should be regarded cautiously, since the drug interaction potential of
the high doses of RSV typically utilized in clinical trials remains poorly
understood (320). Interestingly, plant food sources that are high in RSV also
tend to be conversely low in PCBs, as total PCB concentrations in food tend to
be higher in meats and fish than other sources (11). This would suggest that a
diet that enhances consumption of vegetables and limits PCB containing foods
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(e.g., meat) would simultaneously confer antioxidant protection and lower the
total body burden of these environmental contaminants.
Another interesting finding from this study was that RSV had little effect on
any measured parameter in the absence of PCB-77 administration. This finding
is consistent with recent studies that demonstrate that RSV had no effect in lean
individuals (215), or that RSV improved adipose tissue glucose homeostasis only
under insulin resistant conditions (241). These results suggest that RSV would
not adversely influence glucose homeostasis in the absence of an insult, in this
case, exposure to an environmental toxin. Indeed, protective pathways (e.g.,
NQO1) targeted by RSV are typically quiescent and become activated in
response to an external stimuli (e.g., PCB-77).
Mechanisms for protective effects of RSV in the present study include
reductions in oxidative stress associated with stimulation of the anti-oxidant Nrf2
signaling pathway. Several studies have demonstrated that RSV stimulates Nrf2
expression in various cell types (247, 306, 316).

As described above, RSV

stimulated Nrf2 and NQO1 gene expression only in adipocytes incubated with
PCB-77, suggesting that stimulation of the anti-oxidant system by RSV requires
induction of oxidative stress by a damaging stimulus.

These results are

consistent with in vivo data from the present study demonstrating that RSV
favorably influenced a measure of insulin signaling and NQO1 gene expression
in adipose tissue only when mice were exposed to PCB-77.
In conclusion, results from this study indicate that RSV reduces PCB-77
induced oxidative stress in adipose tissue by enhancing Nrf2 signaling, protecting
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against PCB-77-induced impairment of glucose and insulin tolerance. These
results suggest that supplementation with resveratrol may be a potential therapy
for populations with known PCB exposures to lower the risk of developing
diabetes.
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Gene
Forward
Reverse
CYP1A1 AGTCAATCTGAGCAATGAGTTTGG GGCATCCAGGGAAGAGTTAGG
GAPDH GCCAAAAGGGTCATCATCTC
GGCCATCCACAGTCTTCT
NQO1
AGGATGGGAGGTACTCGAATC
TGCTAGAGATGACTCGGAAGG
Nrf2
CCATATTCCATTCCCTGTCG
TAAGTGGCCCAAGTCTTGCT
Abbreviations: CYP1A1, cytochrome P-450 1A1; GAPDH, glyceraldehyde 3phosphate dehydrogenase; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2,
nuclear factor erythoid 2-related factor 2.
Table 3.1. Primer sequences for real-time PCR.
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Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

Tissue type
Serum
Liver
RPF

VEH
N.D.
N.D.
N.D.

PCB77 (µM)
VEH+RSV
PCB77
N.D.
0.07 + 0.02
N.D.
4.78 + 2.88
N.D.
29.90 + 10.44
Hydroxy PCB77 (µM)
VEH+RSV
PCB77
N.D.
1.53 + 0.38
N.D.
216.19 + 301.58
N.D.
4.25 + 0.98
Dihydroxy PCB77 (µM)
VEH+RSV
PCB77
N.D.
0.31 + 0.08
N.D.
1.50 + 2.07
N.D.
1.77 + 1.11
trans‐Resveratrol (nM)
VEH+RSV
PCB77
0.60 + 0.17
N.D.
0.08 + 0.07
N.D.
0.57 + 0.71
N.D.
Resveratrol‐3‐O‐glucuronide (nM)
VEH+RSV
PCB77
22.44 + 8.21
N.D.
13.15 + 24.13
N.D.
1.11 + 0.54
N.D.
trans‐Resveratrol‐3‐O‐sulfate (nM)
VEH+RSV
PCB77
34.06 + 19.93
N.D.
17.34 + 19.22
N.D.
0.99 + 0.64
N.D.

PCB77+RSV
0.08 + 0.02
3.16 + 2.19
19.12 + 8.65

p‐value
0.249
0.347
0.113

PCB77+RSV
1.73 + 0.48
75.22 + 69.03
3.14 + 0.17

p‐value
0.492
0.338
0.282

PCB77+RSV
0.45 + 0.14
2.39 + 4.47
1.21 + 0.33

p‐value
0.096
0.695
0.346

PCB77+RSV
0.75 + 0.15
0.06 + 0.10
2.87 + 3.44

p‐value
0.174
0.819
0.181

PCB77+RSV
76.90 + 52.18
7.24 + 3.76
1.97 + 1.02

p‐value
0.059
0.603
0.134

PCB77+RSV
30.95 + 9.15
62.63 + 83.76
3.58 + 3.31

p‐value
0.759
0.272
0.125

Table 3.2. Levels of PCB-77, RSV, and their metabolites in serum, liver, and
retroperitoneal fat of mice. Values are mean + SEM from n = 5/group. P-values
established via Student’s t-test of independendent means comparing detectable
groups. N.D., Not detected; VEH, vehicle; RSV, resveratrol; RPF, retroperitoneal
fat.
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Figure 3.1. Resveratrol protects 3T3-L1 adipocytes against PCB-77-induced
oxidative stress and impaired glucose uptake.

A, RSV results in a

concentration-dependent increase in Nrf2 mRNA abundance in 3T3-L1
adipocytes incubated with PCB-77 (3.4 µM). B, RSV (1, 10 µM) promotes NQO1
mRNA abundance in 3T3-L1 adipocytes incubated with PCB-77.

C, PCB-77

increases DCF fluorescence as an index of oxidative stress, which is abolished
by RSV (1 µM). D, PCB-77 abolishes insulin-stimulated 2DG uptake in 3T3-L1
adipocytes, and RSV restores insulin-stimulated glucose uptake. Data are mean
± SEM from n = 2 experimental triplicates. *, P<0.05 compared to DMSO within
RSV concentration or compared to basal in Figure 3.1D; **, P<0.05 compared to
0 within treatment.
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Figure 3.2. PCB-77 increases CYP1A1 mRNA abundance in adipose tissue.
Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2 divided doses
and fed standard mouse diet without and with RSV (0.1%). At 48 hours after the
second PCB-77 dose, adipose tissue was harvested for quantification of gene
expression.

PCB-77 administration significantly increased CYP1A1 mRNA

abundance in adipose tissue of mice in each diet group. Data are mean ± SEM
from n = 5 mice/group. *, P<0.05 compared to VEH within diet group.
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Figure 3.3. RSV prevents PCB-77-induced impairment of glucose or insulin
tolerance. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2
divided doses. Mice in each treatment group were fed either standard mouse
diet or diet enriched with Resvida™ (RSV, 0.1%). A, Blood glucose levels after
administration of glucose. B, Blood glucose levels after administration of insulin.
C, Area under the curve (AUC) for data in A. D, AUC for data in B. Data are
mean ± SEM from n = 5 mice/group. *, P<0.05 compared to PCB77+RSV (A,B)
or compared to VEH (C,D).
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Figure 3.4.

RSV promotes the anti-oxidant NRF2 target, NQO1, and

reverses PCB-77-induced impairment of insulin signaling in adipose tissue.
Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2 divided doses,
and fed either standard mouse diet or a diet enriched with RSV (0.01%). A,
NQO1 mRNA abundance in adipose tissue from mice in each treatment group.
B, Levels of phosphorylated Akt (pAkt), normalized to total Akt, in adipose tissue
from mice in each treatment group in the absence (no insulin) or presence of
insulin. Data are mean ± SEM from n = 5 mice/group. *, P<0.05 compared to
VEH (A) or compared to no insulin (B).
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SECTION IV. SPECIFIC AIM 3
4.1 Summary
Previous

studies

in

our

laboratory

demonstrated

that

coplanar

polychlorinated biphenyls (PCBs) promote adipose tissue inflammation and
impair glucose homeostasis in mice in an aryl hydrocarbon receptor (AhR)dependent manner. PCBs are highly lipophilic, accumulating in adipose tissue, a
recognized site of insulin resistance in type 2 diabetes (T2D). The current study
tested the hypothesis that adipocyte AhR deficiency confers a protective effect
on PCB-77 induced impairments of glucose disposal in vivo. We determined the
effects of adipocyte AhR deficiency on responsiveness to PCB-77 (50 mg/kg)induced disruptions in glucose homeostasis in mice fed low-fat (LF) or high-fat
(HF) diets, as well as in obese mice undergoing weight loss. Mice expressing
transgenic Cre recombinase under the control of the adiponectin (AdQ) promoter
were bred with AhR-floxed mice to generate littermate controls (AhRfl/fl) and
adipocyte AhR deficient mice (AhRAdQ). AhR mRNA abundance was reduced
significantly in both white and brown adipose tissue from AhRAdQ mice compared
to AhRfl/fl mice. Adipocyte AhR deficiency resulted in greater fat mass and
reduced lean mass in two month old, chow-fed mice, but this did not significantly
influence body weight. However, when AhRAdQ mice were challenged with a HF
diet, body weight was significantly increased compared to AhRfl/fl controls.
Notably, body weight increases in HF-fed AhRAdQ mice were associated with
greater deposition of subcutaneous adipose tissue. HF-fed AhRAdQ mice had
significantly increased numbers of adipocytes in both visceral and subcutaneous
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adipose tissue compared to control. Importantly, adipocyte AhR deficiency
protected against PCB-77 induced impairments in glucose and insulin tolerance
following both acute and chronic exposure. We also examined effects of
adipocyte

AhR

deficiency

on

PCB-77-induced

homeostasis during weight loss in obese mice.

impairment

of

glucose

During LF feeding and post

weight loss, AhRAdQ mice had greater total fat mass than littermate controls.
Additionally, AhRAdQ mice dosed with PCB-77 during obesity and then subjected
to weight loss had decreased levels of PCB-77 metabolites in adipose tissue, as
well as decreased expression of cytochrome P450 1A1 (CYP1A1) and tumor
necrosis factor-alpha (TNF-α) in adipose tissue compared to littermate controls.
These results suggest that PCB-77 sequesters to the expanded adipocyte lipid
pools present during obesity, and that weight loss facilitates the interaction of
contaminants with the adipocyte AhR and facilitates subsequent metabolism.
These results demonstrate that the adipocyte AhR is critical in mediating the
disruptive effects of coplanar PCBs on glucose homeostasis, and that the
adipocyte AhR might have novel importance in the regulation of obesity and body
fat deposition.
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4.2 Introduction
The aryl-hydrocarbon receptor (AhR) has well-established roles in
toxicology and phase I drug metabolism, and also influences developmental cell
proliferation and differentiation (67). Studies have demonstrated that adipose
tissue can store xenobiotic ligands of AhR, namely coplanar PCBs (289), likely
contributing to a low-grade internal source of PCBs which can act in an
autocrine or paracrine manner. Adipocytes express AhR, and are likely
chronically exposed to ingested lipophilic POPs given that this cell type stores
most triglyceride in the body (32, 169). Moreover, storage of lipophilic PCBs in
adipose tissue suggests that tonic low grade exposures may influence adipocyte
differentiation and/or inflammation (6-7). While results have demonstrated that
adipocyte

AhR

influence

adipocyte

differentiation

and

expression

of

inflammatory cytokine (6, 277, 321), the precise role that this receptor plays in
normal or disease-related dysfunction of adipose tissue is unclear. Previous
studies demonstrated that whole body deficiency of AhR resulted in improved
insulin sensitivity and glucose tolerance in mice (87), suggesting that the
endogenous AhR influences whole body glucose metabolism. However, the
contribution of adipocyte AhR to effects of whole body AhR deficiency on
glucose homeostasis are unclear.
Studies in humans undergoing weight loss have demonstrated that serum
values of PCBs are inversely correlated with BMI (275-276), and that obese
individuals store a greater body burden of total PCBs than lean counterparts
(294). PCBs stored in adipose tissue may be released to blood to act
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systemically, or alternately interact with the cytosolic adipocyte AhR. We have
previously

demonstrated

that

obese

mice

administered

PCB-77

and

subsequently subjected to weight loss experienced impaired glucose and insulin
tolerance; this effect was also observed in lean mice acutely exposed to PCB-77
(7). One possible explanation for this observation is that weight loss results in
release of hydrophobic PCBs from lipid pools during lipolysis of adipocytes.
Indeed, levels of PCB-77 in adipose tissue were increased by obesity, but
reduced to non-detectable levels following weight loss (7).
Interaction of coplanar PCBs with the adipocyte AhR could impact adipose
tissue insulin sensitivity via several potential mechanisms. Alsharif et. al.
demonstrated that mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
experienced an AhR-dependent increase in superoxide anion (295). Cytochrome
P450, family 1, member A1 (CYP1A1), the detoxifying enzyme activated by AhR,
is known to produce superoxide anion and hydrogen peroxide as part of the
catalytic cycle of xenobiotic hydroxylation (322-323). The association between
oxidative stress and insulin resistance, particularly in adipose tissue, has been
recognized for some time (106-109). However, the role of adipocyte AhR as a
contributor to oxidative stress of adipocytes has not been well defined.
An additional mechanism of PCB-induced insulin resistance mediated by
the adipocyte AhR may stem from the promotion of chronic, low-grade
inflammation in adipose tissue by these toxicants. Previous studies in our
laboratory demonstrated that coplanar PCBs result in concentration-dependent
increases in expression of several proinflammatory cytokines in 3T3-L1
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adipocytes (6).

Moreover, administration of PCB-77 to lean mice impaired

glucose and insulin tolerance, and these effects were associated with adiposespecific elevations in expression of tumor necrosis factor-α (TNF-α) (7). PCBinduced impairment of glucose homeostasis was lost when mice were made
obese from consumption of a high fat (HF) diet. However, when obese mice
exposed to PCB-77 were subjected to weight loss they did not demonstrate the
same degree of improvement in adipose levels of TNF-α compared to control (7).
Collectively, these results suggest that coplanar PCBs act at adipocyte AhR to
influence glucose homeostasis.
In this study, we hypothesized that coplanar PCBs promote insulin
resistance in adipose tissue through direct effects at adipocyte AhR. To test this
hypothesis, we examined effects of PCB-77 in lean and obese mice (with and
without weight loss) on glucose homeostasis in mice lacking AhR in adipocytes.
Results from these studies may have therapeutic implications for populations
exposed to PCBs (from environmental accidents, or from higher levels due to
obesity). In addition, results from these studies suggest that PCBs released from
adipose stores during weight loss act at adipocyte AhR to blunt beneficial effects
of weight loss.

121

4.3 Materials and Methods
4.3.1 Chemical Procurement
3,3’,4,4’-tetrachlorobiphenyl (PCB-77) was purchased from AccuStandard Inc.
(New Haven, CT).
4.3.2 Quantification of PCB-77 and hydroxylated metabolites in serum and
tissues
Tissue samples were weighed and homogenized in dH20. Cold acetonitrile and
50 µL of internal standard (10 µM 13C labeled d6-PCB-77) were added to
homogenates and vortexed, sonicated, and centrifuged at 15,000 rpm for 5
minutes. Supernatants were transferred to glass vials and cold acetonitrile was
added to the pellets and vortexed, sonicated, and centrifuged. Supernatants
were transferred again and 50:50 acetonitrile:dH20 was added to the pellet and
repeated vortex, sonication, and centrifugation. All supernatants were pooled and
dried under nitrogen. The dried samples were reconstituted in 100 µL of 99/1
methanol/dH20 and 0.5% formic acid and 0.1% ammonium formate solution.
PCB-77 was measured using a Shimadzu UFLC coupled with an AB Sciex
4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer in multiple
reaction monitoring (MRM) mode. d6-PCB-77 was used as internal standards.
PCBs were separated using Kinetex 2.6 u C18, 100 A, 100 X 2.10 mm
(Phenomenex) column. The mobile phase consisted of water as solvent A and
acetonitrile as solvent B. For the analysis of PCBs the separation was achieved
using a gradient of 20% B to 60% B for 1 min, 60% B to 100% B in the next 7
min, and maintained at 100% B for the last 2 min with a flow rate of 0.25 ml/min.
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Column was equilibrated back to the initial conditions in 3 min. Column
temperature was maintained at 30 °C. The sample injection volume was 10 µL.
The mass spectrometer was operated in the positive APCI mode with optimal ion
source settings determined by synthetic standards of PCB-77 and d6-PCB-77
with a declustering potential of 36 V, entrance potential of 10 V, collision energy
of 53 V, collision cell exit potential of 10 V, curtain gas of 20 psi, nebulizer current
of 3, ion source gas1 of 40 psi and temperature of 550 °C. MRM transitions
monitored were as follows: 291.9/ 222.1 and 291.9/220 for PCB-77 and
297.9/228.1 and 297.9/226.2 for d6-PCB-77. In the MRM ion transition the
precursor ion represents the M+· and the product ion represents either [M-Cl]+ or
[M-2Cl]+.
Hydroxy PCB-77 was analyzed using Luna 3 u C18 (2), 100 A, 250 X 2.00
mm (Phenomenex) column. The mobile phase consisted of 75/25 of methanol/
water with formic acid (0.5%) and 5 mM ammonium formate (0.1%) as solvent A
and 99/1of methanol/ water with formic acid (0.5%) and 5 mM ammonium
formate (0.1%) as solvent B. Hydroxy PCB-77 was eluted using a gradient of
10% B to 100% B in 4 min and maintained at 100% B for the next 11 min.
Column was equilibrated back to the initial conditions in 3 min. The flow rate was
0.25 mL/min with a column temperature of 30 °C. The sample injection volume
was 10 µL. The mass spectrometer was operated in the negative ESI mode with
optimal ion source settings determined by synthetic standards of 2-hydroxy-2’, 3’,
5’, 6’-tetrachlorobiphenyl with a declustering potential of -60 V, entrance potential
of -10 V, collision energy of -6 V, collision cell exit potential of -7 V, curtain gas of
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20 psi, ion spray voltage of -4200 V, ion source gas1/gas2 of 40 psi and
temperature of 550 °C. MRM transitions monitored were 352.8/306.9 for hydroxy
PCB-77. Precursor ion of the ion transition is a formic acid adduct: [M+FA-H]- and
product ion is [M-H]-.
4.3.3 Animals and experimental diets
All experiments met the approval of the Animal Care and Use Committee of the
University of Kentucky. AhR-floxed (AhRfl/fl) mice were a generous gift of Dr.
Mary Walker, University of New Mexico. Female AhRfl/fl mice were bred to
hemizygous

transgenic

male

Cre

mice

under

control

of

an

adiponectin/promoter/enhancer (B6;FVB-Tg(Adipoq-cre)1Evdr/J; The Jackson
Laboratory, Bar Harbor, ME). Male AhRfl/fl littermates were used for comparison
to mice with adipocyte AhR deficiency. Initial studies examined effects of
adipocyte AhR deficiency on PCB-induced impairment of glucose homeostasis in
lean mice. Male mice (8-9 weeks of age) of each genotype were administered
vehicle (tocopherol-stripped safflower oil) or PCB-77 (50 mg/kg; by oral gavage
given as two separate doses over 2 weeks; n = 3-8 mice/group and were fed a
low fat diet (LF; 10% kcal as fat, D12450B; Research Diets, New Brunswick, NJ)
for 2 or 4 weeks.
Follow up studies examined glucose and insulin tolerance in male mice
administered vehicle or PCB-77 (50 mg/kg; by oral gavage given as 4 doses in
weeks 1,2, 9, and 10; n = 6-8 mice/group) and fed a HF diet (60% kcal as fat,
D12492; Research Diets) for 12 weeks to promote the development of obesity.
After 12 weeks of HF feeding, subsets of mice from each genotype/treatment
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group were euthanatized for tissue harvest. Remaining subsets of mice were
placed on the LF diet for 4 additional weeks to induce weight loss.
Body weights were quantified weekly in all studies. At study end point,
mice were anesthetized (ketamine/xylazine, 10/100 mg/kg, ip) for exsanguination
and tissue harvest (liver, soleus muscle, and visceral adipose).
4.3.4 Measurement of body composition
Body weights of mice were recorded weekly. The body composition of mice was
determined by nuclear magnetic resonance spectroscopy [EchoMRI (magnetic
resonance imaging)] before mice began study diets and within 1 week of study
endpoint.
4.3.5 Measurement of glucose and insulin tolerance
For glucose (GTT) and insulin tolerance tests (ITT), mice were examined at week
2 (LF), 4 (LF), 12 (HF) and 16 (HF then switched to LF diet from week 12-16).
Mice were fasted for 4 or 6 hours for ITT or GTT, respectively, and fasted blood
glucose was quantified by tail vein puncture using a hand held glucometer
(Freedom Freestyle Lite, Abbott Laboratories, Abbott Park, IL). Mice were
injected i.p. with D-glucose (Sigma, 20% in saline, 10 µL/g of body weight) for
GTT and blood glucose was quantified at 15, 30, 60, 90, and 120 minutes post
the bolus injection. For ITT, mice were injected i.p. with human insulin (Novolin,
0.0125 µM in saline/g of body weight), and plasma glucose was quantified at 30,
60, 90, and 120 minutes post ip injection. Total area under the curve (AUC;
arbitrary units) was calculated as previously described (7). The GTT and ITT
results of two vehicle treated mice were excluded from the acute (2 week) PCB-
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77 findings when adipose tissue from these animals was found to be
contaminated with PCB-77.
4.3.6 Quantification of mRNA abundance
Total RNA was extracted from tissues using the SV Total RNA Isolation System
kit (Promega Corporation, Madison, WI), per the manufacturer’s instructions.
RNA from 3T3-L1 cells was extracted in Trizol. RNA concentrations were
determined using NanoDrop 2000 spectophotometer and associated software
(Thermo Scientific, Logan, UT). cDNA was synthesized from 0.4 µg total RNA
with qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) in the
following reaction: 25°C for 5 minutes, 42°C for 30 minutes, and 85°C for 5
minutes. The cDNA was diluted 1:50 for a concentration of 0.4 ng/µL. The diluted
cDNA was amplified with an iCycler (Bio-Rad, Hercules, CA) and the Perfecta
SYBR Green Fastmix for iQ (Quanta Biosciences, Gaithersburg, MD). The
components of the PCR reaction were as follows: Perfecta SYBR Green FastMix
(10 µL), forward and reverse primers (0.125 µL), nuclease free water (4.75 µL),
and diluted cDNA (5 µL for 2 ng of cDNA/reaction). Using the difference from
GAPDH rRNA (reference gene) and the comparative Ct method, the relative
quantification of gene expression in each sample was calculated. Primers
(Eurofins MWG Operon, Huntsville, AL) were designed using the primer design
program available from PubMed.gov (sequences presented in Table 1). The PCR
reaction was as follows: 94°C for 5 minutes, 40 cycles at 94°C for 15 seconds,
58°C or 64°C (based on tested primer efficiency) for 40 seconds, 72°C for 10
minutes, and 100 cycles from 95°C to 45.5°C for 10 seconds. Primer sequences
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were as follows: CYP1A1, forward 5’-AGTCAATCTGAGCAATGAGTTTGG-3’,
reverse

5’-GGCATCCAGGGAAGAGTTAGG-3’;

GCCAAAAGGGTCATCATCTC-3’,
TNF-α,

forward

reverse

GAPDH,

forward

5’-

5’-GGCCATCCACAGTCTTCT-3’;

5’-CCCACTCTGACCCCTTTACTC-3’,

reverse

5’-

TCACTGTCCCAGCATCTTGT-3’.
4.3.7 Determination of adipocyte size and cell number
Sections of formalin (10% wt/vol) fixed pieces of epidydmal or subcutaneous
adipose tissue were stained with hematoxylin and eosin. Images of slides were
taken at 10 magnification. Via use of the “detect edges” setting, image
threshold, and object count features of NIS Elements software (Nikon
Instruments, Inc., Tokyo, Japan), the area of each adipocyte and the number of
adipocytes within a 700  700 µm measurement frame were quantified.
Adipocyte size and number were calculated on three measurement frames within
each section of adipose tissue (n = 3 sections/mouse) from mice in each group (n
= 3 mice/group).
4.3.8 Differentiation of preadipocytes from SVC
Subcutaneous adipose tissue was taken from the inguinal region, minced, and
incubated in basal medium (OM-BM; Zenbio, Research Triangle Park, NC)
supplemented with collagenase (1 mg/ml) and penicillin/streptomyocin mixture
(5%) for 1 h with shaking at 37°C as previously described (324). Two days after
cells had reached 100% confluence, media was changed to differentiation
medium (OM-DM; Zenbio) and changed every other day for 8 days. Cells were
harvested for RNA using TRIzol.
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4.3.9 Statistical analysis
Data are represented as mean + SEM.

Data was log transformed prior to

statistical analysis. A two-way analysis of variance (ANOVA; SigmaPlot, version
12.0; Systat Software Inc., Chicago, IL) was used to determine statistical
significance, which was defined as p < 0.05. Glucose and insulin tolerance tests
were analyzed using repeated measure, two-way ANOVA. Holm-Sidak method
was used for post-hoc analyses.
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4.4 Results
4.4.1 Generation of mice with adipocyte AhR deficiency.
To confirm effective and specific deletion of exon 2 of AhR in adipocytes, AhR
mRNA abundance was quantified in adipose tissues, liver, brain, heart, and
kidneys from mice fed standard laboratory diet (2 months of age). AhR mRNA
abundances were not significantly different in liver, kidney, or brains from AhRfl/fl
compared to AhRAdQ mice (Figure 1A; P>0.05). In heart, AhR mRNA abundance
was reduced in AhRAdQ compared to AhRfl/fl mice, but did not meet criteria for
statistical significance (p = 0.08) (Figure 4.1A). In retroperitoneal (RPF) white
adipose tissue and brown adipose tissue (BAT), AhR mRNA abundance was
decreased significantly in AhRAdQ compared to AhRfl/fl mice (Figure 4.1A;
P<0.05). While no significant difference between genotypes was detected in AhR
mRNA abundance in stromal vascular cells (SVCs) , AhRAdQ mice had no
detectable AhR mRNA in isolated adipocyte fractions from epidydmal adipose
tissue compared to AhRfl/fl mice (Figure 4.1B; P<0.05).
We examined the ability of preadipocytes within SVCs isolated from mice
of each genotype to differentiate into mature adipocytes. No visual differences in
cell morphology or size were noted at any day during differentiation (data not
shown). AhR mRNA abundance was significantly decreased in adipocytes (day
8) differentiated from SVCs of AhRAdQ mice compared to AhRfl/fl controls (Figure
4C, AhRfl/fl, 1.46 ± 0.27; AhRAdQ, 0.60 ± 0.31,  Ct method, 18S used as
reference gene; P < 0.05).
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Chow-fed, two month old male AhRAdQ mice did not have significant
differences in body weight compared to littermate controls (Figure 4.2A);
however, these mice had significantly increased fat mass and reduced lean mass
compared to age-matched AhRfl/fl mice (Figure 4.2B; P<0.05). Additionally, chowfed AhRAdQ mice had significantly larger visceral adipose depots and moderately
larger subcutaneous adipose depots (Figure 4.2C). Because differences in body
fat deposition could potentially affect glucose and insulin tolerance in the
absence of PCB and/or diet, we conducted baseline glucose and insulin
tolerance tests in chow-fed male mice. Neither glucose nor insulin tolerance were
influenced by adipocyte AhR deficiency in chow-fed mice (data not shown).
4.4.2 Adipocyte AhR deficiency improves glucose and insulin tolerance in
lean mice acutely exposed to PCB-77.
We have previously demonstrated that lean mice acutely exposed to PCB-77
develop impaired glucose and insulin tolerance within 48 hours of the last dose
(7). To determine the role of adipocyte AhR in mediating the acute effects of
PCB-77 on glucose homeostasis, LF-fed AhRAdQ mice and littermate controls
were dosed twice with vehicle or PCB-77 (50 mg/kg) and glucose and insulin
tolerance tests (GTT and ITT) were performed. AhRfl/fl mice, but not AhRAdQ
mice, exposed to PCB-77 had impaired glucose and insulin tolerance compared
to vehicle treated controls (Figures 4.3A and 4.3B, respectively; P<0.05).
Surprisingly, regardless of treatment (vehicle, PCB-77), adipocyte deficiency of
AhR resulted in improved insulin tolerance compared to AhRfl/fl controls, as
shown by the area under the curve (AUC) for ITT (Figure 4.3C; P<0.05). An
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additional unexpected finding was an effect of PCB-77 to increase total fat mass,
regardless of genotype (Figure 4.3D; P<0.05).
Due to their lipophilicity, PCBs accumulate in adipose tissue (8). We
quantified levels of PCB-77 and the metabolite hydroxy PCB-77 in retroperitoneal
white adipose (RPF) and serum of AhRfl/fl and AhRAdQ mice following
administration of PCB-77. At week 2 following acute PCB-77 exposure, PCB-77
levels in serum or RPF of AhRfl/fl mice (mean ± SE, serum: 0.77 + 0.09 µM; RPF:
74.35 ± 7.91 μM) were not significantly different from values measured in AhRAdQ
mice (serum: 0.61 ± 0.07 µM, P = 0.61 compared to AhRfl/fl mice; RPF: 53.89 +
4.65, P = 0.06 compared to AhRfl/fl mice). Additionally, serum and RPF levels of
hydroxy PCB-77 were not significantly different in AhRfl/fl mice (serum: 0.01 +
0.01 µM; RPF: 0.69 ± 0.26 μM) and AhRAdQ mice (serum: 0.01 + 0.01 µM, P =
0.84 compared to AhRfl/fl mice; RPF: 0.41 ± 0.15 μM, P = 0.35 compared to
AhRfl/fl mice) with acute PCB-77 exposure.
4.4.3 Adipocyte AhR deficiency promotes the development of obesity during
HF-feeding and alters body fat distribution.
Given that lean mice with adipocyte AhR deficiency displayed increased fat mass
when fed chow diet (Figure 4.2B) in the absence of PCB exposure, we examined
effects of adipocyte AhR deficiency on the development of obesity. Interestingly,
deficiency of adipocyte AhR resulted in significant increases in the development
of obesity (Figure 4.4A,B; P<0.05). There was a trend for adipocyte AhR deficient
mice to exhibit impairments of glucose and insulin tolerance (Figure 4.5A,B), with
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these findings tracking body weight differences between groups (i.e., heavier
groups were more glucose and insulin intolerance than leaner groups).
4.4.4 Adipocyte AhR deficiency resulted in adipose depot-specific changes in
adipocyte cell number in HF-fed mice.
In subcutaneous adipose tissue from HF-fed AhRAdQ mice, adipocytes were
larger in size resulting in fewer number of cells per field compared to tissue from
AhRfl/fl mice (Figure 4.6A,B; P<0.05). In epidydmal adipose tissue, similar trends
were observed with increased adipocyte size of HF-fed AhRAdQ mice compared
to control (Figure 4.6B); however, these increases did not reach statistical
significance in epididymal adipose. Notably, epididymal adipose tissue from HF
fed AhRAdQ mice exhibited pronounced macrophage infiltration, as evidenced by
increased mRNA abundance of F4/80 as a macrophage marker compared to
adipose tissue from AhRfl/fl controls (Figure 4.6C; P<0.05).

Increased

macrophage infiltration was observed in epididymal, but not in subcutaneous
adipose tissue from either group.
4.4.5 Adipocyte AhR deficiency protects against PCB-77 induced disruptions
in glucose homeostasis and adipose tissue inflammation during weight loss.
To examine if adipocyte AhR deficiency would protect against PCB-77 induced
disruptions in glucose homeostasis during weight loss, AhRAdQ mice and
littermate controls were fed the HF diet for 12 weeks and orally gavaged with
vehicle or PCB-77 (50 mg/kg) in weeks 1, 2, 9, and 10. Following the weight gain
portion of the study, mice were then fed the LF diet for 4 weeks to promote
weight loss. Even though AhRAdQ mice gained more weight when fed the HF diet
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(Figure 4.4), all groups reached statistically similar body weights following 4
weeks of weight loss (Figure 4.7).
Similar to previous findings (7), administration of PCB-77 during the
weight gain phase of the study resulted in significant impairments of glucose and
insulin tolerance following weight loss in AhRfl/fl mice (Figure 4.8A-D; P<0.05). In
contrast, effects of PCB-77 to impair glucose (Figure 4.8A,C) and insulin
tolerance (Figure 4.8 B,D) during weight loss were mitigated in AhRAdQ mice. As
indicated by area under the curve quantification of blood glucose levels following
glucose or insulin administration, adipocyte AhR deficiency conferred partial
protection from PCB-77 induced disruptions in glucose tolerance (Figure 4.8C),
and totally prevented PCB-77-induced impairment of insulin tolerance (Figure
4.8D; P<0.05).
We quantified adipose levels of PCB-77 and the metabolite hydroxy PCB77 mice of both genotypes administered PCB-77, in obese mice of both
genotypes at week 12 and post weight loss at week 16. HF-fed AhRAdQ mice
accumulated significantly higher levels of PCB-77, but not hydroxyl PCB-77 in
adipose tissue (Figure 4.9A,B), potentially related to increased body weights and
fat mass of these mice. With weight loss, both genotypes of mice exhibited
reductions in adipose tissue levels of PCB-77 (Figure 4.9A), and increased levels
of the metabolite hydroxyl PCB-77 (Figure 4.9B), suggesting that weight loss
promoted liberation of PCB-77 from adipose lipids with potential CYP1A1mediated metabolism to hydroxyl PCB-77. In addition, adipocyte AhR deficient
mice undergoing weight loss exhibited significantly lower levels of metabolite
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hydroxyl PCB-77 compared to controls (Figure 4.9B; P<0.05), suggesting that
AhR-mediated induction of CYP1A1 contributed to metabolism of the parent
toxin.
To determine the extent of AhR activation in mice of each genotype, we
quantified

epidydmal

adipose

tissue

mRNA

abundance

of

CYP1A1.

Administration of PCB-77 significantly increased mRNA abundance of CYP1A1
in AhRfl/fl, but not AhRAdQ mice (Figure 4.10A; P<0.05).

Similarly, mRNA

abundance of TNF-α was significantly increased by administration of PCB-77 in
adipose tissue of AhRfl/fl, but not AhRAdQ mice (Figure 4.10B; P<0.05).
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4.5 Discussion
Results from this study demonstrate that the adipocyte AhR mediates effects of
PCB-77 to impair glucose and insulin tolerance in lean mice, and in obese mice
experiencing weight loss. Consistent with previously reported findings (7), PCB77 impaired glucose homeostasis in lean wild type mice (week 2 of LF feeding),
effects that were abolished in adipocyte AhR deficient mice. Furthermore, PCB77 had no effect on glucose or insulin tolerance in obese mice of either genotype
(week 12 of HF feeding). However, PCB-77 exposed wild type mice undergoing
weight

loss

demonstrated

previously

reported

impairments

in

glucose

homeostasis, an effect which was not observed in AhRAdQ mice (week 16,
concluding 4 week LF feeding weight loss period). We uncovered the surprising
finding that adipocyte AhR deficiency, in the absence of toxin administration,
promoted an increase in fat mass in mice fed a LF or HF diet. These results
suggest that location of this receptor to adipocytes influences the distribution of
fat mass. Our results confirm previous findings that obese mice exhibit greater
adipose levels of PCB-77(7), and extend these findings to demonstrate that
sequestration to adipose lipids most likely protects the parent PCB-77 molecule
from metabolism and detoxification. However, with weight loss adipose levels of
the parent toxin decrease while metabolite levels increase, and these effects are
most likely mediated through adipocyte AhR-induction of CYP1A1. Moreover,
PCB-mediated induction of TNF-α expression in adipose tissue following weight
loss was abolished in mice with adipocyte AhR deficiency.

Reductions in

adipose TNF-α expression most likely contributed to improved glucose and
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insulin tolerance with weight loss in adipocyte AhR deficient mice previously
exposed to PCB-77. These results indicate a pivotal role for adipocyte AhR in
diabetes-inducing effects of PCB-77.
AhRAdQ mice fed HF diet for 12 weeks demonstrated significant increases
in macrophage infiltration to epidydmal adipose tissue compared to littermate
controls, as shown by mRNA abundance of macrophage marker F4/80.
Epidydmal adipocytes from obese AhRAdQ mice were larger than controls,
however this increase in size did not meet criteria for statistical significance.
Increased macrophage recruitment to epidydmal adipose tissue may have
occurred as a result of this modest epidydmal adipocyte hypertrophy.
Alternatively, the adipocyte AhR may have undocumented effects on the
regulation of macrophage recruitment signaling in adipocytes, which could be the
basis of future studies.
An unexpected finding of the present study was that adipocyte AhR
deficiency led to increased body weight and adipose depot-specific changes to
adipocyte size and cell number during HF feeding. Interestingly, two month old,
male AhRAdQ mice fed standard chow diet also had increased body fat mass and
larger visceral adipose depots, despite displaying no significant differences in
body weights. These findings suggest that the adipocyte AhR plays a previously
unrecognized role in body fat deposition, perhaps in an adipose depot-specific
manner, and that this role becomes more important under HF feeding conditions.
These intriguing findings warrant further study. Currently, there are several
putative endogenous AhR ligands that could have contributed to these findings,
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including arachidonic acid and one of its ecosanoid products, such as lipoxin A4
or prostaglandin G2 (325-326). Bui et. al. demonstrated that treatment of wild
type mice with TCDD led to a significant increase in liver ecosanoids
(unfortunately, adipose tissue was not examined in this study), but this effect was
not observed in mice with whole body AhR deficiency. The authors concluded
that TCDD-mediated binding of AhR resulted in antagonism of the receptors
interaction with endogenous ecosanoid ligands, leading to an increase of these
products in examined tissues (326). Our laboratory has previously demonstrated
that coplanar PCB exogenous ligands of the AhR promoted adipocyte
differentiation when incubated with predipocytes (6). It should be noted that AhR
expression was present in the stromal vascular fraction from mice with adipocyte
AhR deficiency; however, AhR expression levels were reduced in mature
adipocytes that would experience increased expression of the Cre-driven
promoter, adiponectin.

Therefore, increased adipocyte size in mice with

adipocyte AhR deficiency was most likely not the result of regulation of adipocyte
differentiation by an endogenous ligand.
Another potential explanation for the unusual phenotype observed in
AhRAdQ mice may relate to crosstalk between the adipocyte AhR and other
nuclear

receptors

or

transcription

factors.

Interestingly,

recent

studies

characterized a mouse model with adipocyte-specific deficiency of arylhydrocarbon receptor nuclear translocator-like, ARNTL (also known as BMAL1 or
MOP3)(327). Not only has signaling between the circadian protein ARNTL and
AhR been postulated to have metabolic effects on glucose and insulin tolerance
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(87), but the adipocyte-specific ARNTL knock out mice demonstrated a similar
phenotype in response to HF feeding as observed in the present study (327).
Crosstalk between AhR and estrogen receptor-alpha (ERα) and estrogen
receptor-beta (ERß) has been recognized for some time (328-332), with several
studies demonstrating that activation of AhR by synthetic ligands effectively
mutes ER signaling, and vice versa (328-332). Moreover, PCB-77 and its
metabolites can demonstrate both estrogenic or anti-estrogenic properties that
may have influenced findings of the present study (333-334). CYP1B1, a
member of the classical AhR gene battery, is a known monooxygenase activator
of 17beta-estradiol. CYP1B1 hydroxylates 17beta-estradiol to generate catechol
estrogen metabolites with carcinogenic and estrogenic potential (331). Although
the present studies were conducted utilizing male mice, adipose tissue
expresses aromatase and could therefore convert androgens to estrogens. It is
possible that a combination of these factors are contributing to the gynoid pattern
of fat distribution (i.e. larger subcutaneous adipose depots) demonstrated by
male AhRAdQ mice.
Another potential mechanism for the increased fat mass phenotype
observed in AhRAdQ mice might be that removing AhR from adipocytes then frees
the AhR dimerization partner, aryl-hydrocarbon receptor translocator (ARNT) to
interact with other adipocyte transcription factors. Hypoxia has been shown to
inhibit AhR activity in an ARNT-dependent fashion (335), while conversely AhR
activation has been shown to suppress the expression of hypoxia inducible factor
1 alpha (HIF1-α), a transcription factor that is also dependent on ARNT for gene
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regulation (336). Taken together, these findings suggest that activation of AhR or
HIF1-α would tend to sequester ARNT away from the opposing pathway,
effectively muting downstream cellular pathways. Interestingly, Jiang et. al.
demonstrated that adipocyte-specific HIF1-α deficient mice gained less weight
than controls during HF feeding (337). It is possible that deficiency of adipocyte
AhR resulted in increased interaction between ARNT and HIF1-α, functionally
increasing HIF1-α activity and increasing body weight.
In conclusion, the adipocyte AhR may represent a novel therapeutic target
for individuals from PCB exposed populations, or overweight subjects attempting
to lose weight in general. This therapeutic should be cautiously considered until
the mechanisms behind adipocyte AhR regulation of body weight and adipose
tissue deposition are more clearly delineated.
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Figure 4.1. Development of mice with adipocyte deficiency of AhR. A, AhR
mRNA abundance was analyzed in liver, kidney, brain, heart, retroperitoneal fat
(RPF), and brown adipose tissue (BAT). B, mRNA abundance of AhR in stromal
vascular fractions (SVF) and adipocyte fractions from epidydmal adipose tissue
of each genotype. C, AhR mRNA abundance in SVF cells isolated from
subcutaneous adipose tissue of mice from each genotype that were then
differentiated to mature adipocytes.

Data are mean ± SEM from n = 4-6

mice/group. *, P < 0.05 compared to AhRfl/fl.
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Figure 4.2. Body weight and composition of adipocyte AhR deficient mice.
A, Body weights from 2 month old, chow-fed male AhRAdQ mice versus littermate
controls. Circles represent individual mice with mean ± SEM represented as the
horizontal line. B, Body composition from male AhRAdQ mice versus littermate
controls. C, Percent weight of adipose depots normalized as a percentage of
total body weight from AhRAdQ mice compared to littermate controls. Data are
mean ± SEM from n = 10 mice/group. *, P < 0.05 compared to AhRfl/fl; **, P <
0.01 compared to AhRfl/fl.

143

144

Figure

4.3.

Adipocyte

AhR

deficiency

abolishes

PCB-77-induced

impairment of glucose and insulin tolerance in lean mice. A, Blood glucose
levels following administration of glucose. B, Blood glucose levels following
administration of insulin. C, Area under the curve (AUC) for insulin tolerance test
(ITT) in panel B. D, Body composition of AhRAdQ mice compared to littermate
controls. Data are mean ± SEM from n = 6-8 mice/group. *, P < 0.05 compared to
vehicle treated AhRfl/fl; **, P < 0.01 compared to vehicle treated AhRfl/fl; #, P <
0.05 effect of genotype.
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Figure 4.4. Adipocyte AhR deficiency promotes the development of obesity.
A, Body weights during 12 weeks of HF feeding in each genotype. B, Body
composition after 12 weeks of HF feeding in each genotype. Data are mean ±
SEM from n = 6-8 mice/group. *, P < 0.05 compared to AhRfl/fl; **, P < 0.01
compared to AhRfl/fl.
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Figure 4.5. Adipocyte AhR deficiency modestly impairs glucose tolerance.
A, Glucose tolerance test. B, Insulin tolerance test. Data are mean ± SEM from n
= 6-8 mice/group. *, P < 0.05 compared to AhRfl/fl.
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Figure 4.6. Adipocyte AhR deficiency promotes adipocyte hypertrophy and
increases adipose F4/80 gene expression. A, Quantification of adipocyte size
normalized to number of adipocytes/field in subcutaneous adipose tissue from
each genotype. B, Representative subcutaneous and epidydmal adipose tissue
sections. C, Epidydmal adipose tissue F4/80 mRNA abundance. Data are mean
± SEM from n = 3 mice/group for adipocyte quantifications, n = 5 for RT-PCR
measurements. *, P < 0.05 compared to vehicle treated AhRfl/fl.
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Figure 4.7. Following weight loss body weight is similar between genotypes
and treatments. Body weights following 4 weeks of weight loss in mice of each
genotype and treatment group. Data are mean ± SEM from n = 6-7 mice/group.
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Figure

4.8.

Adipocyte

AhR

deficiency

prevents

PCB7-77-induced

impairment of glucose and insulin tolerance following weight loss. A, Blood
glucose levels following administration of glucose. B, Blood glucose levels
following administration of insulin. C, Area under the curve (AUC) of glucose
tolerance test (GTT) data in panel A. D, AUC of insulin tolerance test ( ITT) data
in panel B. Data are mean ± SEM from n = 6-8 mice/group. *, P < 0.05 compared
to vehicle treated AhRfl/fl; #, P < 0.05 effect of genotype.
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Figure 4.9. Adipose levels of PCB-77 and hydroxy PCB-77 metabolite in
obese mice (week 12 of HF feeding) and after 4 weeks of weight loss. A,
PCB-77 levels in epidydmal adipose tissue from mice of each genotype and
treatment group at weeks 12 and 16. B, Hydroxy PCB-77 levels in epidydmal
adipose tissue from mice of each genotype and treatment group at weeks 12 and
16. Data are mean ± SEM from n = 5 mice/group. *, P < 0.05 compared to
AhRfl/fl; ***, P < 0.001 compared to AhRfl/fl ; #, P < 0.05 effect of genotype.
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Figure 4.10. PCB-77-induced increases in mRNA abundance of CYP1A1 and
TNF-α are abolished in mice with adipocyte AhR deficiency. A, Epidydmal
adipose tissue CYP1A1 mRNA abundance in mice of each genotype and
treatment group. B, Epidydmal adipose tissue TNF-α mRNA abundance in mice
of each genotype and treatment group. Data are mean ± SEM from n = 5
mice/group. *, P < 0.05 compared to vehicle treated AhRfl/fl; #, P < 0.05 effect of
genotype.
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SECTION V: GENERAL DISCUSSION
5.1 Summary
The purpose of the studies described in this dissertation was to test the
hypothesis that PCB-77 regulates adipose tissue glucose homeostasis and
inflammation through the adipocyte AhR, and that resveratrol would protect
adipose tissue against PCB-77 induced insulin resistance. A mouse model of
PCB-77 induced diabetes was developed in lean mice and in obese mice
undergoing weight loss. PCB-77 had no effect on glucose or insulin tolerance in
the context of obesity. In lean mice and obese mice undergoing weight loss,
PCB-77 induced impairments in glucose homeostasis were associated with
increased levels of TNF-α specifically in adipose tissue. Administration of
resveratrol supplementation improved glucose homeostasis in lean PCB-77
treated mice, and simultaneously promoted NRF2 activity and restored insulin
signaling pathways in adipose tissue of these mice. Moreover, 3T3-L1 adipocytes
demonstrated a dose dependent increase in NRF2 signaling during cotreatment
with PCB-77 and resveratrol. Also in vitro, resveratrol protected from PCB-77
induced oxidative stress and restored glucose uptake in PCB-77 treated cells in a
concentration-dependent manner. A mouse model of adipocyte-AhR deficiency
was developed using the Cre/LoxP system to investigate the potential roles of
the adipocyte-AhR in mediating toxicities of PCB-77 in lean and obese mice, as
well as obese mice undergoing weight loss. Lean AhRAdQ mice fed a LF diet and
acutely exposed to PCB-77 demonstrated a modest improvement in glucose
tolerance and a more pronounced improvement in insulin sensitivity than AhRfl/fl
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mice. AhRAdQ mice fed HF diet for 3 months unexpectedly gained more weight,
had greater fat mass, and deposited more subcutaneous adipose tissue than
littermate controls; however, PCB-77 had no effect on glucose homeostasis in
obese mice of either genotype. During weight loss, obese AhRAdQ mice exhibited
partial protection against PCB-77 during glucose tolerance test and total
protection from PCB-77 induced insulin resistance (see Figure 5.1 for a summary
of these findings).
5.2 The interplay between adipose tissue and persistent organic pollutants:
Insights from mouse models of PCB-77 induced diabetes
5.2.1. PCB distribution in the body
During exposure to PCBs, these lipophilic pollutants are stored in liver and
adipose tissue (169, 289). This may avert the action of these pollutants in other
susceptible tissues and might be protective to a certain extent or under some
metabolic conditions (i.e. obesity) (7, 338). PCBs released from their storage in
adipose tissue may also represent a source of low-level internal exposure or may
act on the adipocyte directly as obesogens or disruptors of adipose tissue
structure and function (6, 9). Strong evidence from both in vivo and in vitro
studies suggests that PCBs can influence the development of adipose tissue,
principally through the promotion of preadipocyte differentiation at low doses, and
conversely preventing differentiation at high doses (6). Furthermore, storage of
PCBs in adipose tissue could impact offspring via fetal programming, probably
through epigenetic mechanisms, impacting the development of diseases in
adulthood (339-340). Additionally PCBs might alter adipose tissue function and
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structure later in life, primarily through metabolic disruption and inflammation,
conditions which favor the development of metabolic diseases (6-7).
The findings described herein would suggest that obesity could adversely
impact overall health in that expanded adipose stores might improve storage of
lipophilic

POPs,

thus

increasing

total

body

burden

of

environmental

contaminants. If obese subjects subsequently lose weight, this enhanced store
of POPs can then be released from adipose tissue via lipolysis, where they may
have effects systemically or on adipocytes directly. Observations in humans
suggest that pollutants released from adipose tissue are a significant source of
blood POPs. Many studies have demonstrated an increase in blood POPs after
weight loss by either dietary changes alone or coupled with bariatric surgery (9,
341). The importance of fat mass in the regulation of POP blood levels was
additionally reported by Lim et al. (275) who showed an inverse correlation
between long-term weight changes and POP serum concentrations.
An important question is if the release of POPs from adipose tissue during
weight loss could negatively impact other organs and tissues. A limited amount of
data is available in humans from weight loss studies. Studies have demonstrated
that increased serum POPs due to weight loss are associated with impairments
in resting metabolic rates, thermogenesis, and oxidative capacity of skeletal
muscle (276, 342-343). Kim et al. reported that individuals undergoing weight
loss had improved blood lipid and liver toxicity parameters, but those with the
highest serum POP levels had delayed improvement of these metabolic
parameters (9). Thus POPs may counteract the beneficial effects of weight loss.
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5.2.2. Potential target organs of coplanar PCB induced diabetes
5.2.2.1. Adipose tissue
As previously discussed, we have demonstrated that adipose tissue can be a
critical target organ of PCB induced insulin resistance in male C57BL/6 mice (7).
It should be noted that our studies only examined molecular pathways of
impaired insulin signaling in adipose tissue which were dependent on increased
levels of TNF-α expression or reactive oxygen species. Insulin resistance in
adipose tissue can also be regulated by lipolysis and relative free fatty acid
levels, adiponectin, and other proinflammatory cytokines. Kim et. al. dosed
C57BL/6 mice and AhR-KO mice with a single i.p. injection of TCDD (10 µg/kg)
and harvested adipose tissue 48 hours later (277). TCDD significantly increased
a number of additional proinflammatory adipokines associated with insulin
resistance, such as IL-1ß, in wild type mice but not AhR-KO mice, demonstrating
that these effects were AhR-dependent. Additionally, the method of POP dosing
and the metabolic state of experimental animals appears to be a critical factor in
studies of adipose-specific effects of POPs. In a study by Ibrahim et. al. (88),
male C57BL/6J mice were fed a HF diet enriched with low concentrations of
POPs for 8 weeks and glucose and insulin tolerance were measured. Contrary to
findings reported here, obese mice in this study demonstrated significantly
impaired glucose and insulin tolerance in response to POP feeding. Taken with
the findings presented here, this would suggest that the method POP dosing and
metabolic state of experimental animals may have differential effects on POPinduced impairment of glucose homeostasis. Future studies could examine the
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kinetics of different types of PCB dosing and how this modulates subsequent
PCB metabolism and body partitioning. Other modulators of insulin resistance,
influenced by PCBs in adipose tissue could also be explored in future studies.
5.2.2.2. Liver
The liver is also a potential site of insulin resistance, and highly active in the
metabolism of coplanar PCBs. While our efforts to quantify hepatic inflammation
did not yield significant results (7), it is plausible that coplanar PCBs reduce
insulin sensitivity in the liver via other mechanisms, and /or alter hepatic glucose
output, contributing to the PCB-77 induced diabetes observed in male mice. A
consistent observation of the experiments described in this dissertation were that
PCB-77 treated mice demonstrated hepatomegaly due to high levels of ectopic
lipid accumulation in the liver (6). This factor alone could have unexplored
consequences on overall insulin resistance, given that fatty liver is a condition of
other pathologies associated with T2D, such as non-alcoholic fatty liver disease
(NALFD).
Attempts were made in these studies to determine the effect of PCB-77
administration on hepatic gluconeogenesis. Surprisingly, RT-PCR results for
mRNA abundance of an array of gluconeogenic enzymes, in particular
phosphoenol pyruvate carboxykinase (PEPCK), found that expression of all
enzymes were decreased in PCB-77 treated animals compared to controls
(Figure 5.2), suggesting that enhanced hepatic glucose output was not the
mechanism behind impaired glucose tolerance in those mice. This observation
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using PCB-77 is consistent with AhR-dependent effects of TCDD reported by
others (344-345).
In a recent study, Wang et.al. examined glucose tolerance, insulin
resistance, hepatic expression of peroxisome proliferator–activated receptor-α
(PPAR-α), and genes affecting glucose metabolism and fatty acid oxidation
rhythms in wild-type (WT) versus AhR-deficient [knockout (KO)] mice (87). In this
study, KO mice displayed enhanced insulin sensitivity and improved glucose
tolerance, accompanied by decreased hepatic peroxisome proliferator activated
receptor-α (PPAR-α) and key gluconeogenic and fatty acid oxidation enzymes,
indicating a link between AhR signaling and glucose metabolism. The authors
further conclude that hepatic activation of the PPAR-α pathway might be a
mechanism underlying AhR-mediated insulin resistance. Findings presented here
would suggest that the adipocyte AhR is a critical mediator of PCB-induced
insulin resistance, as insulin resistance was completely abolished in AhRAdQ mice
treated with PCB-77 both acutely and chronically (unfortunately the study by
Wang et. al. did not treat experimental mice with either AhR agonists or POPs
(87), making comparison to the studies described here difficult).
Nault et.al. utilized livers from chow-fed C57BL/6 mice for gene
microarray, 1, 3 and 7 days after a single oral gavage of 30 μg/kg TCDD (85).
Administration of TCDD resulted in robust activation of not only genes involved in
the xenobiotic response, but also genes associated with steroid, phospholipid,
fatty acid, and carbohydrate metabolism. Arzuaga et.al. performed gene DNA
analysis on livers from C57BL/6 mice fed diets enriched with high-linoleic acid
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oils (20% and 40% as calories), with half of each group exposed to PCB-77 (84).
This study demonstrated a significant interaction between dietary fat and PCB
exposure, such that deregulated genes were organized into patterns describing
the interaction of diet and PCB exposure. Control animals demonstrated a
significant high-fat mediated induction of genes associated with fatty acid
metabolism, triacylglycerol synthesis and cholesterol catabolism, but this effect
was down-regulated in animals exposed to PCB-77. Several of these genes are
regulated by PPAR-α and as predicted, changes in PPAR-α gene expression
followed the same pattern as described above, demonstrating that dietary fat can
interact with environmental pollutants to compromise lipid metabolism. Taken
together, the results of these gene microarray studies would suggest not only
that there is a distinctive role for the AhR in lipid and glucose metabolism, but
that overall nutritional status and the presence of lipids can modulate the
interaction between AhR and exogenous ligands. These findings would suggest
that the liver could be the subject of future research for its complex roles in PCB
detoxification and nutrient metabolism.
5.2.2.3. Skeletal Muscle
Skeletal muscle can be a potential site of insulin resistance, but was not a major
focus of these studies utilizing PCB-77, given that detectable amounts of PCB-77
were not found in skeletal muscle from treated mice. Additionally PCB-77 treated
mice in our study did not demonstrate differences from controls in skeletal
muscle TNF-α protein levels, a well known contributor to insulin resistance. In a
recent study by Trumble et.al., muscle and blubber samples were collected from
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Weddell seals in Antarctica and measured for 41 different persistent organic
pollutants, including PCBs (346). The greatest distribution of POPs were found in
blubber and reduced amounts found in skeletal muscle; however the muscle
samples demonstrated similar orders of POP prevalence. The author’s further
suggest that POPs may exert local effects on skeletal muscle via their attraction
to intramuscular lipid. An additional possibility is that POPs stored in blubber may
be released over time and constitute a source of low-level internal exposure that
might chronically damage other tissues including skeletal muscle. The chronic
effects of PCB dosing on skeletal muscle were not included in the present study,
but could certainly be examined in future studies.
5.2.2.4. Pancreas
The pancreas is

a glandular organ in

the digestive and endocrine

system,

producing several important hormones, including insulin, glucagon, pancreatic
polypeptide, as well as pancreatic juice which contains digestive enzymes that
assist the absorption of nutrients. These enzymes aid in the breakdown of
carbohydrates, proteins, and lipids. Given that pancreatic beta cell secretion of
insulin is impaired in T2D, PCB toxicities in the pancreas might represent a
further area of study utilizing these mouse models. In our LF diet time course
study in male C57BL/6 mice, mice were administered two or four oral doses
(weeks 1, 2, 9, and 10) of vehicle or PCB-77 (50 mg/kg) and sacrificed at weeks
2, 4, and 12. At weeks 2 and 4, no significant difference in fasting plasma insulin
was observed between treatment groups; however at week 12, PCB-77 treated
mice had a significant decrease in fasting plasma insulin compared to controls
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(Figure 5.3). A possible explanation may be that in longer term PCB dosing
studies, coplanar PCBs may exert beta cell damaging effects, or through some
other mechanism inhibit insulin secretion. Furthermore, it has been previously
reported that pancreatic beta cell lines exposed to TCDD experience high
degrees of cytotoxicity in addition to reduced levels of glucose-stimulated insulin
secretion (347). Taken together, these studies would suggest that pancreatic
beta cell destruction might be an additional mechanism of PCB induced diabetes.
5.2.3. The progression of adipose inflammation in LF time course studies
5.2.3.1. ROS as the initiating event for adipose inflammation
An interesting finding of these studies is that PCBs contribute to a progression of
inflammation in adipose tissue. In time course studies of mice fed a LF diet and
dosed with vehicle or PCB-77 (50 mg/kg, oral gavage), PCB treated mice
experienced an AhR-dependent and adipose-specific increase in TNF-α protein
at week 4 (2 weeks post final PCB dose) which was correlated with observed
impairments in glucose and insulin tolerance (7). However, no difference was
found in adipose TNF-α mRNA abundance in PCB treated mice at week 2 (48
hours post final PCB dose), despite the fact that these animals also exhibited
impaired glucose homeostasis. In subsequent studies using resveratrol as a
therapeutic against coplanar PCB-induced diabetes, mice sacrificed 48 hours
after the last dose of PCB-77 also displayed no difference in adipose TNF-α
expression levels; however, these mice displayed glucose intolerance and insulin
resistance consistent with previously reported findings (7). These results suggest
that acute effects of PCB-77 to increase oxidative stress and impair downstream
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insulin signaling in adipose tissue contribute to deficits in glucose homeostasis,
and these acute effects were ablated by supplementation with resveratrol (7).
It has been hypothesized by others that AhR activation by synthetic
ligands induces oxidative stress in target tissues via the upregulation of
xenobiotic metabolizing enzymes such as CYP1A1 (162, 348). CYP1A1 can
produce hydrogen peroxide and super oxide anions as a byproduct of xenobiotic
catalyzing activity (159, 322-323). However, our results did not define if
progressive increases in adipose tissue TNF-α are dependent on initial
dysregulation of oxidative stress. An informative experiment could utilize the
existing experimental design of PCB induced diabetes with CYP1A1 deficient
mice (or adipose-specific CYP1A1 deficient mice) to better understand the
mechanisms linking AhR, oxidative stress, and inflammation. Conversely,
CYP1A1 si-RNA could be utilized to inhibit enzyme activity in vitro and determine
effects on PCB-induced regulation of oxidative stress and insulin signaling in
adipocytes.
5.2.3.2. Potential role of PCB-77 metabolites
An additional question raised but not directly answered by the present studies
are the potential impact of PCB-77 metabolites on the observed impairments in
glucose homeostasis and adipose inflammation. It is interesting to note that in
both the LF diet time course study as well as the obesity/weight loss time course
study there was no difference in adipose TNF-α mRNA abundance when
extremely high adipose concentrations of the parent molecule PCB-77 detected
in adipose tissue (LF diet time course, week 2). Conversely, the highest levels of
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adipose TNF-α expression occurred in tandem with extremely low adipose
concentrations of parentPCB-77 (LF time course, week 4; obesity/weight loss
time course, week 16) (7). These data suggest that PCB-77 metabolites
contribute to adipose tissue inflammation. Unfortunately, in early studies of this
project, facilities were not available to quantify PCB-77 metabolites in serum or
tissues. It should also be noted that the current mass spectrometry protocol for
PCB-77 metabolite detection only screens for hydroxy and dihydroxy metabolites
of PCB-77, but not the larger pool of potential metabolites such as
glucuronidated or sulfated variants. To more comprehensively address the role of
PCB-77 metabolites, future studies could utilize two different approaches. The
most direct would be to utilize the aforementioned CYP1A1 deficient mice in the
previously established PCB induced diabetes experimental design. However, this
approach ignores other metabolizing enzymes in the AhR gene battery and
would not control for alternate PCB-77 metabolites. An alternative approach
could utilize the existing mouse model of PCB-77 induced diabetes, but instead
dose mice with commercially available PCB-77 metabolite analogues (available
from Canadian distributors).
5.3. The potential therapeutic benefits of resveratrol supplementation in PCB
exposed populations: Insights from resveratrol supplementation mouse model of
PCB-77 induced diabetes
5.3.1. Resveratrol intervention in populations with known PCB exposures
The data presented herein suggest that supplementation with resveratrol or
potentially other AhR antagonizing nutrients or pharmaceuticals may be a
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therapeutic for populations with known coplanar PCB exposures. It should be
noted that a limitation of our study is that it only examined effects of resveratrol
against acute PCB-77 exposure, and that mice were pre fed resveratrol for one
week prior to initiating the study. An experiment with greater implications for
comparison to human exposures would be to dose mice with PCB-77 and then
supplement the diet with resveratrol, because in reality, humans are unlikely to
take large doses of resveratrol as a preventative measure against possible PCB
exposure.
5.3.2. General use of resveratrol supplements for weight loss
This study would more generally suggest that resveratrol might be a beneficial
supplement for patients post bariatric surgery, or even subjects more generally
involved in weight loss programs, given that nearly all individuals are exposed to
persistent organic pollutants on a daily basis via food or air (11), and likely have
significant adipose stores of PCBs to release with increased lipolysis (23). A
relevant follow up experiment would be to dose obese mice with PCB-77, and
then feed a resveratrol enriched LF diet to induce weight loss, and determine if
resveratrol ameliorates the negative effects of PCBs during weight loss. The
ability of PCBs to attenuate the beneficial effects of weight loss might explain in
part why most individuals find sustained weight loss incredibly challenging, and
why compliance in weight loss programs is generally low. For example,
hyperinsulinemia in response to insulin resistance in peripheral tissues can
promote feelings of hunger (91, 93), which may potentially derail an individual’s

170

motivation in regards to weight loss. Blunting the effects of POPs released with
weight loss might improve weight loss program outcomes.
5.3.3. Pharmaceutical resveratrol analogues and resveratrol use in tandem
with other nutritional supplements
Because the levels of resveratrol endogenously available in food are limited, it
would be worthwhile to consider the use of pharmaceutical resveratrol
analogues, should future research demonstrate that this compound is a clinically
relevant strategy for treating PCB exposed populations. A benefit of utilizing
pharmaceutical analogues would be that the compound could be conjugated to
or formulated as a mixture with other nutrients that might protect against PCB
exposure. For example, the fat substitute Olestra has been shown previously to
effectively lower adipose burdens of Arochlor in humans (349). Olestra is a fat
substitute that is resistant to lipases in the human digestive tract; because of
Olestra’s fatty acid-like molecular structure, it has been shown that it can create a
lipophilic ‘sink’ in the intestinal lumen and thereby promote enhanced elimination
of stored PCBs and organochlorines. A pharmaceutical preparation of resveratrol
and Olestra might present a “two-pronged” strategy for protecting against PCB
exposure. However, an interesting study by Arguin et.al. compared plasma
organochlorine concentrations in subjects on vegan, omnivorous, and a fatsubstituted Olestra diet, and found the significant improvement on plasma PCB
levels only in the vegan diet group (350). Because the vegan diet group did not
gain weight over the study, which could promote organochlorine partitioning from
blood to adipose tissue, it is possible that the vegans ate greater amounts of
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plants containing antioxidants and fewer PCB laden foods (i.e. high fat dairy and
meats) (351). It may also be suggested by this study that a pharmaceutical blend
of antioxidants might confer more PCB protective effects than Olestra; however
drug forms of antioxidants are unlikely to change food related behaviors, and
thus the efficacy of this drug in lowering body burdens of PCB might be limited if
users continued to ingest food high in organochlorines. Future research should
determine if this is a clinically relevant avenue of potential drug development.
5.4. Adipose AhR: Role in mediating PCB-77 induced diabetes, and a potentially
novel role in regulating body weight, body composition, and fat deposition
5.4.1 Limitations of the model of adipocyte-AhR deficiency
5.4.1.1. Non-specific reductions in AhR mRNA abundance
The model of adipocyte-AhR deficiency used in these studies was developed
using the Cre/LoxP system, in which exon 2 of the AhR gene was flanked by
LoxP sites and mice were bred to transgenic mice expressing Cre recombinase
driven by the adiponectin (AdQ) promoter. Adiponectin was originally described
as an adipocyte-specific protein and thus the promoter was used by several
groups to reduce gene expression in adipocytes. However, as more models
using this promoter have been developed, it has become clear that the
adiponectin gene is also expressed in other tissues, such as cardiomyocytes.
Indeed, mRNA abundance of AhR in AhRAdQ mice was reduced in the heart, but
these reductions fell short of statistical significance. Quantification of heart weight
to body weight ratios as a measure of cardiac hypertrophy revealed no
differences between AhRfl/fl and AhRAdQ mice (Figure 5.4). Additionally, given that
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these mice were utilized for glucose and insulin tolerance studies and not
examined for cardiovascular parameters per se, it is unknown if AhR deficiency
in the heart impacted other physiologic measures, but it is unlikely to have
influenced study endpoints.
5.4.1.2. Model validation
AhR mRNA abundance was quantified in whole adipose tissue lysates, the
adipocyte fraction of collagenase-digested adipose tissue, as well as in
subcutaneous adipocytes differentiated from isolated stromal vascular cells.
Some level of residual AhR mRNA abundance was detected in all of these
adipocyte sources from AhRAdQ mice. This may reflect sub-optimal efficiency of
Cre recombinase enzyme activity at the LoxP sites surrounding exon 2 of the
AhR gene. Given that there was total deletion of AhR mRNA abundance in
adipocyte fractions from visceral adipose tissue, the minimal AhR expression
seen in subcutaneous adipocytes at Day 8 might suggest residual receptor
turnover.
5.4.2. HF diet induced phenotype in adipose AhR deficient mice
5.4.2.1 Differential expression of AhR in LF versus HF feeding
Preliminary studies in our lab examined if there were diet-induced changes in
AhR gene expression in adipose tissue, liver, and kidney. Tissues were taken
from C57BL/6 mice fed either a LF or HF diet for three months, and RNA was
extracted for subsequent RT-PCR measurements. In liver and kidney, AhR
mRNA abundance did not change between LF and HF feeding (Figure 5.5).
However, in subcutaneous, epidydmal, and brown adipose tissue, HF feeding
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significantly increased AhR mRNA abundance (Figure 5.5). While it should be
noted that the sample size for these preliminary studies was small (n = 34/group), this data may lend support to the hypothesis that the endogenous AhR
ligand is a fatty acid or fatty acid derivative, given that HF feeding would increase
the influx of fatty acids to adipose tissue.
5.4.2.2. Arachidonic acid or ecosanoid metabolites as a potential
endogenous AhR ligand
The unexpected increased body weight phenotype of HF-fed adipocyte AhR
deficient mice may be due to a number or combination of different factors.
Currently, the endogenous AhR ligand(s) remains unknown; however, some
studies have suggested ligands may include arachidonic acid or one of its
eicosanoid products, such as lipoxin A4 or prostaglandin G2 (326, 352). Bui et.
al. demonstrated that treatment with TCDD in wild type mice led to a significant
increase in liver eicosanoids , but this effect was not observed in whole body
AhR deficient mice, demonstrating AhR dependency. The authors concluded that
AhR binding with TCDD antagonized receptor interaction with endogenous
eicosanoid ligands, leading to an increase of these products in examined tissues
(326). Further studies utilizing AhRAdQ mice and lipid profiling techniques may
provide novel insight into the endogenous AhR ligand.
5.5. Further exploration of the adipose AhR: Dietary manipulations
In our studies, adipocyte-AhR deficiency was studied under several conditions
including lean mice, obese mice, and obese mice undergoing weight loss. The
most striking effects of PCB-77 induced impairments on glucose homeostasis
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were observed in obese mice undergoing weight loss, suggesting that the effects
of adipocyte-AhR deficiency may be most relevant when the kinetics of PCB
dosing favor rapid sequestration to expanded adipose stores, and subsequent
chronic release with weight loss. Interestingly, effects of adipocyte-AhR
deficiency on body weight, body composition, and fat deposition were only seen
on the HF diet (60% fat by calories). Dietary manipulations could be performed in
future studies to examine how fatty acid composition of the diet impact effects of
adipocyte-AhR deficiency.
For example, it has been suggested that the polyunsaturated, omega 6
arachidonic acid or eicosanoid metabolites lipoxin A4 or prostaglandin G2 may
be endogenous AhR ligands (35), perhaps leading to the phenotype observed in
HF fed AhRAdQ mice. However, it has also been published by Hennig et.al. that
omega 6 fatty acids can enhance PCB toxicity, whereas polyunsaturated omega
3 fatty acids can protect against the harmful effects of PCBs (348, 354). AhRAdQ
mice and littermate controls could be dosed with PCB-77 during HF feeding of
diets with modified ratios of omega 3 and omega 6 polyunsaturated fatty acids,
and then tested for glucose and insulin tolerance following a weight loss period.
By this method, a dose-response to arachidonic acid in adipocyte-AhR deficient
mice could be observed during obesity, and conversely it could be determined if
omega 3 fatty acids conferred a protective effect against PCB-77 induced
diabetes during weight loss in AhRfl/fl mice.
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5.6. Additional future directions
5.6.1. The role of noncoplanar PCBs in the development of diabetes
An important question raised by this research is the effect that noncoplanar
PCBs might have on the development of T2D and obesity, especially given that
noncoplanar PCBs are also positively associated with T2D in epidemiology
studies (271, 355-357). Mechanistic studies of these compounds would likely
prove challenging given that noncoplanar PCBs can activate both the CAR and
PXR signaling pathways (358). PXR activation by noncoplanar PCBs might be a
more critical pathway in the development of PCB-induced diabetes than the CAR
pathway, given that studies have shown that CAR activation during HF feeding
improves insulin sensitivity (359), whereas PXR ablation alleviates diet induced
and genetic obesity and insulin resistance in mice (360). Furthermore, studies in
our lab using 3T3-L1 adipocytes demonstrated that exposure to noncoplanar
PCB-153 had no effect on inflammation or insulin-stimulated glucose uptake
(6)(Figure 5.6). This would suggest that noncoplanar PCBs might exert their
effects on organs other than adipose tissue, or that this particular cell line is not
responsive to PCB-153. Finally, Shi et.al. have reported that the metabolic
effects of PCB-153 are highly dependent on macronutrient interactions during HF
feeding (361), which might be an additional complicating factor in studies of this
nature.
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5.6.2. The role of mixtures of persistent organic pollutants in the development
of diabetes
A limitation of this data is that only two coplanar PCB congeners were studied; in
reality, it is highly unusual for human subjects to be exposed to only one
congener of PCB. In fact, given that nearly all individuals are exposed to a variety
of persistent organic pollutants on a daily basis via food or air (11), and that
obesity is rapidly increasing in the U.S. (362-363), it is likely that many people
have significant and variable distributions of an assortment of lipophilic POPs
stored in adipose tissue. Ibrahim et. al. pioneered the use of a “POP diet” (88), in
which Atlantic salmon were fed fish feed enriched with low concentrations of
POPs. Salmon were filleted after 8 weeks of feeding, and fillets were
homogenized and fish oil extracted. Fish oil extracts were added to purified
rodent diets (72% kcal as fat), which were subsequently fed to male C57BL/6J
mice for 8 weeks. Interestingly, obese mice in this chronic feeding study
demonstrated dramatically impaired glucose and insulin tolerance in response to
POP exposure compared to controls. This finding, taken with the findings
described in this dissertation, are suggestive that the method of POP exposure
and the metabolic state of experimental mice have a significant impact on the
kinetics of POP body distribution and / or metabolism and the POP-induced
impairment of glucose and insulin tolerance. Experiments utilizing the “POP diet”
developed by Ibrahim et. al. and examining a variety of metabolic states would
be beneficial in determining the efficacy or potential toxicity of resveratrol
supplementation in populations exposed to POP mixtures. Furthermore, feeding
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a similar diet to AhRAdQ mice and littermate controls could give a more complete
understanding of the overall importance of the adipocyte AhR in mediating PCBinduced diabetes during chronic POP exposure through feeding.
5.6.3. Potential gender differences in development of PCB or POP associated
diabetes
Some epidemiology studies, including the Anniston community survey by
Silverstone et.al., have indicated that PCB exposure has a stronger positive
association with development of T2D in females than males (158, 364-365);
however, other clinical studies show no impact of gender on the positive
correlation between POP exposure and diabetes risk or severity (268, 271, 290,
366-368). Whether gender-specific responses to PCB exposure are due to
interaction with additional environmental or genetic factors remains unknown.
Furthermore, it is possible that there are gender differences in AhR expression,
activation, activity, gene regulation, signaling pathways, or receptor turnover,
which could present an alternate avenue of future study. However, it is more
likely that gender differences in response to PCBs stem from AhR crosstalk with
other steroid receptors, particularly by AhR induced inhibition of the estrogen
receptor (369-370). We repeated the experimental design using two oral doses of
either vehicle or PCB-77 (50 mg/kg) administered to female LF-fed mice, and
quantified glucose and insulin tolerance within 48 hours of the second dose
(Figure 5.7A and 5.7B, respectively). At 48 hours post gavage, females exposed
to PCB-77 had a more robust impairment to glucose tolerance than that
observed in males; conversely, females had no impairment of insulin tolerance,
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contrary to what has previously been observed in males (7). While not having
significantly different body weights, PCB-77 treated females had greater fat mass
than controls which was associated with enlarged visceral and subcutaneous
adipose depots, an effect that was not observed in male C57BL/6 mice in
experiments described in this dissertation (Figure 5.8). Gender differences
relating to the AhR represent an important and clinically relevant direction for
future research.
5.7 Clinical Implications
The data presented here raise broad clinical implications. Firstly, our data
suggest that supplementation with resveratrol or potentially other AhR
antagonizing nutrients or pharmaceuticals may be a therapeutic for populations
with known coplanar PCB exposures. It should be noted that our study only
examined effects of resveratrol to protect against acute PCB-77 exposure, and
that mice were pre fed resveratrol for one week prior to initiating the study. An
important and informative experiment would be to dose mice with PCB-77 and
then supplement the diet with resveratrol, as this would more closely mirror the
therapeutic potential of the compound in subjects with known, accidental
exposures to PCBs. As previously noted, it is unusual for human subjects to be
exposed to only one congener of PCB; experiments examining resveratrol
supplementation utilizing the “POP diet” developed by Ibrahim et. al. (88) would
be beneficial in determining the efficacy or potential toxicity of resveratrol in
populations exposed to POP mixtures. Secondly, it would suggest that
resveratrol might be a beneficial supplement for patients post bariatric surgery, or
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even subjects more generally involved in weight loss programs, given that nearly
all individuals are exposed to persistent organic pollutants on a daily basis via
food or air (11), and likely have significant adipose stores of POPs to release with
increased lipolysis (7). An interesting follow up experiment would be to dose
obese mice with PCB-77, and then feed resveratrol enriched LF diet to induce
weight loss, and determine if resveratrol ameliorates the negative effects of
PCBs during weight loss. The ability of POPs to attenuate the beneficial effects
of weight loss might explain in part why most individuals find sustained weight
loss incredibly challenging, and why compliance in weight loss programs is
generally low. For example, hyperinsulinemia in response to insulin resistance in
peripheral tissues can promote feelings of hunger (91, 93), which may potentially
derail an individual’s motivation in regards to weight loss. Blunting the effects of
POPs released with weight loss might improve weight loss program compliance
and outcomes. Finally, study in greater detail of adipocyte AhR regulation of body
weight, body mass, and fat deposition may have significant implications both
clinically or in pharmaceutical research.
5.8 Concluding remarks
Overall these studies suggest a critical role of coplanar PCB-bound AhRs on
adipocytes to promote insulin resistance in adipose tissue during lean and weight
loss conditions, and a more general and novel role in regulating body mass and
fat deposition. The consequences on glucose homeostasis of PCB-77 acting
through adipocyte AhRs are most prominent in lean/weight loss conditions and
are absent in the setting of obesity, lending further credence to the hypothesis
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that lipophilic pollutants are sequestered to lipid pools during obesity and freed
during weight loss. Future studies should explore resveratrol supplementation in
the weight loss model of PCB-77 induced diabetes and investigate the feasibility
of clinical resveratrol supplementation studies in PCB exposed Kentucky
populations.

Additionally, the impact of adipocyte AhR deficiency on body

weight, fat mass, and fat deposition should be studied in greater detail.
Furthermore, this model of adipocyte AhR deficiency may provide important
clues to the identity of the endogenous AhR ligand, which would perhaps have
far reaching clinical implications.
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Figure 5.1. Summary of findings: Proposed mechanism of PCB-77 induced
adipocyte mediated T2D and inhibition with resveratrol. PCB-77 is
transported in blood and highly attracted to expanded lipid pools present in
hypertrophied adipocytes during obesity. During lean or weight loss conditions
(blue pathway), PCB-77 is released from adipocyte lipid droplets with lipolysis,
and returns to blood to act systemically and / or act at the cytosolic adipocyte
AhR. AhR activation leads to increased expression of CYP1A1 and TNF-α, and
the generation of reactive oxygen species. The culmination of these changes
induces glucose intolerance and insulin resistance in adipocytes. Resveratrol
stimulates Nrf2 signaling to suppress oxidative stress and restore insulin
sensitivity and glucose tolerance to adipocytes (red pathway).

182

VEH
PCB-77

Gene/18S

3

p = 0.08

p = 0.07

*

2

1

0

PEPCK

PC

G6P

Figure 5.2. PCB-77 treatment decreases hepatic mRNA abundance of
gluconeogenic enzymes. Mice were administered vehicle (VEH) or PCB-77 (50
mg/kg, two divided doses during weeks 1 and 2). At week 4, hepatic mRNA
abundance

of

phosphoenolpyruvate

carboxykinase

(PEPCK),

pyruvate

carboxylase (PC), and glucose 6-phosphatase (G6P) were measured. Genes
were normalized to reference gene 18S. Data are mean ± SEM from n = 4
mice/group. *, P < 0.05 compared to VEH within gene of interest.
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Figure 5.3. PCB-77 treatment decreases fasted plasma insulin in LF fed
mice. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg, two divided
doses during weeks 1 and 2, a second set of 2 doses during weeks 9 and 10 for
mice studied at 12 weeks). At 2, 4 or 12 weeks, mice in each treatment group
were fasted for 4 hours prior to sacrifice, and plasma was collected for
commercial insulin ELISA. Data are mean ± SEM from n > 5 mice/group. *, P <
0.05 compared to VEH within time point.
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Figure 5.4. Adipocyte AhR deficiency does not affect heart weight. Hearts
were harvested from two month old, male AhRAdQ mice and littermate controls.
Data are mean ± SEM from n = 6 to 8 mice/group.
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Figure 5.5. Differential expression of AhR in adipose tissue during LF vs.
HF feeding. Male C57BL/6 mice were fed either LFD (10% kcal as fat) or HFD
(60% kcal as fat) for 3 months. AhR mRNA abundance was quantified in liver,
kidney, subcutaneous adipose tissue (SUBQ), epidydmal adipose tissue (EF),
and brown adipose tissue (BAT). Genes were normalized to reference gene 18S.
Data are mean ± SEM from n = 3 to 4 mice/group. *, P < 0.05 compared to VEH
within tissue type.
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Figure 5.6. PCB-153 has no effect on insulin-stimulated glucose uptake in
3T3-L1 adipocytes. Coplanar PCB-77 abolishes insulin-stimulated 2DG uptake
in 3T3-L1 adipocytes, while PCB-153 has no effect on insulin-stimulated glucose
uptake. Data are mean ± SEM from n = 2 experimental triplicates. *, P<0.05
compared to basal.
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Figure 5.7. PCB-77 impairs glucose tolerance (A) in female C57BL/6 mice,
but has no effect on insulin tolerance (B). Mice were administered vehicle
(VEH) or PCB-77 (50 mg/kg, two divided doses during weeks 1 and 2). 48 hours
post-second gavage administration, mice in each treatment group were
administered a bolus of glucose (20% glucose, A) or insulin (0.0125 µM/gm body
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weight, B) and blood glucose concentrations were quantified. Data are mean ±
SEM from n = 5 mice/group. *, P < 0.05 compared to VEH within time point. **, P
< 0.01 compared to VEH within time point. ***, P < 0.001 compared to VEH
within time point.
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Figure 5.8. PCB-77 increases adipose depot weight of female C57BL/6
mice. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg, two divided
doses during weeks 1 and 2). Mice were sacrificed at week 4 and adipose depot
weights in retroperitoneal fat (RPF), periovarian fat (POF), and subcutaneous
adipose tissue (SUBQ) were quantified. Data are mean ± SEM from n = 10
mice/group. *, P < 0.05 compared to VEH within tissue type.
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